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Abbreviations 
 
 
ALAT  alanine aminotransferase 
ASAT  aspartate aminotransferase 
AUC  area under the curve 
BW  body weight 
Clhep  hepatic clearance 
Clin  intrinsic hepatic clearance 
Clsys  systemic clearance 
Cmax  maximum concentration 
CYP450 cytochrome P450 isoenzyme 
E  hepatic extraction 
ECG  electrocardiogram 
EEG  electroencephalogram 
F  bioavailability 
fu  unbound fraction 
GI  gastrointestinal 
h  hour 
HAV  hepatitis A virus 
HBV  hepatitis B virus 
HCC  hepatocellular carcinoma 
HCV  hepatitis C virus 
HDV  hepatitis D virus 
HEV  hepatitis E virus 
HPLC  high pressure liquid chromatography 
IS  internal standard 
i.v  intravenous  
INR  international normalized ratio  
Q  blood flow across the liver 
Q0  extrarenal dose fraction 
min  minutes 
MEGX monoethylglycinexylidine 
NSAID non steroidal anti-inflammatory drug 
PB  fraction bound to proteins (protein binding in %) 
PD  pharmacodynamics 
PK  pharmacokinetics 
rpm  revolutions per minute 
s  seconds 
SD  standard deviation  
TDM  therapeutic drug monitoring 
Tmax  time point of Cmax 
t1/ 2  half life  
ULN  upper limit of normal 
Vd  volume of distribution 
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I Summary 
 
 
In my thesis I defined strategies for dosage adaptation of drugs in patients with liver 
disease. The major goal of the thesis was to classify  antineoplastic drugs and central 
nervous agents according to pharmacokinetic principles (hepatic extraction and 
bioavailability) and to provide recommendations for their use in patients with liver 
disease. The antineoplastic drugs and central nervous agents available on the market 
in Switzerland were therefore studied. In a second time a clinical study was planned in 
patients with liver cirrhosis to define methods of dose adaptation for high-extraction 
drugs. 
 
The dose adaptation of drugs in patients with liver disease is more difficult than in 
patients with renal disease. The dosage may have to be adjusted  but the problem is 
to quantify the required changes.    
Ideally, there should be a predictive liver function test that allows a more precise 
dosing in patients with liver disease analogous to the creatinine clearance  for patients 
with renal dysfunction. Unfortunately, no such practical system is available as yet. 
Despite the absence of such a test, kinetic parameters and clinical studies can both 
help determining the kinetic behavior of a drug and providing dosage adjustments. 
 
? Project 1 
In chapter 3.1, the kinetic and dynamic changes in patients with liver disease of the 
most important drugs used in these patients were discussed.  
 
? Project 2 
In chapter 3.2, a guideline for dose reduction in patients with cholestasis for 
antineoplastic drugs with significant elimination via the bile was provided. Dose 
adaptation for liver disease is important in patients treated with antineoplastic drugs  
due to the high prevalence of impaired liver function in this population and the dose-
dependent, frequently serious adverse effects of the drugs.  
The antineoplastic drugs were classified according to their bioavailability / hepatic 
extraction in order to predict their kinetic behavior in patients with decreased liver 
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function. This prediction was compared with kinetic studies (identified by a structured, 
computer-based literature search) carried out with these drugs in patients with liver 
disease. It appears that obvious gaps about the kinetic behavior of drugs in patients 
with liver disease include data about hepatic extraction and kinetic studies of drugs 
with biliary elimination in patients with cholestasis.  
 
? Project 3 
Central nervous agents often need to be prescribed to patients with preexisting liver 
disease. In chapter 3.3, as for antineoplastic drugs, central nervous agents were 
classified according pharmakokinetic principles to provide recommendations for their 
use in patients with liver disease.  
 
? Project 4 
In a next step a clinical study was planned to define strategies of dose adaptation for 
high-extraction drugs (like propranolol) in patients with liver cirrhosis (chapter IV). It 
has been shown convincingly that the bile acid concentration in portal and peripheral 
venous blood is significantly correlated to the magnitude of portal-systemic shunts in 
patients with mild to moderate liver cirrhosis. Since bioavailability of high-extraction 
drugs is in part a function of the magnitude of portal-systemic shunts, it was 
hypothesized that the bioavailability of propranolol, a high-extraction drug, shows a 
linear correlation with serum bile acid concentrations in patients with liver cirrhosis. 
The relationships between the bioavailability of propranolol and serum bile acid 
concentration in patients with liver cirrhosis were therefore investigated.  
 
In the current study we did not find a significant correlation between serum bile acids 
and bioavailability of propranolol in patients with liver cirrhosis. It is therefore possible  
that the serum bile acid concentration is not a reliable marker for porto-systemic 
shunts and can therefore not be used to predict bioavailability of high extraction drugs 
such as propranolol.  
Individual bile acids provide more information about porto-systemic shunts and may 
therefore be able to predict bioavailability of propranolol. Individual bile acids will 
therefore be determined by GC-MS. 
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When the oral clearance of propranolol in patients with liver cirrhosis is correlated with 
the serum bile acid concentration, an inverse relationship between the two parameters 
was detectable. A small increase in the serum bile acid concentration (in cirrhotic 
patients a marker of  liver function) can be associated with an important decrease in 
propranolol clearance. When only the data from cirrhotic patients with serum bile acids 
values under 50 µmol/l were considered, the clearance was negatively correlated. 
In patients with liver cirrhosis, propranolol has a bioavailability of 60% and is therefore 
kinetically similar to drugs with medium extraction. In this situation, mainly intrinsic 
hepatic clearance predicts hepatic clearance of  a drug. The serum bile acid 
concentration may therefore reflect not only porto-systemic shunting but also intrinsic 
hepatic clearance in patients with liver cirrhosis. 
 
No significant correlation was found between serum bile acids and bioavailability of 
propranolol in patients with liver cirrhosis. The serum bile acid concentration seems 
not to be a reliable marker for porto-systemic shunts and can therefore not be used to 
predict bioavailability of high extraction drugs in patients with liver cirrhosis.  
There are currently not enough data for safe use of cyctostatics and central nervous 
agents in patients with liver disease. Pharmaceutical companies should urged to 
provide kinetic data (especially hepatic extraction) used for classification of such drugs 
and to conduct kinetic studies for drugs with primarily hepatic metabolism in patients 
with impaired liver function allowing to give quantitative advise for dose adaptation. 
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II General introduction 
 
 
2.1 Anatomy and function of healthy liver 
 
The liver is the largest gland in the human body and accounts for approximately 2.5% 
of total body weight. In the adult, the liver weighs almost 1500g. It receives a dual 
blood supply; approximately 20% of the blood flow is oxygen-rich blood from the 
hepatic artery, and 80% is nutrient-rich blood from the portal vein arising from the 
stomach, intestines and spleen (1).  
The majority of cells in the liver are hepatocytes, which constitute about 80% of the 
mass of the liver. The remaining cells are Kupffer cells (members of the 
reticuloendothelial system), stellate (fat-storing) cells, endothelial cells and other cells 
of blood vessels, bile epithelial cells and supporting structures. The liver appears to be 
organized in lobules, with portal areas at the periphery and central veins in the center 
of each lobule (2). Blood flowing into the portal areas has therefore to flow through the 
sinusoids. The sinusoids are lined by unique endothelial cells that have prominent 
fenestrae, allowing the free flow of plasma but not cellular elements (3). The plasma is 
thus in direct contact with hepatocytes in the subendothelial space of Disse (figure 
1.1).  
The cell mass of the liver performs diverse metabolic and excretory functions with 
substrates being presented directly from the gut lumen (like nutritional substrates and 
also xenobiotics), from the gut-related endocrine organs (gut peptides) and pancreas 
(insulin, glucagon) and indirectly from the general circulation. The liver is exposed to a 
wide variety of potentially harmful influences (drugs, toxins, infectious agents and 
inflammatory substances) because of its strategic position in relation to the gut and its 
processing of 20 to 25% of the total circulation (4). A diverse range of disease 
processes in the liver derive from these noxious stimuli, resulting in loss of cell mass, 
circulatory disturbances, destruction of normal architecture and reduction in functional 
capacity.  
Liver disease has general implications for health (nutritional and metabolic balance, 
maintenance of body fluid and electrolyte balance, coagulation control). However, 
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pharmacologists have taken particular interest in the influence of liver disease on drug 
dosage requirements and drug action. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic representation of the relationships between the hepatic sinusoid, the space 
of Disse and hepatocytes in the healthy liver. Top: the anatomy of the junction between a hepatic 
arteriole and the sinusoid in addition to the macroscopic relationships. Bottom: the free exchange of 
fluid and substrate(s) between the sinusoidal lumen and the space of Disse (5). 
 
“Liver disease” is an umbrella term for a wide variety of syndromes resulting from 
infectious agents (viral, bacterial and parasitic), xenobiotics, alcoholism, circulatory 
disturbances (like cardiac failure) and autoimmune inflammation. Most noxes result in 
cell damage with cell death and/or pathological repair processes (4). Liver disease in 
humans can lead to a reduction in liver blood flow, extrahepatic or intrahepatic 
shunting of blood, hepatocyte dysfunction, quantitative and qualitative changes in 
serum proteins, and changes in bile flow. Different forms of hepatic disease may 
produce different alterations in drug absorption, disposition, and pharmacological 
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effect. The pharmacokinetic or pharmacodynamic consequences of a specific hepatic 
disease may differ between individuals or even within a single individual over time. 
 
 
2.2 Liver disease relevant for drug metabolism 
 
2.2.1 Liver cirrhosis 
Cirrhosis often represents the final common pathway of a number of chronic liver 
diseases. The development of cirrhosis is characterized by the appearance of 
fibroblasts and collagen deposition in the liver. This is accompanied by a reduction in 
liver size and in the formation of nodules of regenerated hepatocytes. These 
modifications are associated with - and may be responsible for - a reduction in liver 
blood supply, the presence of intra- and extrahepatic portal-systemic shunting, 
capillarization of the sinusoids (loss of fenestrae in sinusoidal epithelia) and a 
reduction in the number and in the activity of the hepatocytes. (6). Loss of functioning 
hepatocellular mass  and capacity may lead to jaundice, edema, coagulopathy and a 
variety of metabolic abnormalities which may contribute to alterations in the 
pharmacokinetic behavior of many drugs; fibrosis and distorted vasculature lead to 
portal-hypertension and its sequelae, including gastro-esophageal varices and porto-
systemic shunts. Ascites and hepatic encephalopathy results from both hepatocellular 
insufficiency and portal-hypertension (2,7). Cirrhosis can alter the relationship between 
serum drug concentration and response. A general principle is that the 
pharmacological response to a drug is a function of its free concentration in blood. An 
increase in the free fraction of some drugs, as a result of a reduced serum albumin 
concentration, is one of the well-known effects of cirrhosis (8).     
 
2.2.2 Alcoholic liver cirrhosis 
Alcoholic cirrhosis is the most common type of cirrhosis encountered in many parts of 
Western Europe, North and South America. With continued alcohol intake and 
destruction of hepatocytes, fibroblasts appear at the site of the injury and deposit 
collagen. With continuing hepatocyte destruction and collagen deposition, the liver 
shrinks in size and acquires a nodular appearance.  
Alcoholic cirrhosis may be clinically silent, and many cases (10 to 40%) are discovered 
incidentally.  
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Although patients with liver cirrhosis may stabilize if drinking is discontinued, over a 
period of years, patients may become emaciated, weak, and chronically jaundiced. 
Ascites and other signs of portal hypertension may become increasingly prominent. 
Progressive renal dysfunction often complicates the terminal phase of the illness (2). 
 
2.2.3 Viral hepatitis 
Hepatitis is an inflammatory condition of the liver that is caused by viruses or 
hepatotoxins. Viral hepatitis is a systemic infection affecting the liver predominantly 
which is in almost all cases caused by one of five viral agents: hepatitis A virus (HAV), 
hepatitis B virus (HBV), hepatitis C virus (HCV), the HBV-associated delta agent or 
hepatitis D virus (HDV) and hepatitis E virus (HEV). Although these agents can be 
distinguished by their molecular and antigenic properties, all types of viral hepatitis 
produce a clinically similar illness. This ranges from asymptomatic and inapparent to 
fulminant and potentially fatal acute infections common to all types, on the one hand, 
and from subclinical persistent infections to rapidly progressive chronic liver disease 
with cirrhosis and even hepatocellular carcinoma (9). Several informative studies 
about the effects of acute viral hepatitis on drug disposition were conducted  (10-13). A 
small number of patients was studied during the time when they had acute viral 
hepatitis and subsequently after recovery. The drugs that were administered included 
phenytoin (10), tolbutamide (11), warfarin (13) and lidocaine (12). The most consistent 
finding was that the plasma protein binding of both phenytoin and tolbutamide was 
reduced during acute hepatitis. No consistent changes were observed in warfarin and 
lidocaine kinetics during acute viral hepatitis. The reason for this difference is not 
clear. In general, drug elimination during acute viral hepatitis is either normal or only 
moderately impaired. Observed changes tend to be variable and related to the extent 
of hepatocellular damage incurring. If the acute hepatitis resolved, drug disposition 
returns to normal. Drug elimination is likely to be impaired most significantly in patients 
who develop chronic hepatitis B virus-related liver disease, but even then only late in 
the evolution of this disease (14).  
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2.2.4 Cholestasis 
Cholestasis is the result of impaired hepatobiliary transport of substances and water 
and may be classified as extra- or intra-hepatic. 
Extra-hepatic cholestasis encompasses conditions with physical obstruction of the bile 
ducts, which is usually located outside the liver. In intra-hepatic cholestasis, there is no 
demonstrable obstruction of the major bile ducts. Causes are e.g. disturbed transport 
or hormones (15). 
Prolonged cholestasis can lead to biliary cirrhosis; the time taken for its development 
varies from months to years.  
Cholestasis causes the retention in the blood of all substances normally excreted in 
the bile. In patients with cholestasis, the clearance of drugs with predominant biliary 
elimination is reduced, serum bile acids are increased.  Drug metabolism in humans 
with cholestatic liver disease has also been predicted to be impaired based on studies 
of antipyrine clearance. An analysis of biopsy samples from 12 patients with 
intrahepatic cholestasis revealed a 30% decrease in microsomal cytochrome P450 
(CYP) activity (16), other studies showed a impaired activity of CYP2E1 and CYP2C 
(17,18). In patients with cholestasis, drugs which are metabolized by CYP’s can 
therefore have a diminished hepatic clearance, potentially needing adjustment of their 
dose. 
 
 
2.3 Drug metabolism and liver disease 
 
2.3.1 Introduction 
Hepatic drug clearance depends on 3 major determinants: the extent of drug binding 
to the blood components, hepatic blood flow and hepatic metabolic activity. Drugs can 
be classified on the grounds of their hepatic extraction ratio: highly extracted drugs – 
the elimination of which is dependent mainly on the blood flow- and poorly extracted 
drugs, the elimination of which is sensitive only to changes in the intrinsic ability of the 
liver to eliminate the drug (intrinsic clearance). In liver disease, drug metabolism can 
be impaired because of  hepatocyte dysfunction and portosystemic shunting. There 
are two types of hepatic metabolic processes. Phase I reactions, involve enzymes 
(mono-oxygenases) that belong to the CYP superfamily, and play a role in the 
hydrolysis, oxidation, dealkylation or reduction of lipophilic molecules reaching the 
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smooth endoplasmic reticulum. Phase II reactions involve conjugation of the parent 
compound or its hydrophilic metabolite with an endogenous molecule (such as 
glucuronic acid, sulphate, an amino acid, acetate or glutathione) rendering it more 
water soluble to assist excretion (8). 
The oxidative metabolism of many drugs has been reported to be markedly impaired in 
patients with chronic liver disease, whereas glucuronide conjugation appears to be 
relatively unaffected (20). However this is not a general phenomenon; the elimination 
of certain drugs that are extensively glucuronidated in humans can be significantly 
impaired in patients with liver cirrhosis. For example, both phenolic and acyl 
glucuronidation pathways of diflunisal – a salicylic acid derivative that is almost entirely 
eliminated from the body by glucuronide and sulphate conjugation- are significantly 
impaired in cirrhosis (21). Furthermore, it has been reported that cirrhosis may exert 
differential effects on the various CYP isoforms (22,23). 
 
2.3.2 Phase I biotransformations 
Oxidative metabolism plays a fundamental role and it is largely catalyzed by enzymes 
belonging to the CYP family (24). Hepatic disease is associated with reduced 
metabolic capacity for most drugs that undergo oxidative biotransformation (25).  
There is direct evidence that there is a change in enzyme concentration and in the 
activity of drug metabolizing enzymes in cirrhosis (26,27), but this is not uniform 
among enzyme classes, since there are differences between the individual CYPs (28). 
As can be seen from the results of two in vitro studies, the CYP1A2 content is 
consistently reduced (by 53 to 71%) in cirrhosis (17,18,29,30). An in vivo study in 
patients with liver cirrhosis has indicated that the clearance of S-mephenytoin, a 
CYP2C19 substrate, was decreased by 63% in patients with mild cirrhosis and by 96% 
in patients with moderate cirrhosis, whereas administration of debrisoquine to these 
patients indicated normal function of CYP2D6 (19). Significant reductions in the 
expression and activity of CYP2E1 and CYP3A have also been found (17,18,29,30). In 
fact, the CYP3A4 pathway responsible for metabolizing lidocaine to its metabolite, 
monoethylglycinexylidine (MEGX) was well preserved in patients with mild and 
moderate chronic hepatitis. However, MEGX levels fell significantly in patients with 
cirrhosis and were well correlated with the clinical stage of cirrhosis (30).  
These studies, in which the clearance of probe drugs has been examined in patients 
with different stages of liver disease, suggest the approximate relationships that are 
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shown in Figure 2.1. However, even when the metabolic pathway for a given drug is 
known, prediction of hepatic drug clearance in individual patients is complicated further 
by the effects of pharmacogenetic variation and drug interactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Schematic diagram showing the effects of various stages of liver disease severity on the 
intrinsic clearance of drugs mediated by representative metabolic pathways (31). Estimates for 
glucuronidation (32), CYP2D6 (19), CYP3A4 (30) and CYP2C19 (19) pathways are based on the 
literature sources indicated in parentheses .  
 
 
2.3.3 Phase II biotransformations 
Data in humans accumulated over many years indicate that, in cirrhosis, drug 
glucuronidation is relatively spared compared with drug oxidation (19,33). In the case 
of conjugation by glucuronidation, there is general agreement that for the majority of 
drugs studied there is minimal impairment. This has led to the hypothesis that 
glucuronidation is relatively unaffected in liver disease (34). In cirrhosis, there is no 
evidence of impairment of the metabolism of temazepam (35,36) and lorazepam (37), 
both substances which are metabolized to the ether glucuronide. Oxazepam (38; 39) 
and morphine (32,40,41) are also metabolized to the ether glucuronide and 
impairment of their metabolism is observed only in severe cirrhosis. However, other 
studies suggest that clearance of other drugs that are predominantly conjugated, to 
instance lamotrigine, can also be reduced in patients with liver cirrhosis (42). Thus, 
16 
Dose adaptation in patients with liver disease  
___________________________________________________________________ 
 
conjugation reactions are less affected by liver cirrhosis than phase I reactions, but 
they are not completely spared. 
 
2.4 Assessment of liver function 
 
Although there are numerous causes of hepatic injury, it appears that the hepatic 
response to injury is a limited one and that the functional consequences are 
determined more by the extent of the injury than by the cause. At this time there is no 
generally available test that can be used to correlate changes in drug absorption and 
disposition with the degree of hepatic impairment. Measurements such as creatinine 
clearance have been used successfully to adjust dosing regimens for drugs eliminated 
primarily by the kidneys.  Similar measures of hepatic function have been proposed 
using endogenous marker substances, which are affected by liver such as bilirubin 
and albumin, or functional measures such as prothrombin time, or the ability of the 
liver to eliminate exogenous marker substrates such as antipyrine (43), indocyanine 
green (43), monoethylglycine-xylidide (MEGX) (28), and galactose (44). Despite 
extensive efforts, no single measure or group of measures has gained widespread 
clinical use to allow estimation in a given patient of the degree of hepatic impairment 
that will affect the pharmacokinetic and/or pharmacodynamic of a drug. The primary 
problem of all these test substrates is the considerable intersubject variability in their 
clearance, both in healthy individuals and in patients with liver disease, usualy leading 
to considerable overlap between these two groups (23,45,46). Another difficulty is 
represented by some confounding factors in the interpretation of the pharmacokinetic 
results of CYP-dependent test substrates, such as influence of genetics, age, gender, 
environmental factors and the concomitant administration of  other drugs that modify 
the activity of the metabolizing enzymes in the liver (8).  
An useful classification scheme that is used most commonly in studies designed to 
formulate drug dosing recommendations for patients with liver disease is the Pugh 
modification of Child’s classification of liver disease severity (Table 2.1) (47). The 
Child-Pugh score is calculated by adding the scores of the five factors and can range 
from 5 to 15. Child-Pugh class is either A (a score of 5 to 6), B (7 to 9), or C (10 and 
above).  
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Table 2.1 Pugh modification of Child’s classification of liver disease severity 
 Assigned score 
 
Assessment parameters 
 
1 point 2 points 3 points 
 
Encephalopathy grade * 
Ascites 
Serum bilirubin, mg/dL 
Serum albumin, g/dL 
Prothrombin time (sec >control) 
 
0 
Absent 
1-2 
< 3.5 
1-4 
 
1 or 2 
Slight 
2-3 
2.8-3.5 
4-10 
 
3 or 4 
Moderate 
>3 
< 2.8 
> 10 
 
 
                                                                           Classification of clinical severity 
    
 
Clinical severity 
 
Mild 
 
Moderate 
 
Severe 
Total points 5-6 7-9 >9 
 
 
 
   
* Encephalopathy grade    
 
Grade 0  normal consciousness, personality, neurological examination, 
electroencephalogram 
Grade 1  restless, sleep disturbed, irritable/agitated, tremor, impaired 
handwriting, 5 cps (characters per second) waves 
Grade 2  lethargic, time-disoriented, inappropriate, asterixis, ataxia, slow triphasic 
waves 
Grade 3  somnolent, stuporous, place-disoriented, hyperactive reflexes, rigidity, 
slower waves 
Grade 4  unrousable coma, no personality/behavior, decerebrate, delta activity 
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Even though clinically useful measures of hepatic function are not generally available 
to predict drug pharmacokinetics and pharmacodynamics, clinical studies in patients 
with hepatic impairment, usually performed during drug development, can provide 
information that may guide initial dosing in patients. However, because patients with 
only mild or moderately severe liver disease usually are enrolled in these studies, 
there is relatively little data from patients with severe liver disease, in whom both 
pharmacokinetic changes and altered pharmacologic response are expected to be 
most pronounced. 
It would therefore be of importance to be able to predict pharmacokinetic and 
pharmacodynamic changes of high extraction drugs in the patients with liver disease 
using routine liver function tests.  
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2.5 Aims of the thesis 
 
The major goal of the thesis was to define strategies for dose adaptation of drugs in 
patients with liver disease.  
 
The dose adaptation of drugs in patients with liver disease is more difficult than in 
patients with renal disease. Ideally, there should be a predictive liver function test that 
allows a more precise dosing in patients with liver disease analogous to the creatinine 
clearance  for patients with renal dysfunction. Unfortunately, no such practical system 
is available as yet.  
 
In order to contribute to this field of research, the following points were elaborated 
during this project: 
 
 
1. Guidelines for dose reduction in patients with liver disease (especially 
cholestasis) for antineoplastic drugs with significant elimination via the bile     
and central nervous agents were established. The antineoplastic drugs and 
central nervous agents available on the market in Switzerland were therefore 
studied in order to provide quantitative advise for dose adaptation in patients 
with liver disease (project 1, 2,3). 
 
 
It has been shown convincingly that there is a linear relationship between the serum 
bile acid concentration and the hepatic shunt index (Ohkubo et al., 1984).   
 
 
2. In order to determine, if the serum bile acid concentration may therefore be a 
suitable parameter to predict proper dosing of drugs with a high hepatic 
extraction in cirrhotic patients, a clinical trial was undertaken to study the 
relationship between the serum bile acid concentration and the 
20 
Dose adaptation in patients with liver disease  
___________________________________________________________________ 
 
bioavailability of propranolol, a high extraction drug, in patients with liver 
cirrhosis (project 4).  
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III Dose adaptation in patients with liver disease 
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Project 1 
 
3.1 General recommendation of dosing in patients with liver 
disease 
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Introduction 
 Dose adaptation of drugs in patients with liver disease is more difficult than in 
patients with renal disease, since there is not yet an endogenous marker for hepatic 
clearance established, which could be used as a guide for dosing of drugs. In order to 
estimate the kinetic behavior of a given drug in patients with liver cirrhosis, drugs can 
be grouped according to hepatic extraction. For drugs with a high hepatic extraction 
(or low bioavailability) in subjects with normal hepatic function, bioavailability increases 
and hepatic clearance decreases in cirrhotic patients. Therefore, if such a drug is 
administered orally, the initial dose has to be reduced in cirrhotic patients according to 
hepatic extraction. Furthermore, the maintenance dose of such drugs has to be 
reduced irrespective of the way of administration, according to kinetic studies in 
patients with liver disease and taking into account effect and toxicity of such drugs. For 
drugs with a low hepatic extraction, bioavailability is not affacted by liver disease, but 
hepatic clearance may be reduced in cirrhotic patients. In this case, only the 
maintenance dose has to be reduced according to the estimated decrease in the 
activity of the enzymes metabolizing this drug in cirrhotic patients. Many drugs are 
between these two extremes and have an intermediate hepatic extraction. For these 
drugs, initial oral doses should be chosen in the low range of normal in cirrhotic 
patients, and maintenance doses should be reduced as described for high extraction 
drugs. In patients with cholestasis, the clearance of drugs with predominant biliary 
elimination is reduced, necessitating dose reduction according to the toxicity profile of 
the drug considered. Guidelines for dose reduction in patients with cholestasis exist for 
most antineoplastic drugs with significant elimination via the bile, but are mostly 
lacking for other drugs with predominant biliary elimination. For the clinicians it is 
important to realize that not only drugs eliminated primarily by the liver, but also those 
with renal elimination may have to be adapted in patients with liver disease. Patients 
with liver cirrhosis often have an impaired renal function, despite a normal serum 
creatinine concentration. In cirrhotic patients, creatinine clearance should therefore be 
measured or estimated routinely, in order to have a guideline for dosing of drugs with 
predominant renal elimination. Since the creatinine clearance tends to overestimate 
glomerular filtration in these patients due to increased secretion of creatinine, the dose 
of a given drug may still be too high after adaptation to creatinine clearance. The 
clinical monitoring for effects and toxicity of a drug is therefore important in patients 
with liver cirrhosis also for drugs with predominant renal elimination. 
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 Besides the mentioned kinetic changes, the effect of some drugs is altered in 
cirrhotic patients also due to changes in their dynamics. Examples of such drugs 
include opiates, benzodiazepines, nonsteroidal antiinflammatory drugs and diuretics. 
Such drugs may exhibit unusual adverse effects which clinicians should be aware of, if 
they want to use these drugs safely in cirrhotic patients. 
 In this paper, we discuss the kinetic and dynamic changes in patients with liver 
disease of the most important drugs used in these patients. It is important to realize, 
however, that the predictions for dose adaptation remain general and cannot replace 
accurate clinical monitoring of patients with liver disease treated with drugs owing a 
narrow therapeutic range. 
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An alcoholic patient with physical signs of liver cirrhosis enters the hospital 
because of a seizure. After intravenous temazepam for the seizure, he is treated with 
oral clomethiazole as a prophylaxis for delirium tremens. After the first dose of 
clomethiazole, he experiences hypoventilation resulting in global respiratory failure, 
eventually necessitating intubation and artificial ventilation. No further doses of 
clomethiazole are administered and sedation is achieved with intravenous midazolam. 
After extubation, prophylaxis for delirium tremens is performed with oral oxazepam 
which is well tolerated by the patient and can be withdrawn gradually after 5 days. 
The present article deals with the kinetic and dynamic changes of drugs in patients 
with chronic liver disease and should help avoiding situations as described above. 
 
Changes in pharmacokinetics 
Chronic liver disease, in particular liver cirrhosis, can modulate many factors 
determining the behavior of drugs in the body. The most important alterations in the 
kinetic behavior of drugs will be discussed in the following sections. 
 
Drug absorption 
Since patients with liver cirrhosis are frequently affected by gastritis and ulcers of 
the upper gastrointestinal tract (1, 2), absorption of orally administered drugs may be 
impaired. However, the amount of drug absorbed is generally not decreased in 
cirrhotic patients (3), but the absorption of orally administered drugs may be delayed. 
Delayed absorption, which is not explained by gastritis or ulcers, has for instance been 
shown for furosemide in cirrhotics (4, 5), but not for torasemide, another loop diuretic 
used in patients with ascites (6). The studies with furosemide suggested that impaired 
gastrointestinal motility may be a mechanism for delayed drug absorption in cirrhotic 
patients. Cirrhotic patients have indeed delayed gastric emptying (7, 8), possibly 
resulting from a decreased action of gastrointestinal hormones such as secretin, 
glucagon, cholecystokinin or motilin (9). Prokinetic agents such as erythromycin or 
cisapride, which act differently as compared to the gastrointestinal hormones 
mentioned above, can speed up gastric emptying in cirrhotic patients (10, 11), 
indicating that the reasons for impaired gastric emptying are functional and not organic 
in nature. Impaired gastric emptying may be relevant for preparations with delayed 
drug release, since the action of these drugs may be delayed further in this group of 
patients and may therefore be unpredictable. 
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Drug distribution 
 In patients with liver cirrhosis, who have edema and/or ascites, the volume of 
distribution of hydrophilic drugs is increased. As a consequence, the loading dose of 
hydrophilic drugs may have to be increased in cirrhotic patients, when a rapid action is 
needed (e.g. for beta-lactam antibiotics or for digoxin). In cirrhotics with ascites, initial 
dosing of such drugs should therefore be performed according to body weight, if a 
rapid and complete effect of the drug is desired. On the other hand, an increase in the 
volume of distribution is associated with an increase in the elimination half-life of such 
drugs (3). A slower elimination velocity in cirrhotics with ascites has indeed been 
demonstrated for furosemide (4, 5) and for beta-lactam antibiotics such as ceftazidime 
or cefprozil (12, 13). However, the influence of edema and/or ascites on the 
elimination velocity of hydrophilic drugs used in this group of patients appears to be 
small and has therefore usually no practical consequences (5). Since many hydrophilic 
drugs are excreted non-metabolized primarily by the kidney, renal function has also to 
be taken into consideration for such drugs. This aspect is discussed below (see 
section “renal clearance”). 
 
Hepatic clearance 
While the creatinine clearance can be used for dose adjustments in case of 
impaired renal function (14), there is no naturally occurring substance which can be 
used to estimate the hepatic clearance of drugs (Clhep). The Child-Pugh classification 
is used widely for the assessment of the prognosis in patients with liver cirrhosis (15), 
but has not been shown to be useful to predict the kinetic and/or dynamic behaviour of 
drugs (16). Regarding the lack of endogenous markers for hepatic clearance of drugs, 
exogenous compounds might serve as an alternative. As shown in Table 1, the 
kinetics of several substances have been investigated, but none of them has gained 
wide acceptance in the prediction of drug kinetics in patients with liver disease. The 
most important reason for this observation may be the complexity of the hepatic 
metabolism of drugs. As discussed in the following sections, drugs can be metabolized 
by different enzymes (e.g. different cytochrome P450 isoenzymes [CYP] and different 
enzymes for drug conjugation) and can be excreted by the bile. One probe drug or 
exogenous substance is therefore most probably not sufficient to predict the kinetics of 
all drugs used in cirrhotic patients.  
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Table 1. Substances investigated for quantification of liver function/liver metabolism 
Substance (application) E 
(%) 
Metabolism    Clinical use Reference
Serum bile acids 
(endogenous) 
>90  Hydroxylation and
conjugation, enterohepatic 
cycling 
May be useful for estimation of porto-systemic shunt (20) 
Indocyanine green (i.v.) 90 Biliary excretion Estimation of hepatic blood flow (108) 
Galactose (i.v.) 95 Rate-limiting step is 
phosphorylation 
First-order elimination reflects “functional hepatic 
capacity”. Extrahepatic metabolism is problematic 
(109) 
Sorbitol (i.v.) >80  Estimation of hepatic blood flow (110) 
Lidocaine (i.v.) 80 CYP3A  (111) 
d-Propoxyphene (p.o.) 70 CYP3A Ratio norpropoxyphene/d-propoxyphene may be 
useful to estimate proto-systemic shunt 
(112) 
Erythromycin (i.v.) 30 CYP3A CO2 exhalation is used as a marker of CYP3A 
activity 
(113) 
Antipyrine (p.o.) 5 Different CYPs Reflects activity of different CYPs (114) 
Aminopyrine (i.v.) <30 Different CYPs CO2 exhalation is used as a marker of general CYP 
activity 
(115) 
Caffeine (p.o., i.v.) <30 CYP1A2, N-acetyltransferase 
type 2 (NAT2) 
CO2 exhalation measures activity of CYP1A2 (116) 
E: hepatic extraction 
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A cocktail of probe drugs could be used (16), but analysis of the substances applied 
would be time consuming and might therefore not be helpful in most clinical 
situations. 
Another possibility to predict the kinetic behavior of drugs and to avoid dose-
dependent drug toxicity in patients with liver disease is to classify drugs according to 
their handling by the liver. In order to understand the basis and consequences of this 
classification, hepatic extraction (E) and hepatic clearance (Clhep) of drugs have to be 
defined. Clhep can be expressed for a given drug as the product of the blood flow 
across the liver (Q) and the extraction of this drug (E) during its first passage across 
the liver: 
 
in
outin
hep C
CCQEQlC −×  (1) 
 to the hepatic outflow concentration), E can also 
e expressed as described in (3): 
 
=×=
 
Cin is the concentration of a drug in the portal and Cout in the liver veins. According to 
the venous equilibrium model (the concentration of a substance in the liver is 
assumed to be uniform and equal
b
)( iu
iu
ClfQ
ClfE ×+
×=   (2) 
e liver to metabolize a certain 
. 
sing this expression for E, Clhep can be written as: 
 
 
Cli is the intrinsic hepatic clearance and fu the fraction of a drug not bound to serum 
proteins (free fraction). Cli reflects the capacity of th
drug independently of the blood flow across the liver
U
)( iu
hep ClfQ ×+
)( iu ClfQCl ××=  (3) 
 
 For drugs with a high hepatic extraction, (fu x Cli) is >> Q and Clhep is 
approximating Q. These drugs are therefore called “flow-limited” or “high extraction”. 
Alternatively, for drugs with a low extraction, (fu x Cli) is << Q and Clhep is 
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ainly determined by the capacity of the liver to metabolize such 
rugs. Many drugs are in between these two extremes, showing properties of both 
High extraction drugs undergo a high extraction during the first passage across 
e liver (≥ 60%), and have therefore a bioavailability of ≤ 40% (see Figure 1).  
 
 
on can have intra- and extrahepatic porto-
stemic shunts, preventing the drugs from reaching the hepatocytes and from being metabolized. Furthermore, important drug-
mes have a reduced activity in cirrhotic livers. These are the two main factors being responsible for an 
crease in the bioavailability of high extraction drugs in cirrhotics (adapted from 17). 
 
f portal blood is not cleared by hepatocytes, potentially leading to a significant 
crease in the bioavailability of high extraction drugs administered orally (Figure 2).  
approximating (fu x Cli). These drugs are called “enzyme-limited” or “low extraction”, 
and their Clhep is m
d
groups (Table 2). 
 
High extraction drugs 
 
th
Bioavailability
• Definition: fraction of drug administered reaching the
systemic circulation
• Significance: dosage of drugs with a high hepatic extraction
Dissolved
drugDrug in
tablet
Undissolved
drug
Non-absorbed
drug
Absorbed
drug Bioavailable
dose fraction
(F)
Drug in portal
vein
Contents of stomach
and intestine
Gut wall Liver
Loss during
first liver passage
Bioavailability
losses (1-F)
Figure 1. Effect of liver cirrhosis on the bioavailability of high extraction drugs. After oral administration, only a fraction of a drug 
reaches the systemic circulation. Most of the drug not reaching systemic circulation is either not absorbed or metabolized during 
the first passage across the liver. Patients with liver cirrhosis and/or portal hypertensi
sy
metabolizing enzy
in
 
 
Since the blood flow across the liver is typically decreased in patients with liver 
cirrhosis (18, 19), the elimination of high extraction drugs is retarded in comparison to 
patients with normal liver function. In addition to decreased blood flow across the 
liver, patients with liver cirrhosis frequently have porto-systemic shunts, preventing 
the exposure of hepatocytes to drugs (3, 20). As a consequence, a variable amount
o
in
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traction, the maximal plasma concentration and bioavailability increase, and elimination is slowed. For drugs with a low 
ilability of such drugs in 
irrhotic patients. Accordingly, initial and first maintenance doses should be reduced 
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gure 2. Effect of liver cirrhosis on the kinetics of drugs with high or low hepatic extraction. For drugs with a high hepatiFi
ex
hepatic extraction, only elimination is slowed. Accordingly, for drugs with a high hepatic extraction, both initial and maintenance 
dose have to be reduced, whereas for drugs with a low hepatic extraction, only the maintenance dose has to be adapted (21). 
 
For example, the bioavailability of clomethiazole is 10% in healthy persons and may 
increase to 100% in patients with liver cirrhosis (22). This 90% increase in 
bioavailability is associated with a 10-fold higher drug exposure, eventually leading to 
adverse drug reactions. In Table 3, the observed increase in the bioavailability of 
some drugs in patients with liver cirrhosis as compared to healthy persons is listed. 
Therefore, for high extraction drugs administered orally, both the initial and the 
maintenance doses have to be reduced in patients with liver cirrhosis. The extent of 
this reduction cannot be predicted accurately, however, since neither the porto-
systemic shunt nor the hepatic blood flow are usually known in a given patient. A 
conservative approach is to assume a 100% oral bioava
c
taking into a  
 
   
100
ilitybioavailabdosenormaldoseducedRe ×=  (4) 
“Normal dose” is the starting dose in a patient without liver disease and 
“bioavailability” the percentage of a drug ingested orally reaching the systemic 
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patic blood flow using Doppler 
sonog
may therefore be helpful 
r initial dosing of high extraction drugs. However, to the best of our knowledge, 
currently no studies are available addressing this question. 
 
by Ohkubo et al., there 
 a linear relationship between these two variables (Ohkubo). The determination of the serum bile acid concentration may 
oper dosing of drugs with a high hepatic extraction in cirrhotic patients. 
 
circulation in a healthy person. The maintenance dose should be adjusted taking into 
account the desired pharmacological effect and toxicity of the drug used. Using this 
approach, a possible reduction in drug clearance due to impaired hepatic blood flow 
is not considered, but may be neglectable compared to the assumed increase in 
bioavailability. On the other hand, for high extraction drugs administered 
intravenously, a normal initial dose can be administered and the maintenance doses 
have to be reduced according to hepatic clearance, which is reflected by blood flow 
across the liver. Theoretically, assessment of the he
raphy might be helpful in this situation, but to best of our knowledge, clinical 
studies supporting this hypothesis are so far lacking. 
As shown in Fig. 3, a linear relationship has been described between the 
serum bile acid concentration and the extent of porto-systemic shunting in patients 
with liver cirrhosis (20). The serum bile acid concentration 
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Figure 3. Relationship between serum bile acid concentration and the hepatic shunt index. As described 
is
therefore be suitable to predict pr
Low extraction drugs 
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 enzymes (CYPs and 
sms affecting CYP activity and/or protein 
con
trated for 
zido
 Low extraction drugs undergo a low extraction during the first passage across 
the liver (≤ 30%), and their Clhep is mainly determined by the product fu x Cli. These 
drugs have a bioavailability which is ≥ 70% (unless dissolution in the gut and/or 
intestinal absorption are incomplete). Important examples of such drugs are listed in 
Table 2. As shown in Figure 2, their bioavailability is not affected grossly by liver 
cirrhosis but their clearance may be reduced, depending on their hepatic metabolism 
(reflecting Cli) and binding to albumin (fu). Accordingly, the maintenance dose of 
these drugs should be reduced, whereas therapy can be started with a normal dose. 
Similar to high extraction drugs, it is impossible to predict precisely by how much the 
maintenance dose of such drugs has to be reduced. Studies assessing the protein 
content and/or the activity of important drug metabolizing
conjugation reactions) in livers from cirrhotic patients show that enzyme activities and 
protein content are reduced with increasing disease severity as expressed by the 
Child score, but with a large interindividual variability (23-25). 
 The reduction in Cli associated with liver cirrhosis appears not only to be a 
function of the Child score, but also of the metabolic reaction involved. Conjugation 
reactions such as glycosylation and transfer of sulfate groups (phase II reactions) are 
considered to be affected to a lesser extent by liver cirrhosis than CYP-associated 
reactions (phase I reactions) (3). For instance, the clearance of oxazepam (26) or 
temazepam (27), two benzodiazepines which are only conjugated, are not reduced in 
patients with liver cirrhosis, whereas the clearance of diazepam (28, 29) or 
midazolam (30), both undergoing phase I and phase II reactions, is decreased. As 
discussed above, the decrease in CYP activity and/or protein content is highly 
variable in cirrhotic patients (23, 25, 31-34). This variability can be explained at least 
to some extent by the different mechani
tent, such as impaired transcription for CYP 1A, 3A and 2C (31, 34), altered post-
translational modification for CYP 2E1 (31) or increased sensitivity to cholestasis as 
described for CYP 2E1 and 2C9 (23, 31). 
Several studies have shown that also conjugation reactions can be impaired in 
patients with liver cirrhosis. Reduced glucuronidation has been demons
vudine (35, 36), diflunisal (37), morphine (38, 39), mycophenolate (40), 
lormetazepam (41) and lamotrigin (42). The activity of sulfotransferases was also 
found to be reduced, whereas sulfatase activity appears to be spared (24). 
33 
Dose adaptation in patients with liver disease 
___________________________________________________________________ 
 
 
cological effect and toxicity. For Child class C patients, we 
recommend the use of drugs whose safety has been demonstrated in clinical trials 
ase or for which therapeutic drug 
mon
ed in cirrhotics. 
This argumentation is only valid, however, when the total drug concentration (free 
and bound to albumin in this case) is considered. For the free concentration only, fu 
would equal 1 and Clhep for low extraction drugs would approach Cli. 
drugs with a high binding to albumin is decreased when their free concentration is in 
Considering the large interindividual variability of the activity of drug metabolizing 
enzymes in cirrhotic patients, it is difficult to give general rules for dosing low 
extraction drugs in this group of patients. For drugs which are new on the market, 
kinetic studies in patients with impaired hepatic function due to liver cirrhosis are 
requested by the drug agencies for approval. Dosing recommendations for most of 
these drugs can therefore be found in the physician’s desk reference or similar 
publications, but usually only for patients with Child class A or B, but not C (43). 
Despite the finding that conjugation reactions are also impaired in cirrhotic patients, it 
appears to be justified to recommend preferentially drugs which are mainly 
eliminated by conjugation, since only one metabolic pathway is involved. If no studies 
are available, we recommend using a maintenance dose of 50% of normal in patients 
with Child class A and of 25% in patients of Child class B and to adjust this dose 
according to the pharma
and/or whose kinetics is not affected by liver dise
itoring is available. 
 
Low extraction drugs with high binding to albumin 
Low extraction drugs with a high binding to albumin (≥90%) may represent an 
exception from the rule that hepatic clearance is mainly determined by the activity of 
drug metabolizing enzymes (Cli). In patients with reduced serum albumin 
concentrations, a frequent finding in patients with liver cirrhosis, the free fraction (and 
possibly also the free concentration) of such drugs is increased. Such drugs may 
therefore be metabolized more rapidly in cirrhotic patients. According to equation 3, 
Clhep of such drugs may remain unchanged or may even be increas
 
 
 
Importantly, in patients with hypalbuminemia, the total plasma concentration of 
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r to avoid toxicity by overdosing, free drug levels 
should be determined and used to guide therapy of such drugs in cirrhotic patients, 
e.g. for phenyto
 
 albumin concentration to 33% of normal (binding capacity 33%), the free 
ncentration remains 10, the free fraction increases to 25% and the total serum concentration of the drug drops to 40. When 
ason for this finding should be sought and the free drug concentration should 
 
normal and maintenance doses should be adjusted as described above for low 
extraction drugs (Compate Table 4). Examples of such drugs are also listed in Table 
2. 
the normal range (due to a decrease in drug concentration bound to albumin, see 
Fig. 4 for explanation). In orde
in or valproate. 
 
Figure 4. Effect of the serum albumin concentration on the total serum concentration and free fraction of drugs with high 
albumin binding. The free concentration of a drug with high binding to albumin (≥90% at a normal serum albumin concentration) 
is kept constant at 10. Under normal conditions (normal serum albumin, binding capacity 100%), 90% of the drug is albumin-
bound and 10% is free. The total plasma concentration is 100. When the serum albumin concentration is lowered by one third 
(binding capacity 67%), the free concentration remains 10. The free fraction increases to 14% and the total serum concentration 
decreases to 70. After lowering the serum
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the free fraction of a drug is above normal, the re
be used for therapeutic drug monitoring (21). 
Intermediate extraction drugs 
The hepatic clearance of drugs with a hepatic extraction between 30% and 60% 
(”intermediate extraction drugs”) is determined by both Q and (fu x Cli). Since the 
bioavailability of these drugs is 40% or more, the influence of porto-systemic shunts 
is less pronounced as compared to “high extraction” drugs (compare Table 3). In 
general, Clhep of these drugs is reduced, necessitating adjustment of their 
maintenance dose. Treatment should be started with an initial dose in the low range 
of 
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 Table 2. Classification of drugs metabolized by the liver according to pharmacokinetic characteristics 
 
 
Hepatic 
extraction (E) 
 
 
Effect of porto-
systemic shunts on 
bioavailability 
 
Examples of drugs 
 
 
 
  
Low extraction/low protein binding(<90%) 
  
 
<0.30  
  
  
Not relevant Benzodiazepines: alprazolam, bromazepam, clobazam, flunitrazepam, flurazepam, nitrazepam, triazolam; 
Other hypnotics and sedatives: methaqualone, zopiclone; Antidepressants: citalopram, fluoxetine, 
fluvoxamine, moclobemide; Antipsychotics: risperidone; Antiepileptics: carbamazepine, ethosuximide, 
lamotrigine, levetiracetam, phenobarbital, primidone, topiramate; Anti-Parkinson drugs: pramipexole; 
Antineoplastic and immunosuppressive agents: cyclophosphamide, hydroxycarbamide, letrozol, melphalane, 
temozolomide; Antibacterial drugs: doxycycline, metronidazole; Tuberculostatic drugs: isoniazid; 
Corticosteroids: methylprednisone, prednisone; Analgesics: paracetamol; Bronchodilators: theophylline; 
Antihistamines: diphenhydramine; Antiemetics: metoclopramide 
 
Low extraction/high protein binding(>90%)  
 
 
<0.30 Not relevant Benzodiazepines: chlordiazepoxide, diazepam, lorazepam, oxazepam, temazepam; Other hypnotics and 
sedatives: zolpidem; Antidepressants: maprotiline, trazodone; Antipsychotics: sertindole; Antiepileptics: 
phenytoin, tiagabine, valproate; Anti-Parkinson drugs: tolcapone; Analgesics: methadone; Antineoplastic and 
immunosuppressive agents: chlorambucil, mycophenolate; Antibacterial drugs: ceftriaxone, clarithromycin, 
clindamycin; Tuberculostatic  drugs: rifampicin; Corticosteroids: prednisolone; Antidiabetic drugs: glipizide, 
tolbutamide; Antihyperlipidemic drugs: clofibrate, gemfibrozil; Antiulcer drugs: lansoprazole; Anticoagulants: 
phenprocoumon; Antiestrogens: tamoxifen, toremifen; Antiandrogens: cyproterone 
 
 
 
 
 
 
 
 
 
  
 
 
Hepatic 
extraction (E) 
 
 
Effect of porto-
systemic shunts on 
bioavailability 
 
Examples of drugs 
 
 
Intermediate extraction 
   
  
   
  
0.30 - 0.60 May clinically be 
relevant 
Benzodiazepines: midazolam (0.31); Antidepressants: amitriptyline (0.6), clomipramine (0.5), mirtazapin 
(0.43), nortriptyline (0.34), paroxetine (0.38); Antipsychotics: amisulpride (0.52), clozapine (0.45), 
fluphenazine (0.47), haloperidol (0.55), olanzapine (0.4), zuclopenthixol (0.51); Psychostimulants: 
methylphenidate (0.54); Anti-Parkinson drugs: entacapone (0.48); Analgesics: codeine (0.52); Antineoplastic 
and immunosuppressive agents: azathioprin (0.4), etoposide (0.48); Antibacterial drugs: ciprofloxacin (0.4), 
erythromycin (0.38); Antifungal agents: itraconazole (0.4); Antiarrhythmics and anesthetic agents: 
Amiodarone (0.54), lidocaine (0.4); Beta-adrenergic blockers: carvedilol (0.41); Calcium channel blockers: 
diltiazem (0.55), felodipine (0.56), nifedipine (0.33); Antihyperlipidemic drugs: atorvastatin (0.55), pravastatin 
(0.32), simvastatin (0.35); );  Antiulcer drugs: omeprazole (0.35), ranitidine (0.48); Progestogens: 
medroxyprogesterone (0.55); Prolactine inhibitors: lisuride (0.53); 
 
High extraction 
>0.60 Clinically relevant Hypnosedatives, antianxiety drugs: buspirone (0.96), clomethiazol (0.9), zaleplon (0.73); 
Antidepressants: dibenzepine (0.75), doxepin (0.72), imipramine (0.61), mianserine (0.67), sertraline (1), 
trimipramine (0.67), venlafaxine (0.73); Antipsychotics: chlorpromazine (0.68), chlorprothixen (n/a), 
flupenthixol (n/a), quetiapin (0.91), perphenazine (0.8), sulpiride (n/a); Anticholinesterases: tacrine (n/a); Anti-
Parkinson drugs: bromocriptine (0.60), levodopa (n/a), selegiline (1), biperiden (n/a); Analgesics: morphine 
(0.76), pentazocine (0.8), propoxyphene (n/a); Antineoplastic and immunosuppressive agents: ciclosporine 
(0.72), fluorouracil (0.71), idarubicin (1), mercaptopurine (0.80), sirolimus (n/a), tacrolimus (0.75), vinorelbine 
(n/a); Beta-adrenergic blockers: labetolol (n/a), metoprolol (0.67), propranolol (0.75); Calcium channel 
blockers: nicardipine (0.82), verapamil (0.70); Antianginal agents: isosorbide dinitrate (0.78), nitroglycerine 
(1); Antihyperlipidemic drugs: fluvastatin (0.71), lovastatin (0.95); Prokinetic drugs: cisapride (0.65); 
Antimigraine agents: sumatriptan (0.82); Antihelmintics: praziquantel (n/a); Antihistamines: promethazine 
(0.76); Phosphodiesterase inihibitors: sildenafil (0.62) 
 
 
In brackets are the values for hepatic extraction (E), calculated as described in equation (5), or as estimated from bioavailability;  n/a: value not available. 
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Problems in the classification of drugs according to hepatic extraction 
 In order to compare the prediction of the kinetic behavior as estimated using 
hepatic extraction with kinetic studies performed in patients with liver cirrhosis, we 
recently studied the antineoplastic agents on the market in Switzerland (44). Of the 
64 antineoplastic drugs identified, the available kinetic data of only 49 were sufficient 
to allow a classification according to hepatic extraction. Values for hepatic extraction 
(E) are published only for a minority of them, however. E had therefore to be 
estimated based on the bioavailability or by using the following equation (derived 
from equation 1 and from the definition of Q0): 
 
      
Q
ClQ
E sys
×= 0      (5) 
. The values for Q0 and for Clsys 
refore used both approaches 
 
Q0 is the fraction of a drug metabolized by the liver (Clhep = Q0 x Clsys), Clsys the 
systemic clearance of this drug and Q liver blood flow
can be obtained from different sources (43, 45, 46). 
 Both approaches, using oral bioavailabilitay as a surrogate for hepatic extraction 
or calculation of hepatic extraction using equation 5, have their limitations. Oral 
bioavailability can be less than 100% not only due to a first liver pass effect but also 
due to incomplete dissolution of tablets in the gut, incomplete absorption in the gut 
and/or degradation in the enterocytes (compare Fig. 1). Enterocytes contain 
CYP3A4, which can metabolize CYP3A4 substrates such as midazolam (47) or 
cyclosporine (48), before they reach the liver. They also contain P-glycoprotein, 
which can transport drugs from the enterocytes back to the intestine, as shown for 
digoxin (49). On the other hand, oral bioavailability can be measured directly in 
humans, which is difficult for hepatic extraction. A weakness of the calculation of 
hepatic extraction using equation 5 is that the systemic clearance of a drug is 
measured usually in plasma and not in blood. For substances with a different 
concentration in plasma and in erythrocytes (e.g. drugs which are trapped in 
erythrocytes such as ribavirin), the results of this approach will therefore be wrong. In 
our study concerning antineoplastic drugs (44), we the
and detected an acceptable agreement between them. 
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ibit 
ose-dependent, systemic toxicity which may be accentuated in patients with 
ease. Similar studies for other drug classes are so far lacking. 
 
ics (55, 62). The 
seru
nal elimination 
For 17 of the 64 antineoplastic drugs studied, kinetic studies had been reported in 
patients with impaired liver function, most of them in patients with cholestasis due to 
hepatic metastases. Kinetic studies in patients with impaired hepatic function due to 
liver cirrhosis have been published for only 4 of the 64 antineoplastic drugs identified. 
 Our study reveals that there are currently not enough data for safe use of 
antineoplastic drugs in patients with liver disease. While the kinetics of drugs with 
biliary excretion has been studied quite well in patients with cholestasis, there are 
many antineoplastic drugs for which hepatic extraction and/or metabolism are not 
known to a satisfactory extent. This is surprising, since most of these drugs exh
d
preexisting liver dis
Renal clearance 
It is well established that cirrhotics have reduced effective renal plasma flow and 
glomerular filtration rates, also in the absence of ascites (50-52). On the other hand, 
several studies have shown that patients with liver cirrhosis tend to have low serum 
creatinine concentrations (53-55), indicating that glomerular filtration rates cannot be 
estimated using the serum creatinine concentration. The low serum creatinine 
concentration in cirrhotics can be explained by impaired synthesis of creatin and a 
reduced skeletal muscle mass (55). For the same reasons, calculation of the 
creatinine clearance using the Cockcroft formula (54) may overestimate glomerular 
filtration (57-59). Theoretically, the determination of the creatinine clearance based 
on urinary excretion of creatinine should yield accurate results, even in patients with 
impaired creatin synthesis and/or reduced muscular mass. While one study has 
shown that the measured creatinine clearance reflects glomerular filtration in cirrhosis 
accurately (57), other studies indicate that glomerular filtration is overestimated, in 
particular in patients with reduced glomerular filtration rates (54, 59-61). This finding 
has been explained by an increased secretion of creatinine in cirrhot
m cystatin C concentration, another endogenous marker for renal function, may 
reflect glomerular filtration more accurately in cirrhotic patients (54). 
Since the glomerular filtration rate is usually decreased in patients with liver 
cirrhosis, also drugs with mainly renal elimination and a narrow therapeutic range 
should be dosed with caution in this group of patients. A decreased re
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in c
ings has been demonstrated among others for 
etoclopramide, which reveals an over-proportional reduction in total body clearance 
h renal failure (72). 
3). In patients with cholestasis, drugs 
atients are performed also with other drugs exhibiting a predominant 
iliary excretion and/or enterohepatic cycling, e.g. phenprocoumon, mycophenolate 
nd others. 
 
irrhotic patients has been shown for several drugs, among them cefpiramide (63), 
cilazapril (64), fluconazole (65), lithium (66, 67) and ofloxazin (68, 69). 
Interestingly, in patients with renal failure, CYP-associated drug metabolism has 
been shown to decrease (70), in particular for CYP 2D6. Similar observations have 
been reported for rats, where several CYPs show a reduced expression (71). The 
clinical relevance of these find
m
in patients wit
 
Cholestasis 
 As mentioned in a preceding section, cholestasis impairs the activity of several 
CYPs, for instance CYP2C (31) and 2E1 (2
which are metabolized by CYPs can therefore have a diminished hepatic clearance, 
potentially needing adjustment of their dose. 
 While it is conceivable that drugs with predominant biliary elimination may have a 
decreased clearance in patients with cholestasis, it is surprising that kinetic studies 
exist for only few of such drugs. As discussed, kinetics and dynamics have been 
investigated in cholestatic patients particularly for antineoplastic agents, among them 
vinca alkaloids (73, 74), doxorubicin and derivatives (75-77) and dactinomycin (78). 
These studies resulted in recommendations for dose adjustment according to the 
serum bilirubin concentration and/or activity of alkaline phosphatase (78). It remains 
unclear, however, whether these two parameters are the best markers for dose 
adjustment in cholestasis or whether other enzyme activities and/or the serum bile 
acid concentration would be more accurate. Considering the impact of cholestasis on 
kinetics and dynamics of antineoplastic drugs (44), it is crucial that kinetic studies in 
cholestatic p
b
a
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 the dose (idiosyncratic or type B reactions) may not be 
for dose adaptation in patients with liver 
creased hepatic toxicity in alcoholics may 
), certain preexisting liver diseases may also be risk 
ctors for type B reactions. 
 
Liver disease and adverse effects of drugs 
 Dose adaptation in patients with liver disease aims at reducing dose-dependent 
adverse effects of drugs (type A reactions). In contrast to type A reactions, adverse 
drug reactions independent of
avoidable by dose reduction. 
 Considering systemic adverse effects, the usefulness of dose adaptation in 
patients with liver disease is most clearly evident for antineoplastic agents, which are 
often associated with dose-dependent, systemic adverse effects. For some of them, 
as discussed above, recommendations 
disease have been established (44, 78).  
 Regarding adverse effects affecting the liver itself, most such events are type B 
reactions (79). Only few drugs reveal a “dose-dependent hepatic toxicity”, among 
them methotrexate (80), acetaminophen (81, 82) and isoniazid (83, 84). Patients with 
preexisting liver disease, in particular alcoholics, who are treated with on of these 
drugs may therefore be at a higher risk for hepatic toxicity. For methotrexate, the 
mechanism for increased toxicity in alcoholics is not completely clarified, but may be 
due to the presence of two different mechanisms associated with liver fibrosis and 
possibly cirrhosis (80). For acetaminophen, an important factor is induction of 
CYP2E1 by alcohol, increasing the generation of N-acetyl-p-benzoquinone imine, a 
toxic metabolite (81, 82). For isoniazid, both preexisting liver cirrhosis and ingestion 
of too much alcohol appear to be risk factors for hepatic toxicity (83, 84). Since 
isoniazid is metabolized also by CYP2E1, in
be due to induction of CYP2E1 by alcohol. 
 The occurrence of hepatic microvesicular steatosis associated with the ingestion 
of drugs is a typical type B reaction. Microvesicular steatosis is a life-threatening 
condition caused by impaired β-oxidation of liver mitochondria (85, 86) and has been 
described in patients treated with valproic acid (87), analgetic doses of aspirin (87), 
certain opiates (88) or the uricosuricum benzbromarone (89). Since microvesicular 
steatosis is considered to be more frequent in patients with a preexisting 
mitochondrial disorder, e.g. a defect in β-oxidation or in the urea cycle, or a 
mitochondrial cytopathy (90
fa
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Pharmacodynamics 
 Patients with liver cirrhosis have been reported to be more sensitive to central 
adverse effects of morphine (38, 91) and benzodiazepines (92, 93), and to renal 
adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) (92), whereas the 
sensitivity to the natriuretic effect of loop diuretics was found to be reduced (3). 
 An early study described precipitation of hepatic encephalopathy after 
intravenous administration of morphine in patients with decompensated liver cirrhosis 
at low doses (8 mg i.v.) (91). In contrast, in a more recent study, none of 6 cirrhotics 
developed encephalopathy after i.v. administration of higher doses of morphine (95). 
Since several studies have shown that the oral bioavailability of morphine is 
increased and its elimination is impaired (39, 96, 97), morphine should be used with 
caution in cirrhotics, irrespective of the presence of an increased sensitivity to central 
adverse effects. 
 Patients with liver cirrhosis appear to be extremely sensitive to the sedative 
effects of benzodiazepines (92, 93). In cirrhotics, benzodiazepines may induce 
encephalopathy which can be reversed by the administration of benzodiazepine 
antagonists (98). While impaired hepatic metabolism has been demonstrated in 
cirrhotics for midazolam (92) and diazepam (28, 29, 93, 99), no such changes were 
detected for oxazepam (26), temazepam (27) or triazolam (100), suggesting that 
increased sedation of benzodiazepines in cirrhotics is partially due to 
pharmacodynamic alterations. 
 Despite their disadvantages, benzodiazepines are difficult to replace as 
sedatives in cirrhotic patients. Neuroleptics undergo extensive hepatic metabolism 
and can also precipitate encephalopathy. Contrary to the benzodiazepines, they have 
the disadvantage that they cannot be antagonized. Clomethiazole, a sedative used 
widely for the prevention of delirium tremens in Europe, has a high first liver pass 
effect with an unpredictable oral bioavailability in cirrhotics (compare Table 3). As 
illustrated in the first section of this article, an unexpectedly high bioavailability can 
result in toxic drug levels with life-threatening respiratory depression. Considering 
benzodiazepines, substances with a long half-life should be avoided, and those 
eliminated by conjugation only, e.g. oxazepam or lorazepam, should be preferred. 
 In comparison to healthy individuals, a higher tubular concentration of diuretics 
is needed in cirrhotics to excrete a given amount of sodium. This has been shown for 
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the loop diuretics torasemide (101, 102), bumetanide (103) and furosemide (102, 
104, 105). For torasemide, a diuretic metabolized by the liver, the kidney 
compensates for reduced hepatic metabolism in cirrhotics. A larger amount of drug is 
therefore eliminated by the kidney, leading to an apparently normal pharmacological 
effect in cirrhotics (101). 
 NSAIDs are known to precipitate renal failure in patients with cirrhosis and 
ascites (94). Patients with portal hypertension have a low peripheral resistance and 
hyperdynamic circulation due to increased production of vasodilating substances 
such as nitric oxide (106). In order to prevent a large drop in the arterial pressure, the 
renin angiotensin aldosterone and the sympathetic nervous system are activated, 
leading to renal arterial vasoconstriction. For the maintenance of a sufficient filtration 
pressure, local production of vasodilatory prostaglandins is necessary for dilating the 
renal arteries. After ingestion of NSAIDs, renal production of prostglandins is 
abolished, eventually leading to renal failure in cirrhotics. Although no clinical data 
have been published for selective cyclooxygenase 2-inhibitors, it has to be assumed 
that they induce similar effects, as suggested by the impaired renal perfusion 
associated with the ingestion of celecoxib by salt-depleted normal subjects (107). 
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 Table 3 Comparison of the oral bioavailability of selected drugs in control subjects and patients with liver cirrhosis 
Bioavailability Drug 
Control subjects Cirrhotic patients Increase (factor) 
Reference 
Clomethiazole 0.10±0.07  1.16±0.25 11.6 (22)
Encainide 0.26±0.20   0.76±0.42 2.92 (117)
Flumazenil 0.28±0.06   0.65±0.26 2.32 (118)
Labetalol 0.33±0.09   0.63±0.19 1.91 (119)
Meperidine 0.48±0.13   0.87±0.27 1.81 (120)
Midazolam 0.38±0.16   0.76±0.37 2.00 (30)
Morphine 0.47±0.14   1.01±0.43 2.15 (97)
Nifedipine 0.51±0.17   0.91±0.26 1.78 (121)
Nisoldipine 0.04±0.02   0.15±0.10 3.75 (122)
Pentazocine 0.18±0.05   0.68±0.21 3.78 (120)
Propranolol 0.36±0.02   0.60±0.10 1.67 (123)
Verapamil 0.10±0.02   0.16±0.05 1.60 (124)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. Adaptation of the drug dosage in patients with liver disease according to excretion, metabolism and hepatic extraction (if no studies available)  
 
Elimination pathway Expected changes in the kinetics  Recommended dosage adaptation 
 
Drugs with predominant renal elimination Qo<0.5 
• In cirrhotics  with edema and/or ascites:  
Vd↑ 
• Clren↓ 
 
In cirrhotics with edema and/or ascites: initial dose: 
adjustment according to body weight2. 
Dose reduction of maintenance therapy according to 
creatinine clearance, especially for drugs with a 
narrow therapeutic range. 
• High extraction drugs:  
F↑, Clhep↓ 
 
Oral: Initial dose: reduced dose = normal dose x 
F/100.Maintenance doses: adjustments according to 
clinical effect and drug toxicity. 
Intravenously: Initial dose: no dose adaptation 
necessary. Maintenance doses: dose reduction as 
for low extraction drugs, adjustments according to 
clinical effect and drug toxicity. 
• Intermediate extraction drugs: 
F↑, Clhep↓ 
 
Oral: Initial dose: in the low range of dosage for 
patients without liver disease. Maintenance doses: 
adjustments such as for low extraction drugs.  
Intravenously: Initial dose: no dose adaptation 
necessary. Maintenance doses: dose reduction as 
for low extraction drugs, adjustments according to 
clinical effect and drug toxicity.  
 
 
 
 
 
 
 
Drugs with predominant hepatic elimination 
Qo≥0.5
 
• Low extraction drugs: 
F→, Clhep↓ 
 
 
 
 
 
• Low extraction drugs with protein binding >90%: 
Clhep↓, → or ↑, fu↑ 
Oral or  intravenously: Initial dosage: no dose 
adaptation necessary Maintenance doses: if no 
studies available adjustment according to Child 
class: Child class A: 50% dose reduction; Child 
class B: 75% dose reduction; Child class C: choose 
drugs whose kinetics is not affected by liver disease 
and/or TDM is available. 
Use the free drug levels to guide the therapy of such 
drugs in the case of TDM. 
 
Drugs with significant biliar elimination(≥5%) 
• In patients with cholestasis: 
Clhep↓, → or ↑ 
Dose reduction according to serum bilirubin 
concentration and/or activity of alkaline phosphatase 
(guidelines exist only for some antineoplastic drugs). 
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Conclusions 
The most dangerous drugs in patients with liver cirrhosis are those with a low 
bioavailability and a narrow therapeutic range when administered orally. For these 
drugs, both initial and maintenance doses have to be reduced by 50% or more of the 
normal dose, depending on the severity of liver disease, hepatic extraction and 
metabolism, and toxicity of the drug. For most other drugs metabolized by the liver, 
only the maintenance dose has to be adjusted. It is important to realize that renal 
function can be impaired in cirrhotic patients despite normal serum creatinine. If no 
immediate pharmacological effect is needed, drug therapy should be started 
cautiously in this group of patients and titrated individually until the desired 
pharmacological effect is achieved or toxicity appears. Obvious gaps in our 
knowledge about the kinetic behavior of drugs in patients with liver disease include 
data about hepatic extraction and kinetic studies of drugs with biliary elimination in 
patients with cholestasis. 
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Summary 
 Dose adaptation for liver disease is important in patients treated with 
antineoplastic drugs due to the high prevalence of impaired liver function in this 
population and the dose-dependent, frequently serious adverse effects of these 
drugs. We classified the antineoplastic drugs marketed in Switzerland by the end of 
the year 2001 according to their bioavailability/hepatic extraction in order to predict 
their kinetic behaviour in patients with decreased liver function. This prediction was 
compared with kinetic studies carried out with these drugs in patients with liver 
disease. The studies were identified by a structured, computer-based literature 
search. 
 Of the 64 drugs identified, 49 had a predominant extrarenal (in most cases 
hepatic) metabolism and/or excretion. For 47 drugs, hepatic extraction could be 
calculated and/or bioavailability was available, allowing classification according to 
hepatic extraction. For 16 drugs, kinetic studies have been reported in patients with 
impaired liver function, with the findings generally resulting in quantitative 
recommendations for adaptation of the dosage. In particular, recommendations are 
precise for 13 drugs excreted by the bile (e.g. doxorubicine and derivatives, and 
vinca alkaloids). Validation studies comparing such recommendations with kinetics 
and/or dynamics of antineoplastic drugs in patients with decreased liver function 
have not been published. 
 We conclude that there are currently not enough data for safe use of cyctostatics 
in patients with liver disease. Pharmaceutical companies should be urged to provide 
kinetic data (especially hepatic extraction) used for classification of such drugs and to 
conduct kinetic studies for drugs with primarily hepatic metabolism in patients with 
impaired liver function allowing to give quantitative advise for dose adaptation. 
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Introduction 
Dose adaptation for patients with liver disease is more difficult than for patients 
with impaired renal function. The main reason for this statement is the fact that, 
unlike the creatinine clearance for the kidney, for the liver there is no in vivo 
surrogate to predict drug clearance. Due to the lack of such in vivo markers, 
predictions concerning dose adaptation in patients with liver disease can only be 
made based on the kinetic properties of the drugs to be administered and on kinetic 
studies of such drugs in patients with liver disease. 
 Several reviews have covered this subject during the last years (1-5). In these 
reviews, drugs are listed according to pharmacokinetic variables which are derived 
from the hepatic clearance of drugs. The hepatic clearance (Clhep) of a drug is given 
by: 
 
Q)Clf(
Q)Clf(Cl
iu
iu
hep +×
××=    (1) 
 
where fu is the unbound fraction and Cli the intrinsic clearance of a drug, respectively, 
and Q the blood flow across the liver. Cli represents the maximal capacity of the liver 
to metabolize a given drug, not taking into account limitations by liver perfusion (6). 
Cli can therefore reach values which are larger than Q, which is important for 
understanding the special situations discussed below. 
Equation (1) can be simplified for the two extremes (fu x Cli) >> Q or Q >> (fu x Cli). 
For the first case, (fu x Cli) >> Q, the denominator in equation (1) simplifies to (fu x 
Cli), and Clhep equals: 
 
QlhepC =    (2) 
 
For such drugs, the liver has a very large metabolic capacity, and the blood flow 
across the liver becomes rate-limiting for hepatic clearance. These drugs are 
therefore called “flow-limited” or “high capacity” and are usually cleared by the liver to 
a substantial degree already during the first hepatic passage. Therefore, they have a 
high hepatic extraction or a low bioavailability. Since portal blood is impaired in 
patients with liver cirrhosis (7, 8), hepatic clearance of such drugs is decreased, 
necessitating a reduction of the maintenance dose in this group of patients. A second 
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potential problem of such drugs is an increase in bioavailability when they are 
administered orally. Since these drugs have a low bioavailability by definition, an 
increase in bioavailability could lead to toxic blood levels. This can be expected to 
happen in patients with porto-systemic shunts, which result from portal hypertension 
due to liver cirrhosis or fibrosis or, of importance in patients with cancer, due to 
multiple metastases (9, 10). Therefore, when such drugs are administered orally, the 
initial and the maintenance doses have to be reduced according to the expected 
increase in bioavailability and to the decrease in hepatic blood flow. For intravenous 
administration, only the maintenance dose has to be reduced according to the 
impairment in hepatic blood flow. A list of such drugs is given in a previous 
publication (1). 
For the second type of drugs, Q >> (fu x Cli), the metabolic capacity of the liver is 
much lower than blood flow across the liver. Equation (1) therefore simplifies to: 
 
   )Clf(Cl iuhep ×=  (3) 
 
These drugs are therefore called “low extraction” or “capacity-limited”. They have not 
a high extraction during the first passage across the liver and have therefore a high 
bioavailability, if bioavailability is not limited by other processes than first pass 
hepatic metabolism and/or biliary excretion. Since Cli decreases for most drugs in 
patients with liver cirrhosis due to a decrease in the activity of cytochrome P450 
isoenzymes (CYP) (11, 12) and/or glucuronyl transferases (13-15), the maintenance 
dose of such drugs has generally to be decreased. For drugs with a high binding to 
albumin (>90%), the situation may be more complex. The free fraction (fu) and the 
free concentration of such drugs can increase in patients with a low serum albumin 
concentration, e.g. patients liver cirrhosis or malnourished patients such as patients 
with cancer. An increase in the free concentration and/or fu of such drugs may be 
associated with increased toxicity, and, as shown in equation 3, also with an 
increased hepatic clearance (16, 17). The actual hepatic clearance of such drugs is 
therefore difficult to predict in patients with chronic liver disease.  
In between of these two extremes, there are drugs with an “intermediate extraction”, 
showing characteristics of both groups. The dosage advice for such drugs in patients 
with liver cirrhosis is to start with a low dose and to up-titrate carefully in order to find 
the correct maintenance dose. 
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 Regarding dose adaptation in patients with cancer, it has to be recognized, 
however, that the dosing guidelines discussed above focus on patients with liver 
cirrhosis or fibrosis, but not on patients with increased transaminases and/or 
cholestasis which are found frequently among patients treated with antineoplastic 
drugs. Since the majority of antineoplastic drugs is metabolized by the liver (see 
Table 2) and is associated with severe dose-dependent toxicity, the question whether 
the dose has to be adapted in a patient with increased transaminases and/or 
cholestasis appears to be an important one. The most prevalent liver disease in this 
group of patients is the presence of liver metastases, possibly resulting in cholestasis 
and/or portal hypertension (10, 18, 19). Since many antineoplastic drugs are 
potentially hepatotoxic themselves (see Table 2), drug-induced liver disease may 
also be common in patients undergoing repetitive cycles of chemotherapy. On the 
other hand, with the exception of hepatocellular carcinoma, liver cirrhosis is probably 
not more prevalent in patients with cancer as compared to an age-matched 
population without cancer, but no exact data are available. 
 The aims of the current study were therefore 1) to categorize the antineoplastic 
drugs used according to pharmacokinetic criteria as discussed above 2) to compare 
this categorization with the dose recommendations in patients with liver disease 
given in the standard literature 3) to create a table with the current recommendations 
for dose adaptation 4) to localize gaps in the current recommendations. 
 
 
Methods 
 We screened Medline and Embase for studies dealing with dose adaptation and 
hepatic adverse effects for all antineoplastic drugs which were on the market in 
Switzerland by the end of the year 2001. The data bases were screened using the 
following MESH terms: antineoplastic agents, drug toxicity, pharmacokinetics, liver 
diseases. The references detected by the search in the databases were screened for 
other references dealing with the subjects. In addition to databases, the standard 
literature was screened for dose adaptation recommendations and adverse effects 
on the liver, including the “Swiss Compendium of Drugs” (20) (similar to the 
“Physicians’ Desk Reference” (21)), “Therapeutic drugs” of Dollery et al. (22) and 
“Hepatotoxicity” of H. J. Zimmerman (23). 
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 The antineoplastic drugs were categorized according to pharmacokinetic 
principles as outlined in the introduction and based on the reviews of Huet and 
Villeneuve (16) and Krähenbühl and Reichen (1). The categorization system used is 
based on the hepatic extraction or bioavailability, and protein binding of the specific 
drugs (see Table 1). Values for bioavailability and protein binding could be found 
either in the original articles (cited in Table 3) or in other sources (20-22, 24). For 
hepatic extraction, data in the literature are rare, making it necessary to estimate 
extraction from bioavailability (see Table 1) or by the following equation: 
 
    
Q
Clsys×  (4) QE = 0
ere obtained from the literature (20-22, 25), and Q was 
acturer as published in the PDR (21) and/or the Swiss Compendium of Drugs 
u (26) and the 
everity of liver disease according to Donelli et al. (27) (see Table 2). 
ata were reported and 48 contained hepatic adverse effects of antineoplastic 
gory 4), 
demonstrating a lack of data about hepatic extraction and/or bioavailability. 
 
where Q0 is the extrarenal dose fraction (the fraction of a drug which is not excreted 
unchanged by the kidney), Clsys the systemic clearance and Q the blood flow across 
the liver. Most of the values for E in Table 3 are estimated using this equation. The 
values for Q0 and Clsys w
assumed to be 1.5 L/min. 
 Dosage recommendations originate either from the original articles or from the 
manuf
(20). 
 Drug-induced liver disease was classified according to Benicho
s
 
 
Results 
 Informations about all antineoplastic drugs on the market in Switzerland by the 
end of the year 2001 were collected. Using our search strategy, we identified a total 
of 109 articles which were found to be relevant for our study. In 61 one of them, 
kinetic d
agents. 
 The 64 antineoplastic drugs on the Swiss market by the end of the year 2001 are 
listed in Table 3. From these 64 drugs, 10 fell into category 1, 10 into category 2 and 
27 in category 3. Seventeen drugs could not be classified (cate
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 Fourtynine out of the 64 drugs had a Q0 value (extrarenal dose fraction, compare 
Table 3) >0.4, indicating that most antineoplastic drugs are heavily metabolized 
and/or excreted by the bile. Seven drugs had a Q0 value ≤0.4 and for 8 drugs, the Q0 
value could not be identified. For 23 drugs, metabolism by the cytochrome P450 
system (CYP) is important, and 18 drugs are excreted to a significant extent (> 5%) 
by the bile (vinca alkaloids, doxorubicin and derivatives, amsacrine, biculatamide, 
dactinomycin, estramustine, exemestan, irinotecan, imitanib, mitoxantrone, paclitaxel 
and topotecan). For 13 of these drugs, dose adaptation recommendations are given 
according to the serum bilirubin concentration and/or activity of alkaline phosphatase. 
For biculatamide, estramustine, exemestan and paclitaxel, there is a general 
statement that the dose should be adapted or stopped in patients with decreased 
liver function. For topotecan, no dose reduction is recommended in patients with liver 
disease. For 16 of the 64 drugs studied, recommendations for dose adaptation are 
based studies in patients with hepatic dysfunction. 
 For 39 of the drugs, significant adverse effects on the liver have been reported. 
This is important to realize, rendering drug-induced liver disease an important 
differential diagnosis in patients with malignant tumors and impaired hepatic function. 
 
 
 
Discussion 
 Our study demonstrates that for antineoplastic drugs, there is a discrepancy 
between the general recommendations of how drugs should be dosed in patients 
with liver disease and the available kinetic data for these drugs. The most important 
gaps are a lack of information regarding hepatic extraction and of kinetic studies for 
critical drugs in patients with impaired liver function. 
 As explained in the introduction, data about hepatic extraction are important for 
classification of a specific drug regarding hepatic elimination in patients with chronic 
liver disease, in particular liver cirrhosis. It is evident that such data are difficult to 
obtain, especially the determination of hepatic extraction of a drug, necessitating an 
invasive procedure which is usually not performed before a drug is marketed. 
Bioavailability is only a surrogate for hepatic extraction, since a low bioavailability can 
be explained by both a high hepatic extraction and/or a low intestinal absorption. For 
drugs with a low bioavailability (<40%), hepatic extraction should therefore be known, 
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since, as explained above, this parameter is critical for rational drug dosing in 
patients with impaired liver function. In order to circumvent this invasive procedure in 
humans, a possibility would be to get such data using perfused livers from animals, 
e.g. pigs. To the best of our knowledge, no data have been published so far 
comparing hepatic extraction data for critical drugs between animals (such as pigs) 
and humans. Another possibility is to estimate hepatic extraction using Q0, systemic 
drug clearance and hepatic blood flow (equation 4 and Table 3). As shown in Table 
3, the values obtained with this technique are in a satisfactory agreement with the 
bioavailability for most drugs, with some exceptions. 
 Regarding antineoplastic agents, many of these drugs are used intravenously 
only, partially explaining the lack of data considering oral bioavailability. Nonetheless, 
taking into account the high prevalence of patients with impaired hepatic function 
among those treated with this type of drugs (28), such data should be available for all 
substances on the market. 
 Kinetic studies have been conducted in particular in two conditions, namely 
patients with cholestasis (as suggested by an increased serum bilirubin 
concentration) and in patients with hepatic metastases. Considering cholestasis, 
studies exist for most antineoplastic drugs with significant biliar elimination (see 
Table 3). These studies resulted in quantitative recommendations for dose 
adaptation in jaundiced patients according to their serum bilirubin concentration. To 
the best of our knowledge, however, these recommendations have not been 
validated by kinetic and dynamic studies (including the incidence and severity of 
dose-dependent adverse effects) in a large series of patients with cholestasis. It 
remains also unclear, whether the serum bilirubin concentration is the best parameter 
for dose adaptation in cholestatic patients or whether, for instance, the serum bile 
acid concentration and/or activity of alkaline phosphatase would be more suitable. 
 Considering hepatic metastases, only few studies exist and they have generally 
not resulted in clear dose adaptation recommendations. Since hepatic metastases 
can be associated with portal hypertension and possibly porto-caval shunts (10, 18), 
the situation resembles patients with liver cirrhosis. Oral administration of drugs with 
a high hepatic extraction should therefore be performed cautiously and kinetic data 
for such drugs should be available in this type of patients when such drugs are 
approved. 
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 As shown in Table 3, treatment with antineoplastic agents can lead itself to liver 
disease or, for drugs metabolized by the liver and/or excreted by the bile, to 
increased systemic toxicity in patients with liver disease. There is a third type of 
toxicity which may be relevant. In several patients with chronic hepatitis B, the 
immunosuppressive effect of antineoplastic agents was associated with a flare up of 
their hepatitis due to increased replication of the hepatitis B virus (29-35). Since this 
condition can be treated but is potentially fatal (35), the immune status regarding 
hepatitis B should be known before treatment with antineoplastic drugs. 
 In conclusion, there are currently considerable gaps in the data needed for safe 
administration of antineoplastic drugs in patients with decreased hepatic function. 
Drug authorities should urge pharmaceutical companies to provide such data before 
the drugs are approved. Considering kinetics, in particular oral bioavailability and 
hepatic extraction should be investigated. For drugs with a predominant hepatic 
metabolism and/or excretion, the kinetics in patients with liver metastases and/or 
cholestasis should have been studied before marketing authorisation is provided. 
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 Table 1. 
 
Categorization of antineoplastic drugs screened according to pharmacokinetic 
variables. 
 
1. High hepatic extraction (category 1) 
• Hepatic extraction > 60% → oral bioavailability < 40% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not 
complete) 
 
2. Intermediate hepatic extraction (category 2) 
• Hepatic extraction 30 - 60% → oral bioavailability 40 - 70% in the case of 
complete intestinal absorption (or accordingly lower, if intestinal absorption is 
not complete) 
 
3. Low hepatic extraction (category 3) 
• Hepatic extraction < 30% → oral bioavailability > 70% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not 
complete) 
• In this category, protein binding may be relevant: for drugs with high binding to 
albumin (>90%), hepatic clearance may increase 
 
4. Hepatic extraction is not known (category 4) 
 
 
 
Table 2. 
 
Classification of liver disease and severity of liver dysfunction 
 
Parameter Pathophysiological condition 
and clinical significance 
Severity1
Alanine 
aminotransferase 
(ALT) 
Breakdown (necrosis or 
apoptosis) of hepatocytes. 
Hepatocellular injury2 if > 2 x 
ULN3  
2-5 x ULN: moderate injury 
> 5 x ULN: severe injury 
Alkaline 
phosphatase 
Cholestasis4 if > 2 x ULN 
 
2-5 x ULN: moderate cholestasis 
> 5 x ULN: severe cholestasis 
Serum bilirubin 
concentration 
Cholestasis (exclude 
prehepatic causes)  
25 – 50 µmol/L: moderate 
> 50 µmol/L: severe 
Serum albumin 
concentration 
Impaired hepatic protein 
synthesis  
30 – 35 g/L: moderate 
< 30 g/L: severe 
Prothrombin 
activity 
Impaired hepatic protein 
synthesis  
40 – 70%: moderate 
< 40%: severe 
 
1The severity is classified according to Donelli et al. (27) with some modifications 
2Hepatocellular injury is defined according to Benichou (26) 
3ULN: upper limit of normal 
4Cholestasis is defined according to Benichou (26) 
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 Table 3. 
 
Kinetic data, hepatic adverse effects and dose recommendations in patients with liver disease of the antineoplastic drugs on the 
market in Switzerland by the end of the year 2001 
 
Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
   Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8  
Aldesleukin        4 Not known 0.18
 
1 - -  Frequent: 
hepatocellular injury, 
cholestasis, or 
hyperbilirubinemia 
(20). 
Recommendation: Monitor patients for adverse 
effects, dose may need to be adjusted patients with 
liver disease (20, 22). Contraindicated in patients with 
elevated serum bilirubin (20). 
Amino-
glutethi-
mide 
3      0.50
N-acetylation, N-
hydroxylation 
(CYP) (22) 
1.00 
 
12 25 95 4.5 0.03 Sporadic: 
cholestasis, 
hyperbilirubinemia 
(23). 
No dose adjustment recommendations available for 
patients with liver disease. 
Amsacrine 
 
4        1
Glutathion 
conjugation, Biliar 
excretion (20) 
1.40 5 97 - Sporadic: 
cholestasis, 
hyperbilirubinemia 
(23). 
Recommendation: 50% dose reduction if serum 
bilirubin > 34 µmol/l (36). Dose reduction (70% of 
normal dose) in patients with severe liver disease (20, 
22). 
Anastrozole 
 
4        0.95
N-dealkylation, 
hydroxylation 
(CYP), glucuroni-
dation (22) 
- 50 45 80 Sporadic: 
cholestasis. 
No dose adjustment recommendations available for 
patients with liver disease. 
Bicaluta-
mide 
 
2 ≈1 
Oxidation (CYP), 
glucuronidation. 
Biliar elimination 
40% (20) 
-     139
 
98 - 30 0.34 One case of 
fulminant liver failure 
(37) 
 
Recommendation: Stop treatment if transaminases > 
3 x ULN or in patients with hyperbilirubinemia (20) 
Bleomycin        3 0.70 0.30 3 - - 5.2 0.04 Case reports: Recommendation: No dose adjustment in patients 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
 Hydrolysis (22) steatosis (23, 38) with liver disease (22). 
Buserelin 
 
3  Not known
 
- 1.6 - 3    No dose adjustment recommendations available for 
patients with liver disease. 
Busulfan 
 
3       1
Oxidation, sulfation 
1.0 2.5 30 70 18.9 0.21 Sporadic: 
hepatocellular injury, 
cholestasis (39, 40). 
Rare: venoocclusive 
disease (23). 
No dose adjustment recommendations available for 
patients with liver disease. 
Capecita-
bine 
1       0.97
Carboxylesterase, 
Cytidine 
desaminase, 
phosphorylation 
- 1.3 54 42 251 >1 Frequent: 
hyperbilirubinemia 
Sporadic: 
cholestasis 
Rare: Hepatocellular 
injury (41) 
Studies: Increased bioavailability by 20% in patients 
with moderate liver disease due to metastases (42). 
Recommendation: No dose adjustment in patients 
with moderate liver disease (42) 
Carboplatin        3 0.25 0.24 3 20 - 4.5 0.01 Rare: hepatocellular 
injury, cholestasis 
(23) 
Recommendation: No dose adjustment in patients 
with liver disease (20) 
Chloram-
bucil 
3       1
β-oxidation (22) 
1.0 1.5 99 87 11 0.12 Rare: hepatocellular 
injury (23) 
Case report: liver 
failure (43).  
Recommendation: Monitor patients for adverse 
effects, dose may need to be adjusted patients with 
liver disease (20) 
Chlorme-
thine 
(Mechlore-
thamine) 
4  1
ethyleneimmonium 
ion (22) 
- - - -    No dose adjustment recommendations available for 
patients with liver disease. 
Cisplatin        3 0.65
non-enzymatic 
degradation (44) 
0.3-1 0.5 90 - 0.3 0.01 Rare: hepatocellular 
injury (23) 
Recommendation: No dose adjustment in patients 
with liver disease (20, 22) 
Cladribine 2 Not known 0.4 6 25 55 60   No dose adjustment recommendations available for 
patients with liver disease. 
Cyclo-
phospha-
mide 
3       0.9
Hydroxylation by 
CYPs 2B6, 2C19, 
2C9, 3A4 (45) 
0.80 7 15 75 4.4 0.04 Rare: Hepatocellular 
injury, cholestasis, 
hyperbilirubinemia 
(23). 
Studies: Decreased clearance of active drug and 
decreased production of active metabolites in patients 
with liver metastases (49), severe liver disease in the 
presence of Hodgkin’s disease (50) or liver cirrhosis 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
Case reports: 
venoocclusive 
disease (46-48) 
(36).  
Recommendation: Monitor patients with liver disease 
for adverse effects. Dose reduction by 25% in patients 
with serum bilirubin > 50 µmol/L (20) 
Cyprotero-
ne 
3        1
hydrolysis, 
hydroxylation, 
conjugation (22) 
19 38 95 88 Sporadic: 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia 
Rare: liver failure 
(51-55) 
Recommendation: Monitor liver function. Stop 
treatment in patients with liver injury (20, 22) 
Cytarabine        2 0.90
cytidine 
deaminase (22) 
3.0 2.3 13 <20 55 0.55 Sporadic to 
frequent: dose-
dependent 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia 
(23) 
Recommendation: 50% dose reduction if serum 
bilirubin > 34 µmol/L, gradual increase while 
monitoring systemic toxicity (36) 
Dacarbazi-
ne 
3  0.30 1.5 0.7 5 - 12 0.04 Case reports: 
venoocclusive 
disease (56, 57), 
hepatic vein 
thrombosis (57) 
No dose adjustment recommendations available for 
patients with liver disease. 
Dactino-
mycin 
4        0.70
Biliar excretion 
50%-90% (22) 
12 36 - - Rare: hepatocellular 
injury, steatosis, 
venoocclusive 
disease (23) 
Recommendation: 50% dose reduction in patients 
with hyperbilirubinemia. Increase gradually while 
monitoring systemic toxicity (36). 
Daunorubi-
cin 
4        0.90
Reduction, biliar 
excretion 40% (22) 
40 27 - - Rare: Venoocclusive 
disease when 
combined with 
radiation (23) 
Recommendation: If serum bilirubin 20 - 50 µmol/L 
25% dose reduction, if serum bilirubin > 50 µmol/L 
50% dose reduction (20, 22) 
Docetaxel       2 1
Oxidation by 
CYP3A4 (22). 
Biliar excretion 
1.6 0.6 (
11 (γ)
95 - 39 0.43  Studies: Population kinetic studies show a 25% 
reduction of clearance in patients with transaminases 
> 1.5 x ULN and alkaline phosphatase > 2.5. In 
patients with moderate liver injury/cholestasis 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
75%, 10% as 
intact drug (20, 22) 
clearance was reduced by 27% (20, 22). 
Recommendation: If transaminases > 1.5 x ULN or 
alkaline phosphatase > 2.5 x ULN 25% dose 
reduction. If serum bilirubin is increased or 
transaminases > 3.5 x ULN or alkaline phosphatase > 
6 x ULN docetaxel should not be adminstered (20, 22) 
Doxorubicin        1 0.95
Reduction to 
doxorubicinol, 
sulfation, 
glucuronidation, 
biliar excretion 
50% (22, 27) 
17 26 80 5 69 0.73 Rare: in combination 
with 
cyclophosphamide, 
etoposide and 
cisplatin cholestasis 
and venoocclusive 
disease (23) 
Studies: In 5 patients with disseminated sarcoma, 
bone marrow toxicity and doxorubicin serum levels 
correlated with hyperbilirubinemia (58). In patients 
with hepatocellular carcinoma, bone marrow toxicity 
and serum doxorubicin/doxorubicinol levels correlated 
with hyperbilirubinemia (59, 60). In 17 patients with 
liver metastases and moderate liver disease kinetics 
of doxorubicin was not changed but the half-life of 
doxorubicinol increased (61). In 4 patients with 
moderate liver disease the half-life of doxorubicin was 
doubled (62). In patients with liver metastases and 
mild increase in transaminases or alkaline 
phosphatase, kinetics and toxicity of doxorubicin was 
not changed (59, 60, 63, 64). 
Recommendation: If serum bilirubin 20 - 50 µmol/l: 
50% dose reduction. If serum bilirubin > 50 µmol/l: 
75% dose reduction (20, 22, 36, 65). Donelli et al. 
advise dose reduction only if serum bilirubin is > 50 
µmol/L (27). 
Epirubicin         1 0.90
Reduction 
Biliar excretion 
40% (66) 
20 39 85 - 89 0.89 
 
Studies: In patients with liver metastases and 
increased serum bilirubin, the half-life of 
epirubicin/epirubicinol was increased (67-69). In 
patients with hepatocellular carcinoma, epirubicin 
kinetics correlates with liver function and serum 
bilirubin (70). In patients with liver metastases, 
epirubicin kinetics correlates better with 
transaminases than with serum bilirubin (71-73). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
Recommendation: If serum bilirubin 20 - 50 µmol/l: 
50% dose reduction. If serum bilirubin > 50 µmol/l: 
75% dose reduction (20, 22, 36) 
Estramusti-
ne 
2        0.90
Oxidation, partial 
biliar excretion (74) 
0.04 1.3 99 44 Sporadic. 
Hepatocellular 
injury, cholestasis 
(20) 
Recommendation: Monitor patients for adverse 
effects, dose may need to be adjusted patients with 
liver disease (20). 
Etoposide        3 0.65
Esterases, 
glucuronidation. 
Biliar excretion 
<10%. 
0.30 8.1 95 50 2.9 0.02 Frequent. 
Hepatocellular injury 
(23).  
Case reports: 
Reactivation of 
hepatitis B virus 
(30), liver failure 
(75) 
Studies: In patients with mild to moderate liver 
disease, etoposide kinetics was not altered (76-78). In 
patients with severe liver disease elimination and AUC 
were highly variable and tended to be increased in the 
case or impaired hepatic protein synthesis or 
hyperbilirubinemia (76-79). 
Recommendation: Monitor patients with mild to 
moderate liver disease. If bilirubin 25 – 50 µmol/L or 
AST > 180 U/L 50% dose reduction (36). 
Contraindicated in patients with decompensated liver 
disease (20, 22). 
Exemesta-
ne 
1       1
CYP3A, biliar 
excretion 40% (80) 
19 24 90 42 609 >1 Sporadic 
hepatocellular injury, 
cholestasis (20) 
Recommendation: Monitor patients for adverse 
effects, dose may need to be adjusted patients with 
liver disease (20). 
Fludarabine      3 0.35 
 
2.4 10-30 - 70 15.5 0.06  Recommendation: No dose adjustment recommended 
in patients with liver disease (20, 22). 
Fluorouracil        1 0.95
Dihydropyrimidine 
dihydrogenase 
0.3 0.25 94 28 67.2 0.71 Sporadic: 
hepatocellular injury 
when administered 
i.v. (23) 
Studies: In patients with liver metastases, a weak 
correlation with cholestasis was present (81), but no 
dose adjustment was recommended. 
Recommendation: Start with 50% of normal dose in 
patients with liver cirrhosis. Increase gradually while 
monitoring systemic toxicity (27, 36). 
Flutamide         4 1
Hydroxylation (82) 
- 8 95 - Sporadic: 
hepatocellular injury, 
hyperbilirubinemia 
(20). 
Recommendation: Monitor liver function (20). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
Case reports: liver 
failure (83-90). 
Formesta-
ne 
1 Not known - 120 93 25    No dose adjustment recommendations available for 
patients with liver disease  
Fosfestrol          3 1 - 0.5 - 80 Recommendation: Monitor liver function (20, 22).  
Gemcitabi-
ne 
1  0.9
Deamination, 
phosphorylation 
(20) 
25 1 – 12 10 - 90 0.9 Frequent: hepa-
tocellular injury (self-
limiting) (20, 22) 
No dose adjustment recommendations available for 
patients with liver disease 
Goserelin         3 0.4 - 4.0 25 - 8.2 0.04 Recommendation: Dose adjustment not 
recommended in patients with liver disease (20). 
Hydroxy-
carbamide 
3    0.4 0.5 5.0 80 80  Case report: 
fulminant liver failure 
(91) 
No dose adjustment recommendations available for 
patients with liver disease 
Idarubicin       1 ≈1 
Oxidation, biliar 
excretion 8 – 17% 
(92, 93) 
- 15.2 96 28 120 ≈1 Frequent: 
hepatocellular injury, 
hyperbilirubinemia 
(20) 
Studies: In patients with metastases, kinetics of 
idarubicin is not changed (94, 95). 
Recommendation: If serum bilirubin 20 - 34 µmol/l: 
50% dose reduction. If serum bilirubin > 34 µmol/l: 
contraindicated (20) 
Ifosfamide        3 0.5
CYP3A (activation) 
(45) 
0.5 6.5 - 100 3.6 0.02 Sporadic: 
hepatocellular injury, 
hyperbilirubinemia 
(23) 
Recommendation: Monitor patients with preexisting 
liver disease (20). Contraindicated in patients with 
decompensated liver disease (22). 
Imatinib         3 0.95
N-demethylation 
(CYP 3A), 20% 
biliar elimination 
(20) 
4.9 18 95 98 Sporadic: 
hyperbilirubinemia, 
hepatocellular injury 
(20). 
Recommendation: Stop treatment if serum bilirubin > 
3 x ULN or transaminases > 5 x ULN (20) 
Irinotecan         3 0.75
Esterases, 
glucuronidation, 
CYP3A4 
Biliar excretion 
75 10 65 - 26 0.21 Study: In patients with gastrointestinal cancer and 
cholestasis the AUC for SN-38 (active metabolite) was 
50% increased (serum bilirubin 1.1-1.5 x ULN) or 
100% increased (>1.5 ULN) (97). 
Recommendation: If serum bilirubin > 1.5 x 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
25% (20, 96) ULN/transaminases > 5 x ULN dose reduction 
according to adverse events. Contraindicated if serum 
bilirubin > 5 x ULN (20). According to (97) 350 mg/2 in 
patients with serum bilirubin 1.1-1.5 ULN and 200 
mg/m2 when serum bilirubin >1.5 ULN. 
Letrozol   3 0.95
CYP3A4, 2D6 (20) 
1.9 45 60 100 2.4 0.03  No dose adjustment recommendations for patients 
with liver disease available 
Leuprorelin        3 Not known 0.5 3 46 - 8.3 0.05 No dose adjustment recommendations available for 
patients with liver disease 
Lomustine        3 1
Cis- and trans-4-
hxdroxylation (98) 
1.70 10 - ≈100 Sporadic: 
hepatocellular injury 
(20) 
No dose adjustment recommendations available for 
patients with liver disease 
Medroxypro
-gesteron 
1  1
CYP3A4 
0.6     36 94 <10 76 0.84 Rare: cholestasis, 
peliosis (20) 
No dose adjustment recommendations available for 
patients with liver disease. 
Megestrol        4 1 
Glucuronidation 
(22) 
- 18 - - Rare: hepatocellular 
injury, 
hyperbilirubinemia 
(20) 
No dose adjustment recommendations available for 
patients with liver disease 
Melphalan        2 0.9
Hydroxylation (22) 
0.6 1.5 80 70 31 0.31  Recommendation: No adjustment recommended in 
patients with liver disease (22). 
Mercapto-
purine 
2  0.9
Xanthine oxidase 
(thiouric acid), 
thiopurine 
methyltransferase 
(22) 
0.6     0.9 19 12 46 0.46 Frequent: dose-
dependent 
hepatocellular injury, 
cholestasis, 
hyperbilirubinemia in 
6 – 40% (23). 
Case reports: liver 
failure (99-102), 
venoocclusive 
disease (23). 
Risk may be higher 
in patients with 
reduced activity of 
thiopurine 
Recommendation: Monitor liver function. 
Contraindicated in patients with decompensated liver 
disease (20) 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
methyltransferase 
Methotre-
xate 
3  0.05 0.70 7.2 50 70 8.8 0.01 Sporadic: Fatty liver, 
fibrosis, cirrhosis 
during long-term 
treatment with 
immunosuppressive 
doses (103-109). 
Case reports: 
hepatocellular injury, 
acute liver failure 
during use as an 
antineoplastic agent 
(30, 110-113) 
 
Studies: No correlation between liver function and 
methotrexate serum levels (114). 
Recommendation: Close monitoring in patients with 
decompensated liver disease. Reduce dose in the 
presence of ascites and/or decreased renal function 
(20, 22) 
Mitomycine 
 
4    0.9 0.3 0.5 - -  Rare: steatosis  
Case reports: 
venoocclusive 
disease (23) 
No dose adjustment recommendations available for 
patients with liver disease 
Mitoxantro-
ne 
2  0.95
mono- or 
dicarboxylation 
(inactive), biliar 
excretion 25% (20) 
10 - 15 57 76 - 45 0.48 Frequent: 
hepatocellular injury 
(23) 
Studies: Clearance reduced by 50% in patients with 
moderate liver disease (115). 
Patients with serum bilirubin < 60 µmol/L tolerate 14 
mg/m2, patients with serum bilirubin > 60 µmol/L and 
bad performance status have higher mortality with this 
dosage (116). In patients with liver metastases, half-
life of mitoxantrone correlated with serum bilirubin and 
cholestasis (117). 
Recommendation: Dose adjustment (8 mg/m2) or 
contraindicated (bad performance status) in patients 
with serum bilirubin > 60 µmol/L (116) 
Nimustine          4 1 - 0.6 34 - No dose adjustment recommendations available for 
patients with liver disease  
Oxaliplatin         4 ≈0.5, 
Reduction (non-
- 260 75 - Recommendation: No dose adjustment in patients 
with liver disease (20). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
enzymatic), biliar 
excretion 5% (118) 
Paclitaxel       3 0.95 
CYP 3A, 2C8. 
Biliar excretion > 
5% (119) 
2.0 3 95 23 0.24 Sporadic: 
hepatocellular injury, 
cholestasis 
Rare: 
hyperbilirubinemia, 
liver failure (20) 
Studies: Liver disease/liver cirrhosis appears to be a 
risk factor liver for systemic toxicity (120, 121). 
Increased risk for myelosuppression in patients with 
increased transaminases and/or serum bilirubin > 25 
µmol/L (122). In patients with increased 
transaminases (3-10 x ULN) and hyperbilirubinemia 
(1.3 – 2 x ULN) clearance was decreased by ≈ 40% 
(123) 
Recommendation: Monitor patients with liver disease 
well for adverse effects. Do not administer in patients 
with decompensated liver disease (20, 123) 
Raltitrexed         4 0.5
Polyglutamate 
derivative (124) 
7.0 2 93 - Frequent: 
hepatocellular injury 
Sporadic: 
cholestasis, 
hyperbilirubinemia 
Case report: liver 
failure (125) 
Recommendation. No dose adjustment in patients 
with mild to moderate liver disease. Contraindicated in 
patients with decompensated liver disease (20). 
Rituximab 4 Not known - 68 - -    No dose adjustment recommendations available for 
patients with liver disease 
Tamoxifen       4 1
Hydroxylation, N-
dealkylation (CYP 
2C9, 2D6, 3A4, 
2C8) (22) 
60 4 – 11 
days 
99 - Sporadic: 
hepatocellular injury, 
cholestasis, fatty 
liver (23). 
Rare: liver failure 
(126-128). 
Studies: In a patient with liver metastases liver 
function deteriorated one year after start of tamoxifen 
(129). In a randomized trial in patients with 
hepatocellular carcinoma, liver function was not 
affected (130). 
Recommendation: Monitor liver function in patients 
with preexisting liver disease. 
Temozolo-
mide 
3    0.9
non-enzymatic 
- 1.8 15 ≈100    No dose adjustment recommendations available for 
patients with liver disease 
Thiotepa       3 0.5 
CYP 2B1, 2C11 
(131) 
- 2.4 99 - 19 0.11 Case report: liver 
failure (132) 
No dose adjustment recommendations available for 
patients with liver disease 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
Tioguanine   4 >0.9,
Thiopurine 
methyltransferase 
- 5 - 9 - -   Rare: hepatocellular 
injury, cholestasis 
(23). 
Case reports: Veno-
occlusive disease 
(133, 134) 
Recommendation: Monitor liver function after 
administration of high doses. Contraindicated in 
patients with decompensated liver disease (20). 
Topotecan        2 0.6
Esterases 
Biliar excretion 
20% (135) 
1.9 2.4 35 32 49.5 0.33  Studies: 14 patients with increased transaminases 
and/or hyperbilirubinemia (some with cirrhosis) were 
treated with 1.5 mg/m2. Topotecan clearance 
correlated with ICG clearance but no more adverse 
effects were observed in patients with liver disease 
(136). On the other hand, two thirds of patients with 
hepatocellular carcinoma treated with topotecan 
developed grade IV neutropenia (137). 
Recommendation: No dose adjustment for patients 
with hepatic dysfunction but monitor patients well for 
systemic toxicity (136). 
Toremifen         3 1,
CYP3A4 (N-
demethylation, 
hydroxylation). 
Enterohepatic 
circulation (138) 
12-15 148 99 ≈100 4.5 0.05
 
 
 
Studies: In 10 patients with liver cirrhosis or fibrosis 
the elimination half-life was increased by 75% and 
clearance decreased by 28% (138). 
Recommendation: Dose reduction in patients with 
liver cirrhosis by 50%, gradual increase while 
monitoring adverse effects (20). 
Trastuzu- 
mab 
4 Not known 0.04 140 - -    No dose adjustment recommendations available for 
patients with liver disease  
Vinblastine         2 1
CYP3A4 
biliar excretion 
>50% (22) 
20 25 75 - 52 0.58 Recommendation: If serum bilirubin > 50 µmol/L → 
50% dose reduction (20). 
Vincristine        3 0.9 
CYP3A4 
biliar excretion 
70% (22) 
8.0 23 75 - 8.5 0.09 Studies: In the presence of 
cholestasis/hyperbilirubinemia -half-life was 
prolonged (139). In patients with leukemia or 
lymphoma and cholestasis, AUC and toxicity were 
increased (140). 
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effects9
Studies performed and dosage 
recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6
(%) 
Clsys7
(L/h) 
E8   
Recommendation: If serum bilirubin > 50 µmol/L → 
50% dose reduction (20). Some authors advise 50% 
dose reduction also if alkaline phosphatase is 
increased (36). 
Vindesine          4 Not known
CYP 3A, biliar 
excretion 
8.8 24 - - 17.5 Recommendation: Monitor patients for adverse 
effects, dose may need to be adjusted patients with 
hyperbilirubinemia (20). 
Vinorelbine        1 0.85 
CYP 3A, biliar 
excretion 50% (22, 
141) 
75 30 15 ≈40 Studies: In 19 patients with liver metastases, 
clearance was reduced by 50% in patients with >75% 
of the liver replaced by tumor (142). 
Recommendation: 50% dose reduction if more than 
75% of liver replaced by tumor (142) or if serum 
bilirubin > 34 µmol/L (141). 
 
1Cat = drug category. Drugs were categorized as follows: Category 1: high hepatic extraction (E) (E > 60%, bioavailability < 40%), category 2: intermediate 
hepatic extraction (E = 30-60%, bioavailability 40-70%), category 3: low hepatic extraction (E < 30%, bioavailability >70%), category 4: hepatic extraction not 
known 
2Q0: extrarenal dose fraction = fraction metabolized or excreted by bile (1 - Q0: fraction excreted unchanged by the kidney) 
3Vd = volume of distribution in L per kg. For calculation, body weight was assumed to be 70 kg. 
4 t½: dominant half-life 
5PB: Fraction bound to proteins (protein binding in %) 
6F: Bioavailability 
7Clsys: systemic clearance (L/min) 
8E: hepatic extraction, calculated as described in equation 4 
9Frequency of hepatic adverse effects: frequent > 10% of patients treated, sporadic: 1-10%, rare: < 1% 
Abbreviations: CYP = cytochrome P450, ULN = upper limit of normal 
Characterization of liver disease and severity of liver dysfunction: compare Table 2 
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Introduction 
The liver is involved in the clearance of many drugs through a variety of 
metabolic pathways and/or biliary excretion of unchanged drugs or metabolites. 
Alterations of these metabolic and/or excretory functions in patients with liver disease 
can lead to drug accumulation or, less often, to failure to form an active metabolite.  
The most important factors affecting drug disposition in patients with chronic liver 
disease have been discussed in numerous reviews (1-9), where drugs are classified 
according to the way they are handled by the liver on the ground of their hepatic 
clearance. 
Hepatic clearance (Clhep) is defined as the volume of blood from which drug is 
removed completely by the liver per unit time. Hepatic clearance can be expressed 
as: 
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××=   (1) 
 
When (fu x Cli) >> Q, equation (1) can be simplified to Clhep ≈  Q. In this case, hepatic 
clearance is said to be blood flow-limited and is insensitive to changes in protein 
binding or enzyme activity (i.e. Cli). Patients with liver cirrhosis may have porto-
systemic shunts, which may increase bioavailability of flow-limited drugs (10,11). 
Blood flow across the liver may be reduced in cirrhotic patients (12), leading to an 
impaired hepatic clearance of such drugs. This may be of particular importance for 
psychotropic drugs since many of them are metabolised primarily by the liver  (13).   
Drugs for which (fu x Cli) >> Q are called low-extraction drugs. For such drugs, 
equation (1) can be simplified to Clhep≈ (fu x Cli).  Clhep is mainly determined by the 
capacity of the liver to metabolise this drugs and is influenced by changes in the 
plasma protein binding of such drugs. Hepatic disease can alter the intrinsic 
clearance of this drugs (by affecting the activity of cytochrome p450 isoenzymes) and 
also their binding to plasma proteins (hypoalbuminemia in cirrhotics patients) (14).  
Few drugs have an intermediate extraction ratio and cannot be assigned to either 
group. The hepatic clearance of these drugs can be influenced from all the 
parameters included in equation (1).  
Psychooanaleptics, psycholeptics, anti-Parkinson agents and antiepileptics often 
need to be prescribed to patients with pre-existing hepatic disease. Sedatives, for 
example, are used in patients with liver cirrhosis as a premedication before upper 
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gastrointestinal endoscopy for the diagnostic assessment of gastrointestinal 
haemorrhage the presence of esophageal varices. Antidepressant drugs may also 
not infrequently be given to cirrhotic patients. In fact, depressive symptoms are not 
uncommon in patients with impaired liver function, since the mental slowing 
accompanying hepatic encephalopathy may be depression (15).  
Most psychoactive medications, with the exception of  lithium, are highly fat-soluble 
and require phase-I (hepatic) metabolism. Therefore, impairment of hepatic 
clearance can lead to drug accumulation and dose-related adverse drug reactions. 
Chronic usage of sedatives including phenothiazine, for example, may precipitate 
somnolence or coma (15-17). The increased cerebral sensitivity to many 
psychoactive drugs observed in patients with liver impairment may be due to 
changes in the pharmacokinetics (resulting in a greater concentration of free drug in 
the brain or to in pharmacodynamics (13). These effects may necessitate dosage 
modification or a change in the medication. 
Classification according to pharmacokinetic properties and conducted clinical trials in 
patients with liver cirrhosis can help to select and administer drugs more rationally in 
patients with liver disease. The aims of this article were to classify psychoanaleptics 
(antidepressants, psychostimulants, anti-Alzheimer agents), psycholeptics 
(antipsychotics, anxiolytics, hypnotics and sedatives), antiepileptics and anti-
Parkinson agents according to pharmacokinetic principles (hepatic extraction) and to 
provide recommendations for their use in patients with liver disease. 
 
Methods 
We used the databases Medline and Embase to detect the clinical studies that have 
been carried out in the topics of hepatic adverse effects, pharmacokinetics and 
pharmacodynamics as well as dose adaptation of psychoanaleptics, psycholeptics, 
antiepileptics and anti-Parkinson agents in patients with liver disease. We restricted 
our search for the drugs that had been registered in Switzerland  by the end of the 
year 2002. To perform our literature search, the following MeSh (Medica Subject 
Headings) terms were used:  
Central nervous system agents, liver disease, pharmacokinetics, drug effects, 
metabolism, drug toxicity.  
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We used the standard literature as well to review thoroughly  dose adaptation 
recommendations, adverse effects and modified pharmacokinetics or 
pharmacodynamics in patients with liver impairment (18,19) (similar to the (20)), (21).   
We categorized the drugs according to pharmacokinetic variables as mentioned in 
the introduction which is based on the hepatic extraction or bioavailability of a given 
drugs. Low-extraction drugs were additionally subdivided according to their protein 
binding in binding sensitive (protein  binding to albumin >90% or fu<10%) and 
binding-insensitive drugs (protein binding to albumin <90% or fu>10%) (see Table 1). 
The pharmacokinetic variables or data for liver toxicity were obtained either from the 
original literature (see Table 4) or from the standard literature (18-21). Hepatic 
extraction was either obtained from the literature or estimated using the following 
equation: 
 
      
Q
Clhep=     (2) E
ince Clhep  can be expressed as Q0 x Clsys, equation (2) can be rewritten as follows: 
 
S
 
Q
QCl
E sys 0
×=       (3)  
s the liver. The values for Q0 and Clsys were found in the literature 
riables of the specific 
 of central nervous agents found in the standard literature (see Table 3) (18, 
 
where Clsys is the systemic clearance, Q0 the extrarenal dose fraction, and Q the 
blood flow acros
(18-20, 22-24). 
Dose recommendations are based on the original articles found in our literature 
search or from the product information published in the PDR (20) or the Swiss 
Compendium of Drugs (22). Where no dose recommendations were available, we 
give concrete suggestions according to the pharmacokinetic va
drugs and the clinical experience of the authors (see Table 4).  
Drug-induced liver disease was classified according to Benichou (25) (see Table 2). 
Since impaired liver function can be associated with increased experience of drugs 
with hepatic metabolism, we have listed the important dose-related  adverse 
reactions
24-26). 
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esults of clinical studies whereas 30 articles reported hepatic 
y excretion. 10 
 
r dose adaptation based on studies in 
epatic adverse drug effects have been reported for 74 of the 114 drugs studied.           
 
 
Results 
With a computer-based literature research, data about psychoanaleptics, 
psycholeptics, anti-Parkinson drugs and antiepileptics marketed in Switzerland by the 
end of the year 2003 were collected. A total of 121 articles dealing with the topic of 
our study, dosing in patients with liver disease were found: 91 articles contained 
kinetic data and r
adverse effects.    
The 114 studied drugs were psychoanaleptics (including psychostimulants, 
antidepressants and anti-Alzheimer drugs), psycholeptics (antipsychotics, anxiolytics, 
hypnotics and sedatives), anti-Parkinson drugs and antiepileptics which are listed in 
Table 4. According to their bioavailability 25 drugs fell into category 1, 24 drugs into 
category 2 and 40 drugs in category 3 whereas 25 drugs fell into category 4 due to 
an absence of kinetic data (hepatic extraction or bioavailability not known). For 19 
drugs neither the hepatic extraction nor the bioavailabilty was available. From this 
114 drugs 89 had a Q0 value (extrarenal dose fraction = fraction metabolized or 
excreted by bile) > 0.4, indicating that the majority of the studied central nervous 
system (CNS) drugs undergoes an extensive metabolism and/or biliar
drugs had a Q0  ≤ 0.4 whereas for 15 drugs the Q0 was not available.  
51 of the 114 drugs undergoes a phase-I hepatic metabolism by the cytochrome 
P450 system and 18 drugs showed a biliar excretion. However for only one drug,
hydroxyzine, a kinetic studies have been conducted in patients with biliary cirrhosis.  
Quantified dosage recommendations based on clinical studies in patients with 
hepatic disease (most of them in patients with liver cirrhosis) could be found for 48 of 
the 114 drugs studied. For one of the 7 psychostimulants, 9 of the 23 
antidepressants, 18 of the 30 anxiolytics and hypnosedatives, 7 of the 20 
antipsychotics, 8 of  the 16 antiepileptics, 2 of the 14 anti-Parkinson and 3 of the 4 
anti-Alzheimer drugs, recommendations fo
patients with liver disease could be found.  
H
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able 1T  
antiepileptics and anti-Parkinson agents 
screened according to pharmacokinetic variables. 
1. High hepatic extraction (category 1) 
• Hepatic extraction > 60% → oral bioavailability < 40% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not complete) 
 
2. Intermediate hepatic extraction (category 2) 
• Hepatic extraction 30 - 60% → oral bioavailability 40 - 70% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not complete) 
 
3. Low hepatic extraction (category 3) 
• Hepatic extraction 0 -30% → oral bioavailability > 70% in the case of complete 
intestinal absorption (or accordingly lower, if intestinal absorption is not complete) 
• In this category, protein binding may be relevant: for binding sensitive drugs (with 
high protein binding >90%), hepatic clearance may increase  
4. Hepatic extraction is not known (category 4) 
able 2
 
Categorization of psycholeptics, psychoanaleptics, 
 
 
 
 
 
T  
lassification of liver disease  
 
 
C
 
Parameter Pathophysiological condition and clinical significance
Alanine aminotransferase (ALT) f hepatocytes. 
 x ULN2  
Breakdown (necrosis or apoptosis) o
Hepatocellular injury1 if > 2
Alkaline phosphatase holestasis3 if > 2 x ULN C
 
Serum bilirubin concentration Cholestasis (exclude prehepatic causes)  
Serum albumin concentration Impaired hepatic protein synthesis  
Prothrombin activity Impaired hepatic protein synthesis  
 
1Hepatocellular injury is defined according to Benichou (25) 
ccording to Benichou (25) 
2ULN: upper limit of normal 
3Cholestasis is defined a
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able 3T  
choleptics, psychoanaleptics, 
ntiepileptics  and anti-Parkinson agents (18,24,26). 
rugs Dose-related adverse reactions 
 
Most important dose-related  adverse reactions of psy
a
 
 
D
 
Psychostimulants 
 
Amphetamines:  
amfepramon, dexamfetamine, 
methylphenidate, phentermine, 
henylpropanolamine 
nts: 
mazindol, modafinil 
iveness, 
ain, 
culatory 
hea, 
(glycogenolysis in liver and adipose tissues). 
p
 
Other psychostimula
Central effects (restlessness, dizziness, 
tremor, hyperactive reflexes, talkativeness, 
tenseness, irritability, weakness, insomnia, 
fever, euphoria). Confusion, aggress
changes in libido, anxiety, delirium, 
hallucinations, panic states, suicidal or 
homicidal tendencies. Fatigue, depression. 
Cardiovascular effects (headache, pallor or 
flushing, palpitation, arrhythmia, anginal p
hypertension or hypotension, cir
collapse). Excessive sweating. 
Gastrointestinal effects (dry mouth, metallic 
taste, anorexia, nausea, vomiting, diarr
abdominal cramps). Metabolic effects 
 
Antidepressants 
 
Tricyclic antidepressants: 
amitriptyline, clomipramine, dibenzepin, 
doxepin, imipramine, lofepramine, melitracen, 
ortriptyline, opipramol, trimipramine 
 
y 
y, sinus 
 
epileptic convulsions. 
n
 
Sedative effects, anticholinergic effects (dr
mouth, sweating, confusion, constipation, 
blurred vision, urinary hesitancy). Weight 
gain. Cardiovascular effects (hypotension, 
alterations in heart rate, delayed conductivity 
and decreased myocardial contractilit
tachycardia, palpitations). Increased
frequency of 
Tetracyclic antidepressants:  
maprotiline, mianserin, mirtazapine 
 
. Skin rashes and seizures in 
verdose.  
ns. Relatively 
igh risk of agranulocytosis.  
 
Maprotiline: 
Lowered consciousness, convulsions, 
confusion, disorientation, visual hallucinations 
and EEG changes similar to tricyclic 
compounds
o
 
Mianserine:  
Reduced anticholinergic and cardiotoxic 
effects, lower risk of convulsio
h
 
Mirtazapine:  
Weakness, fatigue. 
SSRI:  
citalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline 
Gastrointestinal disturbances (such as 
nausea, diarrhea or constipation), CNS-
effects (including insomnia, somnolence, 
tremor, dizziness and headache), effects on 
the autonomic nervous system (such as dry 
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mouth and sweating), sexual disturbances. 
Serotonin precursor: 
xitriptan 
 and 
usion. 
o
 
Frequent stools or frank diarrhea, nausea
drowsiness, agitation and restlessness, 
hyperventilation, hallucination, conf
MAO-A inhibitor: 
moclobemide as 
ects (hepatocellular damage).  
Insomnia, agitation, paresthesias, 
hypotension, autonomic disturbance  such 
dry mouth, sweating, constipation, weight 
gain. Toxic eff
Other antidepressants: 
nefazodone, trazodone, venlafaxine 
 
mouth, 
stipation, headache and 
mblyopia. 
ly priapism (due 
 antiadrenergic actions).  
lar 
Insomnia, nervousness, loss 
of body weight. 
Nefazodone: 
Somnolence, dizziness, asthenia, dry 
nausea, con
a
 
Trazodone: 
Sedation, hypotension. Rare
to
 
Venlafaxine: 
Nausea, sexual dysfunction, cardiovascu
effects with dose-dependent increase in 
blood pressure. 
 
Anxiolytics, hypnotics and sedatives 
 
Benzodiazepines: 
alprazolam, bromazepam, brotizola
clobazam, cloxazolam, diazepam, 
flunitrazepam, flurazepam, ketazolam, 
lorazepam, lormetazepam, midazola
nitrazepam, oxazepam, prazepam
m, 
m, 
, 
lam 
emory 
 
osis may 
benzodiazepines (risk of encephalopathy). 
temazepam, triazo
Drowsiness, ataxia, in-coordination, m
impairment, loss of insight, transient 
euphoria, irritability, aggressive behavior and
excitement. Patients with liver cirrh
be sensitive to sedative effects of 
Imidazopyridine/  
cyclopyrrolone derivatives:  
olpidem, zopiclon 
ves: 
in overdose due to 
z
 
 
Imidazolpyridine, cyclopyrrolone derivati
Like benzodiazepines. Gastrointestinal 
disturbances and visual hallucinations.  
Zolpidem relatively toxic 
respiratory depression.  
Pyrazolopyrimidine: ssion, irritability, agitation, 
zaleplon 
Amnesia, depre
hallucinations. 
Antihistamines: 
diphenhydramine, doxylamin, hydroxyzine, 
ne 
 
ely 
promethazi
Sedation, neuroleptic and anticholinergic side
effects. Gastrointestinal side effects. Rar
blood dyscrasies. Cardiac arrhythmias.  
Aldehyde: 
Chloral hydrate 
y chronic use hepatic damage possible. B
 
Barbiturates:  see antiepileptics 
Carbamate: 
Meprobamate n 
nsion, 
epression, and death.  
Drowsiness and ataxia, impairment of 
learning and motor coordination, prolongatio
of time reaction, by overdose hypote
respiratory d
Other anxiolytics, hypnotics and sedatives: 
buspirone, clomethiazole, methaqualone  the 
 
ory impairment than 
enzodiazepines. 
Buspirone: 
dose-related adverse effects similar to
SSRIs (nausea, headache, insomnia, 
dizziness, and sexual dysfunction). Less
sedation and mem
b
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sal 
sion possible after 
travenous use. 
Drowsiness, headache, nausea, dry mouth. 
 
Clomethiazole: 
Sedation and memory impairment, na
irritation. Hypotension, phlebitis, and 
respiratory depres
in
 
Methaqualone: 
 
Antipsychotics 
 
Benzamides: 
amisulpride, sulpiride, tiapride 
le: 
speridone 
aloperidol, pipamperone  
lozapine, quetiapine 
tive: 
ertindole 
uphenazine, perphenazine, 
ioridazine 
enfluridol 
diazepine:  
lanzapine 
hixen, flupentixol, zuclopenthixol 
s 
linergic 
tion, disturbances of 
ex hormones possible. 
 
 
Benzisoxazo
ri
 
Butyrophenones: 
h
 
Dibenzodiazepines: 
c
 
Indol deriva
s
 
Phenothiazines: 
chlorpromazine, levomepromazine, 
promazine, fl
th
 
Piperidine: 
p
 
Thienobenzo
o
 
Thioxantenes: 
chlorprot
Nervous system side effects like 
extrapyramidal reactions and sedation. Les
frequently seizures, unwanted behavioral 
effects, tardive dyskinesia. Anticho
effects (dry mouth, blurred vision, 
constipation). Postural hypotension. Weight 
gain. Breast engorgement and galactorrhea. 
Amenorrhea, gynecomastia, hyperglycemia, 
hypoglycemia, elevation of growth hormone, 
inappropriate ADH secre
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lithium 
 
ory 
reased 
nd seizures by severe 
intoxication. 
Hand tremor, nausea, vomiting,  diarrhea, 
abdominal pain, sedation, ataxia, coma and
convulsions. Cardiac side effects rare and 
reversible. Transient impairment of mem
possible. Apathy, drowsiness, muscle 
weakness, unsteady gait, dysarthria by mild 
poisoning. Cerebral hemorrhage,  inc
muscle tone a
 
Antiepileptic drugs 
 
Benzodiazepine: 
clonazepam 
emory Drowsiness, ataxia, in-coordination, m
impairment, loss of insight, transient 
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osis may 
y). 
euphoria, irritability, aggressive behavior and
excitement. Patients with liver cirrh
be sensitive to sedative effects of 
benzodiazepines (risk of encephalopath
Barbiturates: 
barbexaclone, phenobarbital, primidone 
 
gmus, 
ic 
mon. Hepatotoxic 
Sedation, fatigue, dizziness, cognitive 
dysfunction, ataxia, dysarthria, nysta
and headache, often dose-related. 
Exacerbation of seizures and psychiatr
reactions not uncom
reactions reported. 
Carbamazepines and derivatives: 
carbamazepine, oxcarbazepine 
d 
ious 
 
ity 
ty, 
Drowsiness, vertigo, ataxia, diplopia, an
blurred vision. Increased frequency of 
seizures possible. Nausea, vomiting, ser
hematological toxicity (aplastic anemia,
agranulocytosis), and hypersensitiv
reactions (dermatitis, eosinophilia, 
lymphadenopathy, splenomegaly). By acute 
intoxication, stupor or coma, hyperirritabili
convulsions, and respiratory depression. 
Succinimide derivatives: 
ethosuximide, methsuximide 
 and 
nd 
nd 
, 
ffects. 
Gastrointestinal effects (nausea, vomiting
anorexia) and CNS effects (drowsiness, 
lethargy, euphoria, dizziness, headache, a
hic-cough). Parkinson-like symptoms a
photophobia. Restlessness, agitation
anxiety, aggressiveness, inability to 
concentrate, and other behavioral e
Urticaria and other skin reactions. 
Hydantoin derivative: 
phenytoin 
ts, 
alacia, and megaloblastic 
utism. 
Dose-related cerebellar-vestibular effec
oculomotor, and cognitive dysfunction, 
behavioral changes, increased frequency of 
seizures, gastrointestinal symptoms, gingival 
hyperplasia, osteom
anemia. Hirs
Fatty acid derivatives: 
tiagabin, valproic acid, vigabatrin izziness, somnolence, and tremor. 
. Rash, 
lopecia. Effects on hepatic function. 
ess, 
taxia, headache, tremor. 
Tiagabine:  
D
 
Valproic acid: 
Weight gain, transient gastrointestinal 
symptoms including anorexia, nausea, 
vomiting. Sedation, ataxia, and tremor
a
 
Vigabatrin: 
fatigue, somnolence, agitation, nervousn
nystagmus,  a
Other antiepileptics: 
gabapentin, lamotrigine, levetiracetam, 
topiramate  
omnolence, dizziness, ataxia, and fatigue. 
lurred or double vision, 
ausea, vomiting.  
omnolence, asthenia, and dizziness.  
Gabapentin: 
S
 
Lamotrigine: 
Dizziness, ataxia, b
n
 
Levetiracetam:  
S
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atigue, weight loss, and 
nervousness. 
Topiramate: 
Somnolence, f
 
Anti-Parkinson agents 
 
Anticholinergic agents: 
biperiden, procyclidine, trihexphenidyl 
 
nticholinergic side effects. 
 
s like chewing and sucking. 
edation. 
nt, 
ent of memory, 
 
 
 
 
 
 
 
 
Biperiden: 
A
 
Procyclidine: 
Anticholinergic side effects, involuntary
movement
S
 
Trihexphenidyl: 
Anticholinergic side effects, exciteme
combined with levodopa acute toxic 
confusional state. Impairm
irreversible brain failure.  
Levodopa 
 mental changes, 
Severe gastrointestinal upsets, postural 
hypertension, dyskinesias,
hallucinations, confusion. 
Amantadine 
ss 
outh, insomnia, lethargy and 
Nausea, psychotic episodes (mania, 
hallucinations, agitation, confusion), restle
legs and convulsions. Livedo reticularis. 
Anticholinergic agents, e.g. blurred vision, 
dryness of the m
rash. Insomnia. 
MAO-B inhibitor: 
y, insomnia.  selegiline 
May accentuate the adverse effects of 
levodopa therapy. Anxiet
Dopamine agonists: 
ergotamine derivatives (bromocriptine, 
lisuride, dihydroergocryptine, pergolide), 
ramipexole, apomorphine 
 
iting, 
ges, confusions, 
allucinations. 
omnolence, nausea, vomiting.  
pe, 
ssness. Gastrointestinal 
p
Ergotamine derivatives: 
Postural hypotension, nausea, vom
psychiatric chan
h
 
Apomorphine: 
S
 
Pramipexole: 
Orthostatic hypotensive effects, synco
tachycardia, chest pain. Drowsiness, 
dizziness, insomnia, increased dyskinesia. 
Hallucinations, restle
symptoms. 
COMT inhibitors: 
entacapone, tolcapone 
 nia. 
astrointestinal adverse effects.  
ausea. Increase of aminotransferases.  
 
Entacapone: 
Fatigue, light-headedness or dizziness. 
Confusion, anxiety, syncope, insom
G
 
Tolcapone: 
Hypotension, hallucinations, dyskinesias, 
n
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m
 
 
Anti-Alzhei er agents 
Anticholinesterases: 
donepezil, tacrine, rivastigmine, galanthamine bdominal cramping, anorexia, nausea, 
rum 
Donepezil, rivastigmine, galantamine: 
Nausea, diarrhea, vomiting, and insomnia. 
 
Tacrine: 
A
vomiting and diarrhea, elevations of se
transaminases.  
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 Table 4 
 
Kinetic data, hepatic adverse effects and dose recommendations in patients with liver disease of the central nervous system agents on the market in Switzerland 
by the end of the year 2001 
 
Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Psychostimulants 
Amphetamines 
Amfepra-
mon 
4  nk
Reduction to 
hydroxy 
derivatives 
(22)  
- 2 - -    No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Dexamfe-
tamine 
4    1
CYP 2D6 (27), 
oxidative 
deamination, 
hydroxylation to 
active metabolite, 
conjugation (18) 
6.11 12 15-
40 
-    No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Methylphe-
nidate 
1  0.95
Oxidase, de-
esterase via non 
microsomal 
esterase to 
retalinic acid (18) 
2      5.6
 
 
20 25
 
28 0.3 Case reports: 
hepatocellular injury 
(21), liver failure 
after high doses 
(28).  
No official dose adjustment recommendations available 
for patients with liver disease.  
Recommendation: Start with a third of normal dose 
(normal dose: 20-30mg/d) in patients with liver cirrhosis. 
Increase dose carefully. 
Phenter-
mine 
4  0.3
Renal elimination 
3.5 20 - -    No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Monitor renal function and adjust the 
dose accordingly. 
Phenylpro-
panolamine 
3  0.15
Renal elimination 
4 4 0 99    No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Monitor renal function and adjust the 
dose accordingly. 
Other psychostimulants 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Mazindol   4 0.9
Conjugation (29), 
(30) 
- 36 77 -    No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Mazindol is extensively metabolised 
by the liver (29, 30), therefore better to avoid in patients 
with liver disease. 
 
Modafinil        3 0.95
Inductor of 
CYP3A4, inhibitor 
of CYP2C19 (22) 
0.9 10.5 62 80 37 0.04 Sporadic: 
cholestatic liver 
injury (22). 
Studies: Half-life is doubled in  
patients with liver cirrhosis (22). 
Recommendation: 50% dose reduction (100-200mg/d) 
for patients with liver disease (22) 
Antidepressants 
Tricyclic antidpressants 
Amitripty-
line 
2 1     
Hydroxylation 
(CYP2D6), N-
demethylation 
(CYP3A4 to 
Nortriptyline), 
conjugation (18) 
14 21 95 48
 
51 
 
0.57 
 
Rare: 
hepatocellular injury 
and cholestatic liver 
injury (21), (22). 
Studies: Altered kinetics (plasma levels and AUC 2-3 
times higher) and strong sedative response in a patient 
with porto-caval anastomosis and cirrhosis (31).  
Recommendation: Caution in patients with porto-caval 
shunts. Start with 50% of normal dose (normal dose: 
75mg/d) and adjust dose according to patient response 
(31). 
Clomipra-
mine 
2  1
Hydroxylation, 
demethylation to 
active metabolite, 
glucuronidation 
(18) 
15      20
 
98 50 45 0.5 Occasionally: 
hepatocellular injury 
(22)  
Rare: 
liver failure (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: According to kinetic behavior, initial 
doses should be reduced by 50% (normal dose: 100 
mg/d) and maintenance dose adjusted according to 
patients response. 
Dibenzepin   1 nk
N-demethylation to 
active metabolite 
(22) 
4.2 5 85 25    No official dose adjustment recommendations available 
for patients with liver disease.  
Recommendation: Based on the low bioavailability, 
initial doses should not exceed 25% of normal (normal 
dose: 300 mg/d) in patients with liver cirrhosis. 
Maintenance doses should be adjusted according to 
patients response. 
Doxepin        1 1
Demethylation, 
20 17
 
95 27
 
65 0.72 Rare: 
hyperbilirubinemia 
Recommendation: Dose adjustment is recommended in 
patients with severe liver disease, but no specification 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
oxidation to active 
metabolite, 
hydroxylation, 
glucuronidation 
(18),  
(22), cholestatic 
and/or 
hepatocellular liver 
injury (21). 
(22). Based on the kinetic data, initial doses should not 
exceed 25% of normal (normal dose: 30-50mg/d), and 
maintenance doses should be adjusted according to 
patient response. 
Imipramine        1 1 
N-demethylation to 
desipramine 
(active metabolite) 
(18) 
 by CYP 2C19 
(32), 1A2 (33), 
2D6 (34), 3A4 (35) 
15 16
 
85 42
 
54.6 0.61 Sporadic: 
cholestatic and 
hepatocellular liver 
injury (21), (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Considering low bioavailability, initial 
dose should not exceed 50% of normal (normal dose: 
100 mg/d). Careful up-titration and monitoring of the 
patient response. 
Lofepra-
mine 
1  1
CYPs (36), N-
dealkylation, 
hydroxylation, 
glucuronidation , 
desipramine 
(active metabolite) 
(18) 
-      2.2
 
99 <10 686 >1 Rare: 
elevation of liver 
enzymes (no 
specification) (22). 
Case report: 
liver failure (36). 
 
Studies: Decreased metabolic clearance in patients with 
severe liver disease (not quantified) (22).  
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Start with <25% of normal dose 
(normal dose: 100 mg/d). Careful up-titration and 
monitoring of the patient response 
Melitracen         4 0.7
Hydroxylation, 
N-demethylation, 
to litracen (active 
metabolite) (22) 
- 19 89 - Sporadic: 
cases of cholestatic 
liver injury (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease.  
Nortripty-
line 
2  1
Inhibitor of 
CYP2D6 (37). 
Demethylation, 
hydroxylation to 
active metabolite 
(by CYP2D6) (18), 
partial biliary 
18     31
 
95 51
 
31 0.34 Occasionally: 
hepatocellular and 
hepatic injury (21). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Start with 50% of normal dose 
(normal dose: 75 mg/d) in patients with liver cirrhosis. 
Careful up-titration. 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
excretion  (38) 
Opipramol 
 
2  0.9
2D6 (22) 
deshydroxyethyl 
metabolite (22) 
10      8
 
91 40 Sporadic: 
hepatic failure (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Starting dose should be reduced by 
50% in cirrhotics (normal dose: 50-100mg/d), careful 
up-titration. 
Trimipra-
mine 
2       0.9
Hydroxylation, 
demethylation to 
active metabolite 
(CYP2D6), 
glucuronidation 
(22),  (18) 
31 23 90 41
 
67 0.67 Rare: 
hepatocellular 
and/or cholestatic 
liver injury (22). 
No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: initial dose should not exceed 50% 
of normal (normal dose: 150 mg/d). Increase dose 
carefully according to effect and toxicity. 
Tetracyclic antidepressants 
Maprotiline  2 1     
Hydroxylation 
(18),  N-
demethylation by 
2D6 (to active 
metabolite), (39),  
25 45 90 68 63.5 0.71 Sporadic: 
hepatocellular injury, 
steatosis,phospho-
lipidosis (21). 
 
Recommendation: The official recommendation is to 
avoid in patients with liver failure (18, 22). In patients 
with liver cirrhosis, the initial dose should be reduced to 
50% of normal (normal dose: 100 mg/d), careful up-
titration. 
Mianserin      2 0.95 
2D6 (40), 
N-oxidation, 
hydroxylation to 
active metabolite, 
N-demethylation to 
active metabolite 
(18) 
10 40 85 68
 
63.5 0.67  No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Start with 50% of normal dose 
(normal dose: 60 mg/d) in patients with liver cirrhosis. 
Increase dose carefully. 
Mirtazapine       2 1 
demethylation to 
active metabolite, 
oxidation (by 
CYP1A2, 2D6, 3A, 
(22) 
4.8 16.3 85 50 38.3 0.43 Sporadic: 
hepatocellular injury 
(22). 
Studies: AUC and half-life increased by 50% in patients 
with liver insufficiency (22). 
Recommendation: Reduce dose by 50% (normal dose: 
30mg/d) in patients with liver cirrhosis (22). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
SSRI 
Citalopram         3 0.95
Weak inhibitor of 
2D6. N-
demethylation  to 
active metabolite 
(CYP 2D6), N-
oxidation and 
deamination  (18) 
14 33
 
80 80
 
18.1 0.19 Rare: 
hepatocellular injury 
(elevation of serum 
transaminases) (41).
Studies: Oral clearance reduced by 40% and 
elimination half-life in cirrhotics about twice that of the 
normal subjects, accumulation possible (42).  
Recommendation: In patients liver cirrhosis 
maintenance dose should not exceed 10-30 mg/d (22). 
Fluoxetine 
 
4  1
N-demethylation to 
norfluoxetine 
(active metabolite) 
(CYP2D6) (18) 
30      48
 
78 -
 
Rare: 
hepatocellular injury, 
hyperbilirubinemia  
(21), (22). 
Elevations of 
bilirubin, of 
transaminases, 
alkaline 
phosphatase and 
gammaglutamyl-
transferase reported 
(43). 
Studies: Increased elimination half-life of fluoxetine 
(from 2-3 days to 7 days) and of norfluoxetine (from 7-9 
days to 12 days) in patients with alcoholic liver cirrhosis 
(20, 44). Increased volume of distribution by 150% and 
plasma clearance two times higher in patient with 
alcoholic liver cirrhosis (45).  
Recommendation: Reduce dose by 50% or increase 
dosage interval from 1 to 2 days in patients with liver 
cirrhosis (22, 45).  
Fluvoxa-
mine 
2      1
Oxidative 
deamination, 
oxidative 
demethylation 
(CYP 2D6) (18), 
(22) 
25 15
 
77 
 
53 
 
89.9 1 Rare: 
elevation of liver 
enzymes (no 
specification) (22). 
Case report: 
elevation of gamma-
glutamyl transferase 
(46).  
Studies: AUC increased by 50% due to longer 
elimination half-life (25h) (47); (18) and 30% decrease 
in clearance in patients with liver cirrhosis (20). 
Recommendation: Reduce initial dose to 50% of normal 
(normal dose: 100mg/d) and monitor maintenance 
therapy carefully in patients with cirrhosis (18, 47).    
Paroxetine         2 0.95
oxidation 
(CYP2D6) (18) 
 
13 17 95 50
 
36.1 0.38  Rare: 
hepatocellular injury 
(21), (22). 
Studies: Doubled plasma levels in patients with 
alcoholic liver cirrhosis (48).  
Recommendation: Dose adjustment recommended 
(10mg/d or 20mg/2d) (22). Initial dose should be at the 
lower end of the range recommended for subjects 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
without liver disease (48).  
Sertraline         4 1
N-demethylation, 
glucuronidation, 
oxidative 
deamination 
(CYP2D6, 3A4). 
Inhibition of CYPs 
2D6, 3A4, 2C9 
(18), (22) 
25 23 98 -
 
160 >1 Rare: 
hepatocellular injury 
(21). 
Case reports: 
liver failure (22). 
Studies: AUC increased by 4 times, half-life by 2.5 
times and Cmax by 1.7 times in patients with liver 
cirrhosis (49), (22). 
Recommendation: Reduce initial dose to 25% of normal 
(normal dose: 50mg/d) (22). Careful increase of dose 
according to effect and toxicity (49).    
Serotonin precursor 
Oxitriptan  4 nk 
conversion to 
serotonin (5-
hydroxytriptophan-
decarboxylase) 
(22) 
- - 19 -    No dose adjustment recommendations available for 
patients with liver disease.  
 
MAO-A inhibitor 
Moclobe-
mide 
2       1
 N-oxidation, 
hydroxylation (18) 
by CYP2C19, 2D6 
(22) 
1.2 1.7 50 55 58 0.64 Case report: 
cholestatic liver 
injury (50). 
 
Studies: Clearance decreased by 25% and three times 
prolonged half-life  in patients with liver cirrhosis (51). 
Recommendation: Reduce initial dose by 50% in 
patients with liver cirrhosis (300mg/d) (or increase 
dosage interval) (51). Careful up-titration according to 
effect and toxicity. 
Other antidepressants 
Nefazodo-
ne 
1        1
Inhibitor of CYP3A 
(18), N-
dealkylation, 
hydroxylation to 
hydroxynefazodon
e (active 
metabolite) (22) by 
CYP3A (52)  
0.5 3.5
 
99 20 Case reports: liver 
failure (53); (54); 
(55). 
The drug has been 
withdrawn from the 
market due to liver 
toxicity. 
Studies: Increased AUC of nefazodone by 60% in 
patients with liver cirrhosis (56, 57).  
Recommendation: Dose adjustment recommended in 
patients with severe liver disease (Child B and C) (18, 
56, 57, 58).  
Initial dose should be reduced to 25% of normal (normal 
dose: 200mg/d). Careful up-titration according to effect 
and toxicity. 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Trazodone         3 1
Hydroxylation (by 
CYP3A4) to 1-m-
chlorophenylpipe-
razine (active 
metabolite, 
CYP2D6) (18), 
(24) 
1.5 6
 
95 75 8.8 0.1 Rare: 
cholestatic and/or 
hepatocellular injury, 
chronic hepatitis 
(21). 
Recommendation: Start with dose in the low range of 
normal (normal dose: 50-100mg) in patients with liver 
disease. Careful up-titration according to effect and 
toxicity.  
Venlafaxine         2 0.95
O-demethylation 
(CYP2D6) to O-
demethylvenlafa-
xine (active 
metabolite), N-
demethylation 
(CYP3A3/4) (22), 
glucuronidation,  
inhibitor of 
CYP2D6 (18),  
6 5
 
27 45
 
92.4 0.98 Case reports: 
hepatocellular injury, 
hepatitis (59); (60). 
Studies: Elimination half-life prolonged by about 30%, 
and clearance decreased by 50% in patients with liver 
cirrhosis. Patient with more severe liver cirrhosis (Child 
C) had a more substantial decrease in clearance (about 
90%) (20).  
Recommendation: Initial dose should not exceed 50% 
of normal (normal dose: 100mg/d) in cirrhotic patients. 
Careful up-titration according to efficacy and toxicity 
(20). Drug should be avoided in patients with cirrhosis 
Child C. 
Anxiolytics, hypnotics and sedatives 
Benzodiazepines 
Alprazolam 3        0.8
CYP3A (61), 
Alpha-OH-
alprazolam (active 
metabolite) 
(18)  
 
1.1 12
 
70 88
 
3.1 0.03
 
Risk of hepatic 
encephalopathy in 
patients with liver 
cirrhosis (18).  
Rare: 
cholestatic liver 
injury (21). 
Studies: Elimination half-life increased by 50% and 
clearance of the drug reduced by 50% in patients with 
alcoholic liver cirrhosis. Changes in elimination half-life 
and clearance indicated that the metabolism of the drug 
is slowed in patients with alcoholic cirrhosis (62). 
Recommendation: Daily dose should be reduced by 
50% in patients with alcoholic liver cirrhosis (62), 
recommended initial dose in patients with liver disease 
is 0.25mg given 2 or 3 times daily (20). 
 
Bromaze-
pam 
2        1
Hydroxylation to 
hydroxybromaze--
0.7 16
 
70 60 2.5 0.03 Recommendation: Dose reduction adjustment 
recommended in patient with liver disease (22). 
Maintenance dose should not exceed 50% of normal 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
pam (22) (normal dose:10mg/d) in patients with liver disease. 
Careful up-titration according to efficacy and toxicity.  
Brotizolam         3 1
Hydroxylation (by 
CYPs) (63) 
0.7 5
 
90 70 7 0.08 Studies: Elimination half-life about two times longer in 
patients with liver cirrhosis than in controls (64).  
Recommendation: Dose adjustment recommended in 
patients with liver disease: 50% of a normal dose 
(0.125-0.250mg) (22). Alternative benzodiazepines, 
which are primarly conjugated (e.g. oxazepam, 
lorazepam) may be preferred in these patients.  
Clobazam          3 1
N-dealkylation to 
active metabolite, 
hydroxylation (18) 
1 20
 
90 >86 1 0.01 Studies: Elimination half-life about twice in patients with 
liver cirrhosis or viral hepatitis compared to normal 
subjects (65).  
Recommendation: Maintenance dose should be 
reduced by 50% (normal dose: 20-30mg/d) (22). 
Cloraze-
pate 
3      1
N-desmethyldiaze-
pam (active 
metabolite) (18) 
1.3 2
 
98 91
 
0.71 0.01 Risk of hepatic 
encephalopathy in 
cirrhotic patients 
(22). 
Recommendation: Smallest effective initial dose 
recommended for patients with liver disease (5mg/d) 
(22). 
Cloxazolam        4 nk 
Chlor-N-
desmethyl-
diazepam (active 
metabolite) (22) 
- - 95 -  Recommendation: Dose adjustment recommended in 
patients with severe liver disease (no specification) 
(22). 
Diazepam      3 1 
N-demethylation 
(CYP 2C19), 
hydroxylation 
(CYP 3A4), 
glucuronidation, N-
desmethyldiaze-
pam, oxazepam 
and temazepam 
are active 
metabolites (18) 
1.5 43
 
98 100
  
2.6 
 
0.02 
 
Rare: 
cholestatic liver 
injury (21). 
Studies: Elimination half-life of diazepam five-fold 
increased in patients with liver cirrhosis compared to 
the controls (66,67). Differences in EEG response at 
similar plasma concentrations in patients with liver 
cirrhosis suggested differences in cerebral sensitivity 
(68). Repeated administration may cause accumulation 
and deeper sedation in patients with liver cirrhosis and 
hepatitis (69). 
Recommendation: Dose adjustment recommended in 
patients with liver disease (69).Based on a clinical 
study, a reduction by approx. 50% is recommended 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
(68).The kinetic data suggest that the maintenance 
dose should not exceed 25% of normal (normal 
dose:10mg/d). Due to the long half-life, there will be 
accumulation and encephalopathy may be more 
accentuated.  
Flunitraze-
pam 
3      1
N-demethylation to 
active metabolite 
(CYP 2C19), 
hydroxylation 
(CYP 3A) (70), 
amination (71) 
3 29 78 85
 
  Risk of hepatic 
encephalopathy in 
patients with liver 
cirrhosis (18).  
 
Studies: Plasma levels and pharmacokinetic 
parameters not altered in patients with hepatic failure 
(liver cirrhosis or hepatitis (72).  
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Considering the extensive hepatic 
metabolism, dosage should be reduced by 50% of 
normal (normal dose: 1mg/d). 
Flurazepam         1 1
N-desalkylation, 
hydroxylation 
(active 
metabolites) (18)  
3.4 2
 
95 30 Rare: 
cholestatic liver 
injury (21). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Considering low bioavailability, 
dosage should be reduced to 30% of normal (normal 
dose: 15-30mg/d). Monitor for drug accumulation. 
Ketazolam         4 1 
N-demethylation to 
oxazepam, 
diazepam (active 
metabolites) (18)  
- 2 93 - Recommendation: Careful dosage recommended in 
patients with liver cirrhosis due to possible 
accumulation of metabolites and induction of hepatic 
encephalopathy (22). 
Lorazepam      3 1 
Glucuronidation 
(18) 
1.3 14
 
90 93
 
4.6 0.05 Risk of hepatic 
encephalopathy 
(22), (18). 
Studies: No changes in the kinetics in patients with 
acute viral hepatitis. Half- life and Vd increased (100%), 
protein binding decreased in patients with alcoholic liver 
cirrhosis (73).  
Recommendation: Dose adjustment recommended, 
50% of normal dose (normal dose: 2mg/d) in patients 
with liver cirrhosis, monitor patients well. Injection to 
avoid in patients with liver failure (22). 
Lormetaze-
pam 
3         0.85
N-demethylation, 
glucuronidation 
4.6 2 85 90 Studies: No changes in the kinetics in patient with liver 
disease (22) and with liver cirrhosis (75).  
Recommendation: Dose adjustment not  
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
(22). Partial biliary 
excretion 0.3-2.8% 
(74) 
necessary in single oral and multiple dose therapy in 
patients with liver cirrhosis (75). 
Midazolam   2 1
3A (76), 
hydroxylation to 
active alpha-
hydroxy-
midazolam (18)  
1  1.9 96 44 27.7 0.31  Studies: Increased AUC by 60% in patients with 
alcoholic liver cirrhosis and increased pharmacological 
effects (77). Prolonged pharmacodynamic effects in 
patients with compensated alcoholic liver cirrhosis (78). 
Decreased clearance by 50% and doubled half-life in 
patients with alcoholic liver cirrhosis. Benzodiazepine of 
choice for patients who require endoscopic procedure 
(79). Doubled bioavailability in patients with liver 
cirrhosis (80).  
Recommendation: Dose adjustment recommended 
(80). 50% of normal dose (normal dose: 7.5-15mg/d) in 
patients with Child A or B cirrhosis, to avoid in patients 
with Child C cirrhosis (22).  
Nitrazepam        3 1
N-reduction (18) 
 
2 30
 
50 78 4 0.04 Case report: 
cholestatic liver 
injury (21). 
Studies: No significant differences in elimination half-
life, clearance and volume of distribution in patients with 
liver cirrhosis. Free fraction increased in patients with 
liver cirrhosis by 35% (81). 
Recommendation: Dose adjustment recommended in 
patients with liver cirrhosis (no quantification) (81). 50% 
dose reduction of normal (normal dose: 2.5-5mg/d) 
Oxazepam     3 1
Glucuronidation 
(18) 
 
1 7
 
98 90 8 0.09 Risk of hepatic 
encephalopathy 
(22), (18) 
Studies: Kinetics not changed in patients with liver 
cirrhosis or acute viral hepatitis (82, 83).  
Recommendation: Dose adjustment not recommend for 
patients with liver cirrhosis or hepatitis (excellent 
sedative for patients with liver disease) (82). Others 
recommend to decrease the dose and  to monitor 
patients (no quantification) (22). 
Prazepam         3 1
Dealkylation to 
Norprazepam 
(active metabolite) 
14 1.3 97 86 10 0.1 Recommendation: Contraindicated in patients with 
severe liver disease due to possible encephalopathy 
(22). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
(22) 
Temaze-
pam 
3 1 
Glucuronidation, 
demethylation, 
enterohepatic 
circulation (18) 
1.4 13 96 80 4 0.04 Risk of hepatic 
encephalopathy 
(22). 
Studies: No significant changes of the pharmacokinetics 
in patients with alcoholic liver cirrhosis (84). Slower 
absorption and delayed hypnotic activity possible in 
patients with liver cirrhosis (85).  
Recommendation: Usually doses (10-20mg/d)) can be 
used in patients with undecompensated cirrhosis (7). 
Caution in patients with liver cirrhosis due to possible 
induction of encephalopathy (84). 
Triazolam   2 1
Hydroxylation to α-
hydroxytriazolam 
(CYP3A) (86) 
, glucuronidation 
(18) 
1.6 3 80 53 23.5 0.26 Risk of hepatic 
encephalopathy in 
patients with liver 
cirrhosis (22). 
Rare: 
cholestatic liver 
injury (21). 
Studies: Risk of disproportional sedative effects in 
patients with cirrhosis, which may be due to decreased 
clearance by 60%, and hypersensitivity of the brain 
(87). Mild to moderate hepatic dysfunction does not 
uniformly result in altered kinetics and drug responses 
(88). 
Recommendation: Should be better avoided in patients 
with liver cirrhosis. However if night time sedation with 
triazolam is deemed appropriate, patients with severe 
liver dysfunction can receive 0.125mg as a start dose 
(89). 
Imidazopyridine/cyclopyrrolone derivatives 
Zolpidem   3 1
Hydroxylation, 
oxidation (by 
CYP3A4) (18), 
partial biliary 
excretion (90) 
0.5      2 93 70
 
18.2 0.2 Case report: 
hepatitis (91). 
Studies: Increased half-life up to 10h  in patients with 
liver cirrhosis (22). 
Recommendation: Initial dose should not exceed 50% 
of normal dose (5mg). Careful up-titration, if necessary 
(22, 92). 
Zopiclone         3 0.95 
N-oxidation (by 
CYP3/4), N-
demethylation, 
oxidative 
decarboxylation 
(22) 
1.4 5
 
45 80
 
14.8 0.16 Studies: Decreased clearance by 40% and prolonged 
half-life (>10h) in patients with liver disease (22). 
Response to zopiclone delayed and possibly 
exaggerated in cirrhosis (93). 
Recommendation: Precautions required when using in 
patients with liver cirrhosis (93). Start with 3.75mg in 
cirrhotics patients Child C or with 7.5mg in  cirrhotics 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
patients Child A/B (94).  
Pyrazolopyrimidine 
Zaleplon 1    1
Aldehyde oxidase, 
CYP3A4, 
glucuronidation 
(22) 
1.4 1
 
60 31 66 0.73  Studies: Oral clearance reduced by 70% and 87% in 
patients with mild or moderate hepatic insufficiency, 
respectively 4-fold increase in Cmax and 7-fold 
increase in AUC (20). 
Recommendation: recommended dose in patients with 
mild to moderate hepatic insufficiency is 5mg. To avoid 
in patients with severe hepatic impairment (20). 
Antihistamines 
Diphenhy-
dramine 
3       0.9
N-demethylation, 
inhibitor of 2D6 
(18) 
4.5 8.5
 
90 72
 
26 0.26  Studies: Elimination half-life increased by 163% and 
protein binding increased by 15% in patients with 
alcoholic liver cirrhosis (95). No apparent increase in 
cerebral sensitivity in patients with alcoholic liver 
cirrhosis (95). 
Recommendation: A single intravenous dose 
(0.8mg/kg) showed to be safe and effective in patients 
with liver cirrhosis (95). Based on the kinetic studies, 
dose should be reduced by 50% (normal dose: 
50mg/d). 
Doxylamine         4 nk
CYP (22), N-
dealkylation, N-
acetyl conjugation 
(96) 
- 10.1 - -  No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Hydroxy-
zine 
4         nk
Cetirizine (active 
metabolite) (97), 
biliar excretion 
70% (22) 
16 3-20 78 - Studies: Prolonged elimination half-life (36.6h) and 
increased volume of distribution (23 L/kg) in patients 
with primary biliary cirrhosis (97).  
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Increase normal dosage interval of 
3-4 times daily to once per 24 hours or less (98). Start 
with low dose, careful up-titration. 
Prometha- 1 1 14 12 85 25 68 0.76  No dose adjustment recommendations available for 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
zine  Sulfoxidation, N-
dealkylation 
(CYP2D6), biliar 
excretion (18) 
patients with liver disease. 
Recommendation: Reduce the dose in patients with 
liver disease to 25% of normal (10mg/d). 
Aldehyde 
Chloral-
hydrate 
4  1
Alcohol 
dehydrogenase to 
trichloroethanol 
(active metabolite) 
(18) 
0.6 8 40 -    No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Carbamate 
Meproba-
mate 
4       0.9
hydroxylation (22) 
0.6 10
 
20 - 3 0.03 Rare: 
hepatocellular injury 
(21). 
Studies: Increased half-life (18-24h) in patients with 
liver cirrhosis and hepatitis (99).  
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Start with reduced dose in patient 
with liver disease, 25% of normal (normal dose: 
1200mg/d).  
Other anxiolytics, hypnotics and sedatives 
Buspirone   1 1
3A (22), oxidative 
dealkylation to 1-
Pyrimidinyl-
piperazine (active), 
hydroxylation, 
glucuronidation 
(18)  
5    2.4
 
95 4
 
92.5 
 
1 
 
 Studies: Cmax about 16 times higher in patients with 
liver cirrhosis than in controls. Elimination half-life in 
cirrhotics about twice that of normal subjects (100). 
Recommendations: Should be used with caution in 
patients with liver disease (100). Due to the high intra- 
and inter-subject variability of the plasma buspirone 
concentration data in patients with liver cirrhosis, dosing 
recommendations cannot be made (101). To avoid in 
patients with liver disease (20). 
Clomethia-
zole 
1        0.95
2A6, 
3A4/5,2B6,1A1,2C
19 (22) 
- 6 65 10 100 1 Studies: Plasma clearance decreased by 30% and 
bioavailability  10 times greater (116%) in patients with 
alcoholic liver cirrhosis (102). 
Recommendation: Dose adjustment recommended in 
patients with alcoholic liver cirrhosis (no specification) 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
(102). To avoid in patients with severe liver disease 
(22). Initial doses should be reduced by at least 50% 
(normal dose: 200-400 mg/d) and increases should be 
made cautiously.  
Methaqua-
lone 
3       0.9
hydroxylation, 
oxidation, 
conjugation (20) 
6 35 80 75 8 0.08  No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: 50% dose reduction of normal 
(normal dose: 250mg) in patients with liver disease.  
Antipsychotics 
Phenothiazines 
Chlorpro-
mazine 
1      1
Hydroxylation, N-
demethylation, N-
oxidation, 
deamination, 
sulfoxidation (18), 
partial biliar 
excretion (22) 
22 30 95 32
 
36.1 0.40 Risk of hepatic 
encephalopathy in 
patients with liver 
cirrhosis (103). 
Sporadic: 
cholestatic liver 
injury (21). 
Studies: Changes in EEG associated with drowsiness 
and increased sensitivity in patients with liver cirrhosis, 
particularly when previous history of encephalopathy 
(103).  
Recommendation: Should be avoid in patients with liver 
cirrhosis due to risk of hepatic encephalopathy (103). 
Fluphena-
zine 
1  1
Hydroxylation to 
active metabolite, 
glucuronidation 
(18), biliar 
excretion, 
enterohepatic 
circulation (22) 
25    20.3
 
90 25.5
 
42 0.47 Risk of hepatic 
encephalopathy 
(22). 
Rare: 
cholestatic liver 
injury (21). 
Recommendation: Dose adjustment recommended in 
patients with liver disease (22). 
Initial oral dose should not exceed 25% of normal 
(normal dose: 10mg/d) 
Levomepro
-mazine 
(methotri-
meprazine) 
4  1
Sulfoxidation, 
glucuronidation, 
demethylation (22) 
30      25 - - Rare: 
cholestatic liver 
injury (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Perphena-
zine 
1  1
N-oxidation, 
hydroxylation, 
sulfoxidation, 
20 
 
 
 
21 90 20 107 1.19 Risk of hepatic 
encephalopathy (18)
Sporadic:  
cholestatic liver 
No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Start with reduced dose in cirrhosis 
patients, 20% of normal (normal dose: 10mg/d), careful 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
glucuronidation 
(18) 
 
 
 
injury  (21). up-titration.  
Promazine   4 1
Hydroxylation, N-
oxidation, 
conjugation (18), 
N-demethylation 
(CYP1A2, 2C19), 
sulfoxidation 
(CYP1A2,3A4) 
(104)  
- - 92 -   Risk of hepatic 
encephalopathy (18)
 
Recommendation: Use not recommended in patients 
with liver disease due to possible encephalopathy (18).  
Thiorida-
zine 
2  1
Sulfoxidation, N-
demethylation, 
hydroxylation 
(CYP2D6), 
conjugation, 
extensive biliary 
excretion (18)  
10 20 97 60   Risk of hepatic 
encephalopathy 
(22).  
Sporadic: 
cholestatic liver 
injury (21). 
Recommendation: Initial dose should be at the lower 
end of the range (up 10mg/d) recommended for 
subjects without disease (22). Increased dose carefully 
according to the effects and/or toxicity.  
Thioxanthenes 
Chlorpro-
thixene 
1        0.95
Sulfoxidation, N-
demethylation, 
hydroxylation, N-
oxidation (22), 
(105) 
15.5 12 99 12 Sporadic: 
cholestatic liver 
injury (21). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: To avoid in patients with liver 
disease. 
Flupentixol        1 1 
Sulfoxidation, N-
dealkylation, 
glucuronidation, 
biliar excretion, 
enterohepatic 
circulation (18) 
14 35 99 40 Occasionally: 
hyperbilirubinemia 
(22). 
Recommendation: Careful dosing due to possible 
accumulation in patients with impaired liver function 
(22). 
Due to low bioavailability, initial oral dose should not 
exceed 50% of normal (normal dose: 3-15mg/d). 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Zuclopen-
thixol 
2        1
Sulfoxidation, N-
dealkylation (2D6) 
(22), 
glucuronidation, 
enterohepatic 
circulation (18) 
20 20
 
99 50 Case reports: 
hepatocellular injury 
(106); (107). 
No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Start with 50% of normal dose 
(normal dose: 2-50mg depending on the indication) in 
cirrhotic patients. Careful up-titration according to the 
effects/toxicity. 
Piperidine 
Penfluridol         3 nk
N-dealkylation, 
enterohepatic 
circulation, biliar 
excretion 80% 
 (22) 
- 100 - 75 Rare: 
hepatocellular injury, 
cholestatic liver 
injury (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Avoid drug in patients with 
cholestatic liver injury. Start with a dose at the  lower 
end of  the range recommended for subjects without 
liver disease (20mg/d), careful up-titration. 
Dibenzodiazepines 
Clozapine 2        1
 
N-demethylation to  
active metabolite 
(CYP1A2, 3A4) 
(108), N-oxidation 
(18) 
5 16
 
95 55
 
25.6 0.3 Rare: 
cholestatic and/or 
hepatocellular liver 
injury (21). 
Recommendation: Monitoring of liver function 
recommended in patients with liver disease. (22). 
According to kinetic behavior, maintenance dose should 
be reduced by approx. 50% (normal dose: 100-
200mg/d). 
Quetiapine       1 0.95
3A4 (22) 
10 6 83 9 79.8 0.84 Sporadic: 
hepatocellular injury 
(22). 
Studies: Clearance decreased by 25% in patients with 
alcoholic liver cirrhosis, plasma levels and AUC 
increased by 40% (20), (22). 
Recommendation: Patients with hepatic impairment 
should be started on 25mg/d. Up-titrate carefully in 
increments of 25-50mg/d to an effective dose, 
depending on clinical response and tolerability (109), 
(20). 
Thienobenzodiazepines 
Olanzapine  2 >0.85     
oxidation (by 
CYP1A2, 2D6, 
14 37
 
93 60
 
18.2 
 
 Frequent: 
hepatocellular injury 
(110). 
Recommendation: Since prolonged half-life probable in 
patients with liver disease, dose reduction 
recommended (no specification) (22). Starting dose 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
, glucuronidation 
(22) 
should be reduced by 50% (normal dose: 10mg/d) in 
cirrhotic patients, careful up-titration.  
Indol derivative 
Sertindole 3        1
Oxidation, N-
dealkylation 
(CYP2D6, 3A) 
(22), (111) 
20 
 
 
 
 
 
72 98 74
 
 
 
Studies: Clearance decreased by 50% in patients with 
liver cirrhosis (22). 
Recommendation: According to (112) dosage should be 
reduced by 50% to offset the expected 50% decrease in 
clearance. Initial dose should be at the lower end of the 
range recommended for subjects without liver disease 
(8-12 mg/d), Careful increase according to toxicity effect 
(22).  
 
Benzamides 
Amisulpride          2 nk
Hydroxylation, 
oxidation, N-
dealkylation (113). 
5.8 12
 
 
16 48 Recommendation: No dose adjustment recommended 
in patients with liver cirrhosis as the drug undergoes 
only modest hepatic meabolism (22) 
Sulpiride        1 0.3 
Renal elimination 
1.5 8 40 30 Rare: 
cholestatic liver 
injury (21). 
No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Monitor the renal function and adjust 
the dose accordingly.  
 
Benzisoxazole 
Risperi-
done 
2       1
9-hydroxylation (by 
2D6) to active 
metabolite, 
oxidative N-
dealkylation (18) 
1.5 3.2 88 66 22.7 0.25 Rare: 
cholestatic and 
hepatocellular liver 
injury (20) 
Studies: No change in single-dose kinetics in patients 
with liver cirrhosis (20). Increased free fraction by 35% 
in patients with liver disease (22). 
Recommendation: Initial dose 2x0.5mg/d, careful up-
titration to 2x1-2mg/d (20,22). 
Butyrophenones 
Haloperidol 2        1
CYP 1A2, 2D6, 
3A, inhibitor of 
CYP2D6, reduced 
17 18
 
92 60
 
49.6 0.55 Case report: 
cholestatic liver 
injury (115). 
 
Recommendation: Dose adjustment recommended in 
patients with liver disease (no specification) (22). 
Dose should be reduced by 50% (normal dose: 3-
9mg/d) in patients with liver disease. 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
haloperidol (active) 
inhibitor of CYP 
2D6 (114) 
Pipampe-
rone 
4       Oxidative N-
dealkylation, 
amide hydrolysis  
- 6 - - Rare: 
hepatocellular injury 
(22). 
Recommendation: Patients with liver disease should be 
started on 10mg daily. Careful up-titration in increments 
of 10mg daily to an effective dose (22). 
Lithium salts 
Lithium 3       0.02
Renal elimination 
0.7 22 100 100
 
1.5 0 Case reports: 
ascites, 
hyperbilirubinemia 
(116), (117). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Monitor the renal function and adjust 
dose accordingly.  
Antiepileptic drugs 
Benzodiazepine 
Clonaze-
pam 
3      1
CYP3A4 (118), N-
reduction (18) 
3 23
 
85 98
 
6.5 
 
0.07 
 
Rare: 
hepatocellular injury 
(21). 
Studies: Plasma protein binding reduced in cirrhotic 
patients (119).  
Recommendation: Dose adjustment recommended in 
patients with severe liver disease (no specification) 
(22). Patients with liver cirrhosis may be sensitive to 
sedative effects of benzodiazepines (120). Dose should 
be reduced by 50% (normal dose: 8mg/d) in patients 
with liver disease. 
Barbiturates 
Barbexa-
clone 
4         nk
Hydroxylation to 
hydroxyphenobar-
bital (121) 
- - 45 - Recommendation: Dose reduction recommended in 
patients with liver disease. The dose should be chosen 
according to the therapeutic concentration (therapeutic 
range:10-40 µg/mL) (22). 
 
Phenobar-
bital 
3       0.7
Inductor of 3A and 
2B6 (122). 
Oxidation (2C19), 
glucuronidation 
(18) 
0.7 99 50 100 0.26 0.01 Sporadic: 
hepatocellular injury, 
cholestatic liver 
injury (21). 
Induction of acute 
intermittant 
porphyria (22). 
Studies: “Modest” impairment in the elimination in 
cirrhosis and/or severe viral hepatitis (123). 
Recommendation: Monitoring of plasma levels 
recommended in patients with liver disease and 
prolonged therapy (123). In patients with severe liver 
disease, it may be contraindicated, in particular if serum 
levels are not monitored. The dose should be chosen 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
according to the therapeutic concentration, closely 
monitoring (therapeutic range:10-40 µg/ml) (22). 
 
Primidone        3 0.6
Oxidation to  
phenobarbital and 
converstion to 
phenylethylmalo-
namide (active 
metabolite) (18) 
0.6 10 20 90 2 0.01 Case report: coma 
reported in one 
patient with acute 
hepatitis (18). 
Very rare: 
hepatocellular injury 
(21). 
Studies: Kinetics not changed in patients with acute 
viral hepatitis (124).  
Recommendation: No dose adjustment recommended 
in patients with acute viral hepatitis (124). Since 
impaired elimination of primidone described in patients 
with sever liver disease, dose adjustment 
recommended (no specification) (22). Monitoring of 
plasma levels may be helpful (18). Dose should be 
reduced by 50% (normal dose: 500-1500mg/d) in 
patients with liver disease. 
Carbamazepines and derivatives 
Carbama-
zepine 
3 1     
Epoxidation to 
active epoxide 
metabolite, 
CYP3A4, 
autoinduction, 
hydroxylation, 
glucuronidation 
(18) 
1.4 
 
15 75 >70 5.46 0.06 Frequent:: 
hepatocellular injury 
(elevation of serum 
transaminases) 
Rare: 
cholestatic liver 
injury. 
Very rare: 
granulomas (21). 
Studies: Metabolism and kinetics not affected by mild to 
moderate hepatic impairment. The kinetics have not 
been evaluated in severe hepatic impairment (20). 
Recommendation: Should not be used in cases of 
aggravated liver dysfunction or active liver disease (20). 
 
Oxcarba-
zepine 
4        nk
hydroxycarbaze-
pine (active 
metabolite), 
cytosylic enzymes, 
(22) 
0.75 28
 
40 -
 
283 Sporadic: 
elevation of γ-
glutamyltranspeptid
ase (125).  
Very rare: 
hepatocellular injury 
(22) 
Recommendation: Dose adjustments not required in 
patients with mild to moderate hepatic impairment (20). 
Succinimide 
Ethosuxi-
mide 
3        0.8
Oxidation (18) 
0.7 45
 
5 100
- 
0.8 0.01  No dose adjustment recommendations available for 
patients with liver disease.  
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effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Methsu-
ximide 
4         1
Oxidation, 
hydroxylation, N-
demethylation to 
active metabolite 
(22) 
- 2.5 - - May precipitate
hepatic acute 
porphyria (126) 
Recommendation: Contraindicated in patients with 
hepatic porphyria. Caution in patients with liver disease, 
monitoring of liver functions recommended (22). 
 
Hydantoin 
Phenytoin         3 1
Hydroxylation 
(CYP2C9), 
glucuronidation, 
CYP induction 
(18), enterohepatic 
circulation (22) 
0.7 24 90 90 Rare: 
hepatocellular or 
mixed injury, 
granuloma  (21). 
 
Studies: Increased percentage (one-third) of unbound 
phenytoin in patients with acute viral hepatitis, however 
no change in half-life or plasma clearance (127). 
Patients with hepatic disease may show early signs of 
toxicity (20). 
Recommendation: Dose adjustment recommended in 
patients with liver cirrhosis (22). No dose adjustment 
recommended in patients with acute viral hepatitis 
(127). In both cases, the free concentration should be 
determined. 
Fatty acid derivatives 
Tiagabine  3 nk        
metabolism by 
CYP3A (22), 
enterohepatic 
circulation (128) 
1 8
 
90 90 8.4 Studies: Increased half-life (11-15h, 50-100% increase) 
in patients with liver disease (22,129). Increased 
incidence of neurological adverse effects in patients 
with liver disease: dizziness, tremor, nausea, 
somnolence, incoordination (129). 
Recommendation: Patients should be monitored closely 
for potential neurological adverse effects (129). Starting 
dose should not exceed 50% of normal dose (normal 
dose: 30mg/d). 
Valproic 
acid 
3      0.95 0.2 14 90 100
 
0.5 
 
0.01 
 
 
Frequent: 
transient 
hepatocellular 
and/or cholestatic 
liver injury (22). 
Glucuronidation, β-
oxidation (18), 
biliary excretion 
7% (130) 
Case reports: 
fulminant liver failure 
Studies: Prolonged half-life by 1.5 time and increased 
volume of distribution by 1.5 time, decreased protein 
binding by 10% in patients with liver cirrhosis. 
Decreased clearance by 50% in patients with liver 
cirrhosis and by 16% in patients with acute hepatitis 
(135).  
Recommendation: To avoid in patients with liver 
 
 Drug Cat1 Kinetic parameters Hepatic adverse 
effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
(131), (132). Hepatic 
liver injury (133), 
(134). 
cirrhosis or significant hepatic insufficiency (18, 20), and 
in patients with mitochondrial diseases (131). 
Vigabatrin       3 0.45
no CYPs 
1 7 0 80 5.6 0.03 Case report: 
liver failure (136). 
No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Dose should be reduced by 50% 
(normal dose: 2g/d) in patients with liver disease. 
Careful up-titration according to toxicity effect.  
Other antiepileptics 
Gabapentin  2 0.35       
Renal elimination 
0.8 6.5
 
0 60
 
6.7 0.03 Case reports: acute 
liver toxicity with a 
mixed pattern of 
cytolosis and 
cholestasis 
(elevations of 
aminotransferases, 
GGT and ALP) 
(137), cholestatic 
liver injury (138). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Monitor the renal function and adjust 
dose accordingly. For patients with creatinine clearance 
of 15ml/min or less dosage should be adjusted 
proportionally (e.g. by clearance of 7.5ml/min dose 
should be one-half of the dose by clearance of 
15ml/min) (20). 
Lamotrigine        3 0.9 1.1 35
 
55 98 1.6 0.02 Case reports:  
 2 cases of mixed 
liver injury (139), 
(140). 
Recommendation: Since clearance is decreased in 
patients with liver cirrhosis, dose should be reduced: 
50% in patients with Child B (12.5-25mg/d), 75% in 
Child C cirrhosis(10-15mg/d) (22). Very careful up-
titration in patients with liver cirrhosis. 
N-glucuronidation 
(18) 
Levetirace-
tam 
3        0.3
Renal elimination 
0.6 7
 
5 100
 
4 0.01 Studies: Decreased total body clearance by 50% in 
patients with severe hepatic impairment (22). 
Recommendation: Monitoring of renal function. 50% 
dose reduction (normal dose: 500-1500mg/d) 
recommended for patients with severe liver disease and 
creatinine clearance <70 ml/min (22). 
Topiramate       3 0.1
Renal elimination 
0.6 21
 
9-17 70 1.3 0.01 Sporadic: 
cases of liver failure 
(22). 
Studies: Reduced clearance in patients with liver 
disease (no specification) (22).  
No dose adjustment recommendations available for 
patients with liver disease. 
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effects9
Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
Recommendation: Adjust according to renal function. 
By creatinine clearance <70ml/min/1.73 square 
meters), one-half of the usual adult dose (normal dose: 
200-400mg/d) is recommended (20). 
Anti-Parkinson agents 
Anticholinergic agents 
Biperiden  1 1 
Hydroxylation (18) 
 
24 1.5 95 33.5    No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Considering the low bioavailability, 
initial doses should be reduced by at least 50% and 
increases should be made cautiously.  
Procycli-
dine 
3      nk - 12 - 75 Recommendation: Caution in patients with liver disease 
(22). A twice daily dosage instead of the usual thrice 
daily dosage had been suggested(141). 
Trihexy-
phenidyl 
4        1
 
- 5 - - Sporadic: 
two cases of 
cholestatic liver 
injury (21). 
Recommendation: Should be used with caution (22). At 
this time no data are available. 
Levodopa 
Levodopa         1 1
Dopa 
decarboxylase to 
dopamine (active 
metabolite) (18) 
1 1.4
 
5 33 Frequent: 
elevation of AST 
levels (incidence 
9%) (21). 
Case reports: two 
cases of mixed liver 
injury with jaundice 
reported (21). 
 
No dose adjustment recommendations available for 
patients with liver disease.  
 
Amantadine 
Amanta-
dine 
3        0.1
Renal elimination 
(18) 
7.5 15
 
67 90
 
20.2 0.02 Rare: 
reversible elevation 
of liver enzymes (no 
specification) (22), 
(20). None (21). 
Recommendation: Should be used with caution in 
patients with liver disease (22). Monitor the renal 
function and adjust dose accordingly.  
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Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
MAO-B inhibitor 
Selegiline 4        1
Oxidative 
dealkylation 
(CYP1A2,3A4) to 
amphetamine, 
methamphetamine 
and  
desmethylselegili-
ne (18), (142) 
4.3 1.9 94 -
 
6300 >1 Sporadic: 
elevation of  liver 
enzymes (no 
specification) (22).  
No dose adjustment recommendations available for 
patients with liver disease. 
 
Dopamine agonists 
Apomor-
phine 
1  nk
Conjugation (22) 
2 0.1 100 1.7    No dose adjustment recommendations available for 
patients with liver disease.  
 
Bromocrip-
tine 
1      1
 
2 7
 
 
96 6
 
56 
 
0.62 
 
Rare: 
two cases of 
hyperbilirubineamia 
(21). 
No dose adjustment recommendations available for 
patients with liver disease.  
Recommendation: Since bromocriptine undergoes 
hepatic metabolism, to avoid in patients with liver 
cirrhosis. 
Dihydroer-
gocryptine 
4  nk
Partial biliar 
excretion (22) 
16 14 50 -    No dose adjustment recommendations available for 
patients with liver disease.  
 
Lisuride        1 1 
Hydroxylation, 
oxidation, N-
desalkylation 
biliar excretion (18) 
2.3 2.2
 
70 15
 
48 0.53 Recommendation: Dose reduction recommended in 
patients with liver disease (decreased elimination, 
increased plasma levels) (22). Start with <25% of 
normal dose, careful up-titration. 
Pergolide    4 1 
Pergolide 
sulfoxide, 
pergolide sulfone 
(both active in 
animals) (22) 
24 27
 
90 -    No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Drug is best avoided in patients with 
liver cirrhosis. 
Pramipexo- 3       0.15 7.1 11.6 15 90 56.7 0.1 Rare: Recommendation: No dose adjustment recommended 
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Studies performed and dosage recommendations 
  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
le Renal elimination elevation of 
transaminase levels 
(143). 
in patients with liver disease, but in patients with renal 
disease (22). Monitor the renal function and adjust 
accordingly.  
Orthopramide 
Tiapride 3    0.25
Renal elimination  
1.4 5
 
0 70    No dose adjustment recommendations available for 
patients with liver disease. 
Recommendation: Monitor the renal function and adjust 
accordingly. 
COMT inhibitors 
Entacapo-
ne 
2       1
 Isomerisation 
(22), 90% biliar 
excretion (144), 
(145), (146), 
inhibitor of 2C9 
(22) 
2.6 0.28
 
98 42 43.3 0.48 Rare: 
elevation of  liver 
enzymes (no 
specification) (22). 
No dose adjustment recommendations available for 
patients with liver disease.  
Studies: 2-fold higher AUC and maximum concentration 
value in patients with a history of alcoholism and 
hepatic impairment after a single dose of entacapone 
(20). 
Recommendation: Due to low bioavailability, initial dose 
should be reduced by 50-70% (normal dose: 
1000mg/d). 
Anti-Alzheimer agents 
Anticholinesterases 
Donepezil  4 0.95      
2D6, 3A (147), 
glucuronidation 
(22) 
12 59.7
 
96 - 12.2 0.13  Studies: Clearance reduced by 20% in patients with 
alcoholic cirrhosis (22). Kinetics not significantly 
changed in patients with compensated liver cirrhosis 
(148). 
Recommendation: Normal initial doses (5mg) in 
patients with liver disease. (22). Maintenance doses 
may be increased according to clinical needs and 
adverse effects 
Galanta-
mine 
3         0.8
N-oxidation, N-
demethylation, O-
demethylation 
(CYP 2D6, 3A), 
glucuronidation, 
2.5 5.7 18 88.5 Studies: Kinetic not altered in patients with Child A 
cirrhosis.  AUC and elimination half-life increased by 
30% in patients with Child B cirrhosis (22). 
Recommendation: In patient with moderately impaired 
hepatic function (Child A, B) the dose should not 
exceed 16mg daily. Avoid in patients with severe liver 
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  Q02, metabolism Vd3
(L/kg) 
t½4
(h) 
PB5
(%) 
F6 
(%) 
Clsys7
(L/h) 
E8   
epimerisation, 
active metabolites 
(22), biliar 
excretion 0.2% 
(149) 
disease (Child C) (20). Carefull uptitration while 
monitoring adverse effects (22).  
Tacrine         1 1
Hydroxylation 
(CYP1A2) (18) 
5 2.5 55 17 Frequent: 
hepatocellular injury 
(21). 
Recommendation: Contraindicated in patients with liver 
disease due to hepatic toxicity (22). 
Rivastig-
mine 
1  1
Cholinesterase 
(22) 
2 1 40 36   Changes in the 
pharmacokinetics in 
patients with liver 
disease should not 
have effects on the 
incidence of adverse 
effects (22). 
Studies: Clearance decreased by 50% and activity of 
cholinesterase, AUC doubled in patients with liver 
cirrhosis (22).  
Recommendation: Dose adjustment is not 
recommended in patient with mild liver disease, but 
may be indicated in patients with Child B or C cirrhosis 
(22). Dose should not exceed 30% of normal dose 
(normal dose: 9mg/d). 
 
1Cat = drug category. Drugs were categorized as follows: Category 1: high hepatic extraction (E) (E>60%, bioavailability < 40%), category 2: intermediate hepatic 
extraction (E=30-60, bioavailability 40-70%), category 3: low hepatic extraction (E<30%, bioavailability >70%), category 4: hepatic extraction not known 
2Q0: extrarenal dose fraction= fraction metabolized or excreted by bile (1 - Q0: fraction excreted unchanged by the kidney) 
3Vd: volume of distribution in L per kg. For calculation, body weight was assumed to be 70 kg. 
4 t½: dominant half-life 
5PB: Fraction bound to proteins (protein binding in %) 
6F: Bioavailability 
7Clsys: systemic clearance (L/min) 
8E: hepatic extraction, calculated as described in equation 3 
9Frequency of hepatic adverse effects: frequent > 10% of patients treated, sporadic: 1-10%, rare: < 1% 
Abbreviations: CYP = cytochrome P450, ULN = upper limit of normal 
Characterization of liver disease: compare Table 2 
 
 
 
 
 
Dose adaptation in patients with liver disease 
___________________________________________________________________ 
 
Discussion 
In order to compare the prediction of the kinetic behavior (estimated using hepatic 
extraction) with kinetic studies carried out in patients with liver disease, we studied 
the psychoanaleptics (including psychostimulants, antidepressants and anti-
Alzheimer drugs), psycholeptics (antipsychotics, anxiolytics, hypnotics and 
sedatives), anti-Parkinson drugs and antiepileptics on the market in Switzerland.  
As explained in the introduction, classification according to pharmacokinetic 
properties and conducted clinical trials in patients with liver disease can help to select 
and administer drugs more rationally in such  patients. The hepatic extraction (E) is 
important to predict the kinetic behavior of drugs and to avoid dose-dependent drug 
toxicity in patients with impaired liver function. However, our studies shows that for 
most of the drugs studied dosage recommendations are not available for patients 
with liver insufficiency. This is due to the absence of published data about hepatic 
extraction (E) (which is essential to help dosing in patients with liver disease) and the 
scarcity of clinical studies performed in patients with liver disease.  
Most of the clinical studies have investigated  the kinetic behavior of drugs in patients 
with liver cirrhosis and, less frequently, hepatitis. There are few data of dosage 
recommendations for patients with liver pathology other than liver cirrhosis.  
Another deficiency of the reported studies is that the majority are single-dose studies 
and do not provide information for the adaptation of the maintenance dosage. In fact, 
patients who need psychotropic drugs are usually treated for a prolonged period of 
time: drugs can cumulate increasing the risk of dose-related adverse effects (as 
shown in Table 3) or leading to stronger pharmacodynamic effects. Often clinical 
studies do not provide quantitative  dosage adjustments or remain vague. In most 
cases, it is obvious that the dosage should be adjusted, but the problem is by how 
much. Another point to take into consideration is that adjusting drug dosage in 
patients with liver disease  should be based on both pharmacokinetics and 
pharmacodynamic changes, since the effects of some drugs are altered due to 
changes in their dynamics. For example, hepatic patients have a greater cerebral 
sensitivity to a number of drugs acting on the central nervous system (CNS). 
Although the mechanism underlying this hypersensitivity remains to be explained, 
there is evidence that this is not caused only by pharmacokinetic alterations.  
In our study, we can conclude that there is a lack of data concerning the safe use of 
drugs acting on the CNS in patients with liver disease: on the one hand data about 
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the hepatic extraction and on the other hand clinical studies which should also 
provide information about pharmacodynamic changes in these patient population.           
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4.1 Introduction 
Some high-extraction (or flow-limited) drugs are frequently used in patients with liver 
cirrhosis (i.e. propranolol, clomethiazole). Hepatic clearance of high-extraction drugs 
is mainly determined by blood flow across the liver (1). By definition, when given 
orally, only a small proportion of high-extraction drugs reaches systemic circulation 
(low systemic bioavailability). 
Patients with liver cirrhosis generally have reduced hepatic blood flow and portal-
systemic shunts impair contact between portal blood and hepatocytes so that a 
variable amount of portal blood cannot be cleared by hepatocytes. These two 
mechanisms lead to reduced hepatic clearance  and increased systemic 
bioavailability of high-extraction drugs. This may potentially lead to toxic reactions, 
depending on the toxicity profile of the drugs. Therefore, in general both the loading 
as well as the maintenance dose of flow-limited drugs must be reduced in patients 
with liver cirrhosis (2). 
Bile acids are removed from portal blood in healthy subjects by flow-limited hepatic 
uptake. They are excreted in bile either unchanged and/or in conjugated form. In 
cirrhosis, plasma bile acid concentrations are elevated due to impaired hepatic 
uptake and/or elimination (3,4,5). It was concluded that intrahepatic shunting was the 
main determinant of serum bile acid concentrations in patients with liver cirrhosis and 
this was supported by Ohkubo (4) who measured the extent of intrahepatic shunting 
and found that serum bile acids correlated well with the degree of shunting.  
Since, as discussed above, bioavailability of high-extraction drugs is a function of the 
magnitude of portal-systemic shunts, we hypothesize that the bioavailability of 
propranolol and other high-extraction drugs shows a linear correlation with serum bile 
acid concentrations in patients with liver cirrhosis. 
 
4.2 Subjects and methods 
Control subjects and patients with liver cirrhosis  
3 healthy individuals (the control group) and 14 patients with liver cirrhosis were 
studied. The control subjects were all in good health and had no evidence of liver 
disease, as assessed by medical history and physical examination. The 14 patients 
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with liver cirrhosis were recruited from outpatients regularly seen at the Hepatology 
Unit of the University Hospital of Basel.  
Details of the patients with liver disease and the control subjects are listed in Table 
4.1. Medicaments taken by the patients in with cirrhosis during the month preceding 
the study are shown in Table 4.1. Patients were assessed by conventional liver tests 
(serum concentration of albumin, bilirubin, prothrombin time, serum activity of alanine 
aminotransferase). In healthy subjects, conventional liver tests were not performed. 
 
Study design 
The study was approved by the Ethics Committee of Basel. After having obtained 
written consent, patients and control subjects were evaluated 2-4 weeks prior to the 
study by clinical examination and by doing the liver function tests detailed above. The 
study had an open cross-over design and consisted of two individual sessions. 
Patients and volunteers received randomly either 0.66 mg propranolol given as an 
intravenous infusion over 10 minutes using a perfusor pump or 40 mg propranolol 
given as an oral tablet. Propranolol was administered at 7.30 AM. A light standard 
meal was served 2 hours after the administration of propranolol. The interval between 
the individual sessions was at least 7 days.  
 
Blood sampling 
An i.v. catheter was inserted in a vein on the forearm and a venous blood sample (5 
ml) was collected into heparinized tubes which were centrifuged at 3000 rpm for 10 
minutes and then stored at - 20°C. In case of intravenous propranolol administration, 
blood sampling was done through an indwelling catheter placed in a vein of the 
contralateral arm. After a single oral dose of 40 mg propranolol or an i.v. dose  of 1 
mg propranolol applied as infusion over 10 minutes using a perfusor pump, blood 
samples were collected at 5 minutes, 0.25, 0.5, 1, 1.5, 2, 3, 5, 8, 14, 24, 36 and 48 
hours. After i.v. application of propranolol, additional samples were collected at 10 
minutes and 0.75 hours. At 24 and 48 hours patients arrived at 8:00 a.m. after an 
overnight fast (see day 1) and two blood samples (5 ml each) were obtained by 
venepuncture. Blood pressure and heart rate were determined at the same time 
points when blood was obtained. 
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Determination of propranolol 
Propranolol plasma levels were measured using a high pressure liquid 
chromatography (HPLC)-assay. A simple and method was developed to determine 
low propranolol concentration in heparinised human plasma using pronethanol as 
internal standard. The mobile phase (optimized for separation of pronethanol and 
propranolol) was aqueous phosphoric acid pH 2.5 (containing  2.5 mM octansulfonic 
acid sodium and 0.01 M potassium dihydrogenphosphat):acetonitrile (68:33, v/v). The 
flow-rate was kept at 0.8 ml/min and the analysis accomplished in less than 12 min. 
The column effluent was monitored with a fluorescence detector at an excitation 
wavelength of 230 nm and an emission wavelength of 340 nm. Extraction was 
performed from 1 ml (intravenous kinetics) or from 0.200 ml human plasma (oral 
kinetics). As internal standard, for the intravenous kinetics a 100-µl volume of 
aqueous pronethanol solution (120 ng/ml) was added to 1 ml human plasma, 
whereas for the oral kinetics 20 µl of aqueous pronethanol solution (600 ng/ml) was 
added to 200 µl human plasma. After addition of 300 µl  (1.4 M)  sodium 
dihydrogencarbonate and vortex mixing for 15 s, 9 ml of extraction medium 
(hexan:ethylacetat 1:1, v/v)  were given to the sample and shaken for 20 min. After 
centrifugation of the tubes (3000 N/min, 5 min), the aqueous layer was frozen and the 
organic layer extracted with 300 µl  (0.01M) sulfuric acid. The samples were shaken 
for 20 min. After centrifugation (3000 N/min, 5 min), 250 µl of the organic layer were 
transferred into autosampler vials, which were closed after 30 minutes and put in the 
autosampler. An aliquot of 10 µl was injected into the HPLC system. The separation 
took place in a 3 µm Luna Pheny-Hexyl column (150x4.60 mm i.d., Phenomenex, 
Germany) protected by a phenyl (phenypropyl) guard column (4x3 mm i.d., 
Phenomenex, Germany) and thermostated at 37°C 
The limit of detection for propranolol was 0.15 ng/ml and the limit of quantification 0.5 
ng/ml. The mean precision was found to be 2.4% and 7.9% for the intra- and interday 
precision, respectively. The mean accuracy for both inter- and intra-day precision 
was found to be 102 and 106%. The analytical recoveries of the drug from 
heparinised human plasma were determined at four concentrations such as 48, 13, 6 
and 1.5 ng/ml and its mean percent of recovery ranged from 85.0 to 95.5%. 
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Determination of bile acids 
The total plasma bile acid pool was determined in the plasma samples obtained at 0, 
24 and 48 hours after propranolol administration using a commercially available 
spectrophotometric assay (Wako, Osaka, Japan). Conventional liver function tests, 
other biochemical determinations and hematological investigations were performed 
by standard methods in the Departments of Clinical Chemistry of the University 
Hospital of Basel. 
 
Pharmacokinetic calculations 
Analysis of the plasma samples provided two individual plasma concentration-time 
curves for each subject for propranolol. Values below the limit of quantification (0.5 
ng/ml) were set at zero for the calculation. The plasma concentration-time curves 
(AUC) was obtained by using a non compartment al model (TopFit, version 2.0).  
The area under the plasma concentration / time curve (AUC) of  propranolol 
concentration after oral and i.v. administration were calculated as follows: 
 
AUC (0-∞)= AUC(0-t) + C(t)/ ke   
 
in which t is 48 hours and ke is the elimination rate constant calculated as the slope of 
the plasma concentration-time curve after semilogarithmic transformation. AUC(0-t) 
was calculated by use of the trapezoidal rule with linear interpolation. 
Bioavailability (F) of propranolol was calculated as follows: 
 
F = (AUCoral X doseiv)/(AUCiv X doseoral) 
 
Tmax and Cmax values were determined from raw data. Elimination half -life and 
clearance were estimated using non-linear-regression analysis as follows: 
 
    CL = F X dose/AUC 
 
With F set at 1 for intravenous administration. The apparent volume of distribution of 
propranolol was calculated as: 
    Vd = F X dose/(AUC X ke) 
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Statistical analysis 
Data are expressed as mean with standard variation. Group means were compared 
by two-tailed unpaired t-test using the SPSS statistical program (SPSS for Windows, 
version 10.1, SPSS Inc., Chicago IL, USA). The level of significance was p=0.05. 
Linear regression analysis was performed by the least squares method, α of 0.05 
was considered to be statistically significant. 
 
4.3 Results and discussion 
The total serum bile acid concentrations and pharmacokinetic parameters of 
propranolol were investigated following oral and intravenous administration to 
patients with biopsy proven cirrhosis (n=14 ) and in healthy control subjects (n=3).  
Results of conventional liver function tests are shown in Table 4.1. As shown in this 
table the patients were older than the control subjects. The main results of the 
pharmacokinetics of propranolol are shown in Table 4.2. The concentration-time 
profiles of propranolol could adequately be described by non-compartmental 
analysis. Although large variations were observed between individual patients, the 
intravenous pharmacokinetic parameters did not differ significantly between patients 
and healthy subjects. However, as expected, the oral pharmacokinetic parameters 
showed a significantly (by 7 times) increased area under the curve (AUC) in patients 
with liver cirrhosis as compared to control subjects. The elimination half-life (t1/2) was 
prolonged by 6 times in cirrhotic patients as compared to controls and the 
bioavailability (F) was found to be 60% in patients with liver cirrhosis and 12% in 
control subjects. This last finding accords with other reports in the literature (6,7). 
134 
 
 
Table 4.1. Details of patients and control subjects. Normal values in parentheses.   
Past history 
 
Subj.   
  
Sex Age
(y) 
Diagnosisa BWa 
(kg) 
Albumin 
(35-52g/l) 
Bilirubin  
(5-26 µmol/l) 
ASTa 
 (11-36 IU/l)
Alkaline  
phosphatase 
(normal: 43-
106 IU/l) 
INRa 
(<1.3) 
Encepha-
lopathy 
Ascites Variceal
bleeding 
Child’s  
score 
Medica-
tionb
 
Patients with liver cirrhosis 
1                
  
   
             
   
              
         
    
               
               
               
m 57 AC 57 35 46 49 142 1.1 - - - A / 7 1,2,3,4
2c f 51 d 76 35 9 175 79 1.1 - - - A / 6 5,6 
3 m 27 NAC
(HBV) 
57 28 183 237 124 1.5 - - - B / 8 4,7,8,9, 
10 
4 m 54 AC 76 17 178 234 327 1.4 + + - C / 12 11,12,13,
14,15 
5 f 47 NAC 59 31 18 107 167 1.4 - - - A / 6 16 
6 m 37 NAC
(HCV) 
70 35 11 85 102 1.0 - - - A / 6 17 
7 m 50 AC d 28 133 63 235 2.2 - - - C / 12 18
8 f 49 AC 53 24 44 37 286 d - + - B / 9 2,3,11,12
18,19 
9 m 50 AC 89.5 27 393 200 314 1.3 + + - C / 11 3,11,12 
10 m 60 NAC
(HBV) 
94 35 29 101 261 1.2 - - - A / 6 2,20,21, 
22,23,24 
11c m 60 AC 92 31 20 21 104 1.3 - - - A / 6
12 m 51 AC 58 25 117 98 286 1.1 - - - B / 9 2,3,11,12
15,25,26 
 
 
 
Past history 
 
Subj.   Sex Age
(y) 
Diagnosisa BWa 
(kg) 
Albumin 
(35-52g/l) 
Bilirubin  
(5-26 µmol/l) 
ASTa 
 (11-36 IU/l)
Alkaline  
phosphatase 
(43-106 IU/l) 
INRa 
(<1.3) 
Encepha-
lopathy 
Ascites Variceal 
bleeding 
Child 
score 
Medica-
tionb
 
13 
 
m 
 
58 
 
AC 
 
63 
 
24 
 
8 
 
20 
 
50 
 
1.1 
 
- 
 
+ 
 
+ 
 
B / 8 
 
13,15,18,
27,28,29,
30 
               
           
             
             
             
               
            
             
14 m 67 NAC 80 36 17 142 101 1.1 - - - A / 5 21, 31 
Mean 51 71.1 29.36 86.14
 
112.07 
 
184.14 
 
1.29
SD 10 13.9 5.45 104.64 72.18 93.10 0.30
 
Healthy control subjects 
REP m 20 - 74 ND ND ND ND ND - - - - .
GEC m 20 - 75 ND ND ND ND ND - - - - .
TCL f 27 - 63 ND ND ND ND ND - - - - .
Mean 22 71 ND ND ND ND ND  
SD 3 5  
 
a Abbreviations: AST, serum aspartate aminotransferase; AC, alcoholic cirrhosis; BW, body weight; INR, international normalized ratio; NAC, nonalcoholic 
cirrhosis (due to viral hepatitis); ND, not determined; SD: standard deviation 
b Medicaments used during the month preceding the study: 1, lamivudine; 2, torasemide; 3, spironolactone; 4, calcium and colecalciferol; 5, losartan;6, 
calcitriol; 7, ciclosporin; 8, mycophenolic acid; 9, prednisone; 10, omeprazole; vitamine B-complex; 12, thiamine, 13, ciprofloxacine; 14, vitamine K; 15, 
lactose; 16, morphine; 17, diflucane; 18, propranolol; 19, amoxicillin; 20, acetylsalicylic acid; 21, atenolol; 22, valsartan; 23, simvastatin; 24, insulin; 25, 
acid folic; 26, potassium chloride; 27, furosemide; 28, pantoprazole; 29, tazobactam; 30,dalteparin; 31, hydrochlorothiazide 
c  patients with cholecystectomy 
d missing data 
 
 
 
 
Table 4.2. Pharmacokinetic parameters of propranolol in patients and control subjects 
Intravenousa OralbSubj 
 
 Cmax 
(ng/ml) 
tmax 
(min) 
AUC  
(0-∞) 
(ng.min/ml) 
Cl 
(ml/min) 
Vd 
(l) 
ke  
(1/min) 
 
t1/2
(min) 
Cmax 
(ng/ml) 
tmax 
(min) 
AUC 
(0-∞) 
(ng.min/
ml) 
Cl 
(ml/ 
min) 
Vd 
(l) 
ke  
(1/min) 
 
t1/2
(min) 
              
 
Patients with liver cirrhosis 
 
F(%) 
 
 
1 2.25 10 662.08 997 407 2.45 x10-3 283 89.8 120 40097.25 997 406 2.45 x10-3 283 99.93 
2 18.7 5 1560.3 423 217 1.95 x10-3 356 59.1 90 48608.17 423 490 8.63 x10-4 803 51.4 
3 10 10 1338.65 493 163 3.03 x10-3 229 52.1 480 55084.17 493 428 1.15 x10-3 601 67.90 
4 2.4 10 2982.8 221 276 8.02 x10-4 864 156.1 181 141779.4 221 217 1.02 x10-3 680 78.43 
5 6.3 10 752.92 877 666 1.32 x10-3 527 24.7 90 22275.62 879 1064 8.24 x10-4 841 48.82 
6 12.1 5 768.56 859 396 2.17 x10-3 319 50.03 90 14593.68 858 385 2.22 x10-3 312 31.33 
7 7 7 1686.73 391 228 1.72 x10-3 403 63 180 73506.24 391 616 6.36 x10-4 1090 71.91 
8 7.4 5 3482.2 190 191 9.9 x10-4 700 61.9 180 86988.89 190 309 6.13 x10-4 1130 41.22 
9 2.2 10 1482.05 445 500 8.9 x10-4 779 32.7 304 48318.72 289 293 6.8 x10-4 1020 53.79 
10 8.3 5 942.69 827 424 1.95 x10-3 355 20.3 60 13846.89 701 720 9.72 x10-4 713 24.24 
11 10.6 5 1373.67 480 358 1.34 x10-3 517 132.4 182 73555.36 481 500 9.61 x10-4 722 88.35 
12 5.9 8 2700.42 541 824 6.56 x10-4 1060 31.8 60 62609.77 541 1337 4.05 x10-4 1710 84.63 
13 2.2 18 2349.5 281 375 7.48 x10-4 926 52.5 180 42239.13 281 214 1.31 x10-3 528 29.66 
14 11.8 5 1002.26 659 261 2.52 x10-3 275 82.2 60 43838.26 658 695 9.48 x10-4 732 72.17 
             
Mean 7.3 8.3 1699 540 387 1.5x10-4 563 63.6 169 55654 529 548 2.24x10-4   
  
803 59.4
SD 4.6      263 39 111 33004 248 311 2.8x10-4 364 23.5 3.6 876 256 184 0.7x10-4
              
 
 
 
Intravenousa OralbSubj 
 
 Cmax 
(ng/ml) 
tmax 
(min) 
AUC  
(0-∞) 
(ng.min/ml) 
Cl 
(ml/min) 
Vd 
(l) 
ke  
(1/min) 
 
t1/2
(min) 
Cmax 
(ng/ml) 
tmax 
(min) 
AUC 
(0-∞) 
(ng.min/
ml) 
Cl 
(ml/ 
min) 
Vd 
(l) 
ke  
(1/min) 
 
t1/2
(min) 
              
 
F(%) 
 
 
 
Healthy control subjects 
 
REP 7.2 10 842.58 783 381 2.05 x10-3 338 9.1 90 1222.15 791 90.99 8.7 x10-3 79.7 2.42 
GEC 14.1 5 1085.51 608 253 2.41 x10-3 288 59.7 120 16581.21 613 145.46 4.22 x10-3 164 25.43 
TCL 8.9 5 1884.37 350 194 1.81 x10-3 383 22.3 180 8368.37 353 84.99 4.16 x10-3 166 7.39 
 
             
Mean 
SD 
10.1 
3 
6.7 
2.4 
1271 
445 
580 
178 
276 
78 
2.21x10-4 
2x10-4 
336 
39 
30.4 
21.4 
130 
37.4 
8724 
6275 
467
183
451
332
5.7x10-4 
2.1x10-4 
137 
40 
11.8 
9.89 
 
  
              
 
P-Values (Patients vs. healthy control subjects) 
 
         
 
  
 NS NS NS NS NS NS NS NS NS P<0.05* NS NS NS P<0.01* P<0.01* 
                
 
Abbreviations: AUC = area under the concentration-time curve; Cl = clearance; t1/2 = elimination half-life; T max = time point Cmax; Vd = oral volume of distribution 
a dosis 0.66 mg except for patient 12 who became 1.46 mg 
b dosis: 40 mg 
*significant differences between patients and control subjects, by two-tailed unpaired t-test (p<0.05, p<0.01) 
NS: not significantly different from control
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Serum bile acid concentrations determined in the plasma sample obtained at the two 
sessions before propranolol administration (time 0 hours) are shown in Table 4.3.  
 
 
Table 4.3. Bioavailability of propranolol and serum bile acid concentrations in patients and control 
subjects 
 
Serum bile acid concentration 
(µmol/l) 
 
 
Subject 
 
F 
 (%) 
 
0h 
(just before iv 
administration) 
 
0h 
(just before oral 
administration) 
 
 
0h  
(mean) 
     
1 99.9 8.2 3.7 6.0 
2 50.8 19.0 31.6 25.3 
3 67.9 200.0 139.1 169.4 
4 78.4 25.7 35.1 30.4 
5 48.8 17.4 7.9 12.7 
6 31.3 13.0 3.9 8.5 
7 71.9 82.9 92.5 87.7 
8 41.2 88.5 73.1 80.8 
9 53.8 43.7 36.4 40.1 
10 24.2 9.2 27.8 18.5 
11 88.4 20.7 38.6 29.7 
12 84.6 41.3 74.0 57.7 
13 29.7 28.2 25.9 27.1 
14 72.2 15.3 12.3 13.8 
REP 2.4 3.9 3.7 3.8 
GER 25.4 3.0 2.4 2.7 
TCL 7.4 1.3 2.1 1.7 
 
 
In order to check the reliability of the serum bile acid determination, the serum bile 
acid concentrations obtained before oral propranolol administration were correlated 
with those obtained before intravenous propranolol administration. There was a 
significant linear correlation (Fig. 4.1). 
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Fig. 4.1. Correlation between bile acid concentrations obtained before intravenous and oral 
propranolol administration (t=0h). The equation was y = 1.26x + 4.27 (r 2 = 0.92), P<0.05 
 
 
Since there was good correlation between the bile acid values obtained before oral 
and intravenous propranolol administration (t = 0h), mean values were used to 
investigate the correlation with the bioavailability of propranolol in patients (Fig.4.2), 
and patients and normal subjects ( Fig. 4.3). 
 
 
 
Fig. 4.2. Correlation between the serum bile acid concentration and the bioavailability of propranolol in 
patients with liver cirrhosis 
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Fig. 4.3. Correlation between the serum bile acid concentration and the bioavailability of propranolol in 
patients with liver cirrhosis and control subjects 
 
 
As shown in Fig. 4.2 and 4.3 no significant correlation was found between serum bile 
acid concentrations and propranolol bioavailability in patients alone or in patients 
combined with the control group. The relationship of indices of liver function such as 
Child-score, INR, serum bilirubin and serum albumin with the bioavailability of 
propranolol in cirrhotic patients was also investigated (Fig. 4.4).  
 
 
 
Fig. 4.4 Correlation of serum bile acid concentration with liver function tests in cirrhotic patients  
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As shown in Fig. 4.4., no statistically significant correlations were found between 
bioavailability and the various indices of liver function (Child score, INR, serum 
bilirubin and albumin) in the cirrhotic patients.  
However, when the oral clearance of propranolol in patients with liver cirrhosis is 
correlated with the serum bile acid concentration, an inverse relationship between the 
two parameters was detectable (Fig. 4.5.A). A small increase in the serum bile acid 
concentration (in cirrhotic patients a marker of  liver function) can be associated with 
an important decrease in propranolol clearance. When only the data from cirrhotic 
patients with serum bile acids values under 50 µmol/l were considered, the clearance 
was negatively correlated (r = 0.919)  (Fig 4.5 B.).  
Fig. 4.5 Correlation of serum bile acid concentration with the oral clearance in A) all the 14 cirrhotic 
patients, and B) with the patients with serum bile acids values <50 µmol/l (n=10) 
 
As shown in Fig. 4.6. similar trends were found when the bile acid concentration was 
correlated with the intravenous clearance of propranolol in patients. 
 
Fig. 4.6 Correlation of serum bile acid concentration with the intravenous clearance in A) all the 14 
cirrhotic patients, and B) with the patients with serum bile acids values <50 µmol/l 
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In control subjects, the bioavailability of propranolol is approximately 26 ± 10 % 
(7,8,9), indicating that propranolol is a drug with high hepatic extraction. Factors that 
determine the bioavailability of drugs with high hepatic clearance include liver blood 
flow and/or shunting of portal blood (1). For a drug like propranolol, increased porto-
systemic shunting would be expected to increase its bioavailability. In patients with 
cirrhosis, the serum bile acid concentration is considered to represent a measure of 
porto-systemic shunting (4). It has been shown convincingly that there is a linear 
correlation between the bile acid concentration in portal and peripheral  venous blood 
and the magnitude of portal-systemic shunts in patients with mild to moderate liver 
cirrhosis (4). A positive linear correlation has previously been found between the 
serum bile acid concentration in patients with liver cirrhosis and the Cmax of spirapril, 
a drug with a low to moderate hepatic clearance  (10). Despite this previous findings, 
in the current study we did not find a significant correlation between serum bile acids 
and bioavailability of propranolol in patients with liver cirrhosis.  
The negative correlation between the serum bile acid concentrations and hepatic 
clearance may be surprising. In patients with liver cirrhosis, propranolol has a 
bioavailability of 60% ( 11,7) and is therefore kinetically similar to drugs with medium 
extraction. In this situation, mainly intrinsic hepatic clearance predicts hepatic 
clearance of  a drug (2). The serum bile acid concentration may therefore reflect not 
only porto-systemic shunting but also intrinsic hepatic clearance in patients with liver 
cirrhosis. 
 
4.4 Conclusion and outlook 
In the current study we did not find a significant correlation between serum bile acids 
and bioavailability of propranolol in patients with liver cirrhosis. It is possible that the 
serum bile acid concentration is not a reliable marker for porto-systemic shunts and 
can therefore not be used to predict bioavailability of high extraction drugs such as 
propranolol. 
Individual bile acids may provide more information about porto-systemic shunts and 
may therefore be able to predict bioavailability of propranolol. Individual bile acids will 
therefore be determined by GC-MS. 
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V General discussion and outlook 
 
 
Adaptation of the dosage of drugs in patients with liver disease is more difficult than 
in patients with renal disease, since there is no endogenous marker for hepatic 
clearance, which could be used as a guide for dosing of drugs. 
In this thesis strategies for dosage adaptation of drugs in patients with liver disease 
were defined.  
 
In chapter 3.1. (project 1), the kinetic and dynamic changes in patients with liver 
disease of the most important drugs used in these patients were discussed. The 
conclusion was that the predictions for dose adaptation remain general and cannot 
replace accurate clinical monitoring of patients with liver disease treated with drugs 
owing a narrow therapeutic range. 
 
In chapter 3.2. and 3.3. (project 2 and project 3), the antineoplastic drugs and 
central nervous system agents marketed in Switzerland were classified according to 
their bioavailability / hepatic extraction in order to predict their kinetic behaviour in 
patients with decreased liver function. This prediction was compared with kinetic 
studies carried out with these drugs in patients with liver disease.  
Both studies showed that for most of the drugs studied, dosage recommendations 
are not available for patients with liver insufficiency. This is due to the absence of 
published data about hepatic extraction (E) (which is essential to help dosing in 
patients with liver disease) and the scarcity of performed clinical studies in patients 
with liver disease.  
 
 
The correlation between the bioavailability of propranolol and the plasma bile acid 
concentration in patients with liver cirrhosis   was investigated in chapter IV (project 
4).  
In this study we did not find a significant correlation between serum bile acids and 
bioavailability of propranolol in patients with liver cirrhosis. It is therefore possible that 
the serum bile acid concentration is not a reliable marker for porto-systemic shunts 
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and can therefore not be used to predict bioavailability of high extraction drugs such 
as propranolol.  
Individual bile acids provide more information about porto-systemic shunts and may 
therefore be able to predict bioavailability of propranolol. Individual bile acids will 
therefore be determined by GC-MS.  
When the clearance of propranolol in patients with liver cirrhosis is correlated with the 
serum bile acid concentration, an inverse relationship between the two parameters 
was detectable. When only the data from cirrhotic patients with serum bile acids 
values under 50 µmol/l were considered, the clearance was negatively correlated. 
In patients with liver cirrhosis, propranolol has a bioavailability of 60% and is 
therefore kinetically similar to drugs with medium extraction. In this situation, mainly 
intrinsic hepatic clearance predicts hepatic clearance of  a drug. The serum bile acid 
concentration may therefore reflect not only porto-systemic shunting but also intrinsic 
hepatic clearance in patients with liver cirrhosis. 
 
There was no significant correlation between serum bile acids and bioavailability of 
propranolol in patients with liver cirrhosis. The serum bile acid concentration seems 
not to be a reliable marker for porto-systemic shunts and can therefore not be used to 
predict bioavailability of high extraction drugs in patients with liver cirrhosis.  
There are currently not enough data for safe use of cyctostatics and central nervous 
agents in patients with liver disease. Pharmaceutical companies should urged to 
provide kinetic data (especially hepatic extraction) used for classification of such 
drugs and to conduct kinetic studies for drugs with primarily hepatic metabolism in 
patients with impaired liver function allowing to give quantitative advise for dose 
adaptation. 
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